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Genetic Exploration of Hereditary Immune Diseases 
Abstract 
An autoimmune disease is a condition arising from an abnormal immune response to a normal body part. 
There are at least 80 types of autoimmune diseases, rheumatoid arthritis and systemic sclerosis are two 
of them. My study focuses on these two diseases. Our hypothesis is that mutated genes lead to 
autoimmune diseases that cause the immune system to attack the human body. The mutated genes 
cause the gene expression levels to change which fail to properly regulate the body's functions, resulting 
in immune system diseases. I used existing mouse models to improve the understanding of these two 
diseases. 
The first study concerns Arthritis (Chapter 2). This study has been designed to evaluate the molecular 
mechanism that regulates spontaneous arthritis disease (SAD) in mice that are deficient in production of 
interleukin 1 receptor antagonist protein (IL-1ra). Mice with a BALB/c genomic background and IL-1Ra 
deficiency (BALB/c-/-) have shown susceptibility to SAD while those with a DBA/1 background are 
resistant to SAD. This study was based on our data accumulated over a decade of working with this 
mouse model of SAD. Our hypothesis is that there are nucleotide mutations in the gene or genes that 
cause the differences in expression level between BALB/c-/- and DBA/1-/- to regulate resistance or 
susceptibility to SAD. We obtained the IL-1Ra BALB/c-/- mouse model from the laboratory of Dr. John 
Stuart in order to test the susceptibility of IL-1Ra deficient mice on different genetic backgrounds. By 
transferring the IL-1Ra mutation onto the DBA/1 background, it was found that although BALB/c-/- mice 
spontaneously developed chronic inflammatory arthritis, DBA/1 IL-1Ra–deficient (DBA/1-/-) mice did not. 
We then determined the location of a genomic component that regulates susceptibility to SAD by 
identifying a QTL for spontaneous arthritis on mouse chromosome 1 from a F2 population derived from 
DBA/1-/- and BALB/c-/- mice. We created a congenic strain carrying the DBA/1-/- region of chromosome 
1 that contains the QTL on the BALB/c-/- background. We also created a congenic strain carrying the 
BALB/c-/- region of chromosome 1 that contains the QTL on the DBA/1-/- background. We then tested the 
susceptibility of these strains to SAD. When the DBA/1-/- fragment was placed on a BALB/c-/- 
background, arthritis was delayed and became less severe. When the BALB/c-/- fragment was placed on 
a DBA/1-/ background, arthritis occurred in varying degrees. A study of the whole genome expression 
profiles of these congenic strains and their parental strains was performed in order to identify a candidate 
gene. We linked the Ifi204 gene in Ifi200 cluster to the potential causal pathway of spontaneous arthritis 
in a mouse model. We identified the function of Ifi204 gene in congenic strains and their parental strains 
to confirm our theory. We used state of the art technology to investigate the molecular mechanism that 
regulates the susceptibility to SAD. Through this analysis, a strategy to improve the therapeutic outcome 
of drugs designed based on alternative targets of the interleukin-1 (IL-1) receptor antagonist may be 
identified. 
The second study concerns systemic sclerosis (SSc) (Chapter 3). SSc is a polygenic autoimmune 
disorder. It is of unknown etiology and is characterized by the excessive accumulation of extracellular 
matrix (ECM) proteins, vascular alterations, and v 
autoantibodies. The tight skin 2 (Tsk2/+) mouse model of SSc demonstrates signs similar to SSc 
including tight skin and excessive deposition of dermal ECM proteins. Our hypothesis is that ENU caused 
single nucleotide mutations in one or more genes in the Tsk2/+ locus interval that determines the disease 
phenotype. From the literature, Tsk2/+ mice have a mutation on chromosome 1 between 42.5 and 52.5 
megabases. We used microarray data to analyze the genes’ expression level to narrow down the number 
of candidate genes. Based on studies of the genes’ functions, we determined that Fhl2 is our primary 
candidate gene. We performed both RNA sequencing of skin transcripts and DNA sequencing of the 
region spanning this gene in Tsk2/+ and wild-type littermates. As of now, we have not found any 
nucleotide polymorphisms between Tsk2/+ and normal mice. We found that there are two transcripts of 
this gene and they are expressed differently in the various tissues. This can help us explain why there is 
only fibrosis in skin. We compared the expression levels of the two transcripts in each organ. The high 
expression level of one of the transcripts in the skin can help us understand the mechanism of skin 
fibrosis manifested by Tsk2/+ mice. Understanding the mechanism of skin fibrosis in the mouse model 
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 An autoimmune disease is a condition arising from an abnormal immune response 
to a normal body part. There are at least 80 types of autoimmune diseases, rheumatoid 
arthritis and systemic sclerosis are two of them. My study focuses on these two diseases. 
Our hypothesis is that mutated genes lead to autoimmune diseases that cause the immune 
system to attack the human body. The mutated genes cause the gene expression levels to 
change which fail to properly regulate the body's functions, resulting in immune system 
diseases. I used existing mouse models to improve the understanding of these two 
diseases.  
 
 The first study concerns Arthritis (Chapter 2). This study has been designed to 
evaluate the molecular mechanism that regulates spontaneous arthritis disease (SAD) in 
mice that are deficient in production of interleukin 1 receptor antagonist protein (IL-1ra). 
Mice with a BALB/c genomic background and IL-1Ra deficiency (BALB/c-/-) have 
shown susceptibility to SAD while those with a DBA/1 background are resistant to SAD. 
This study was based on our data accumulated over a decade of working with this mouse 
model of SAD. Our hypothesis is that there are nucleotide mutations in the gene or genes 
that cause the differences in expression level between BALB/c-/- and DBA/1-/- to regulate 
resistance or susceptibility to SAD. We obtained the IL-1Ra BALB/c-/- mouse model 
from the laboratory of Dr. John Stuart in order to test the susceptibility of IL-1Ra 
deficient mice on different genetic backgrounds. By transferring the IL-1Ra mutation 
onto the DBA/1 background, it was found that although BALB/c-/- mice spontaneously 
developed chronic inflammatory arthritis, DBA/1 IL-1Ra–deficient (DBA/1-/-) mice did 
not. We then determined the location of a genomic component that regulates 
susceptibility to SAD by identifying a QTL for spontaneous arthritis on mouse 
chromosome 1 from a F2 population derived from DBA/1-/- and BALB/c-/- mice. We 
created a congenic strain carrying the DBA/1-/- region of chromosome 1 that contains the 
QTL on the BALB/c-/- background. We also created a congenic strain carrying the 
BALB/c-/- region of chromosome 1 that contains the QTL on the DBA/1-/- background. 
We then tested the susceptibility of these strains to SAD. When the DBA/1-/- fragment 
was placed on a BALB/c-/- background, arthritis was delayed and became less severe. 
When the BALB/c-/- fragment was placed on a DBA/1-/ background, arthritis occurred in 
varying degrees. A study of the whole genome expression profiles of these congenic 
strains and their parental strains was performed in order to identify a candidate gene. We 
linked the Ifi204 gene in Ifi200 cluster to the potential causal pathway of spontaneous 
arthritis in a mouse model. We identified the function of Ifi204 gene in congenic strains 
and their parental strains to confirm our theory. We used state of the art technology to 
investigate the molecular mechanism that regulates the susceptibility to SAD. Through 
this analysis, a strategy to improve the therapeutic outcome of drugs designed based on 
alternative targets of the interleukin-1 (IL-1) receptor antagonist may be identified. 
 
 The second study concerns systemic sclerosis (SSc) (Chapter 3). SSc is a polygenic 
autoimmune disorder. It is of unknown etiology and is characterized by the excessive 
accumulation of extracellular matrix (ECM) proteins, vascular alterations, and 
 
v 
autoantibodies. The tight skin 2 (Tsk2/+) mouse model of SSc demonstrates signs similar 
to SSc including tight skin and excessive deposition of dermal ECM proteins. Our 
hypothesis is that ENU caused single nucleotide mutations in one or more genes in the 
Tsk2/+ locus interval that determines the disease phenotype. From the literature, Tsk2/+ 
mice have a mutation on chromosome 1 between 42.5 and 52.5 megabases. We used 
microarray data to analyze the genes’ expression level to narrow down the number of 
candidate genes. Based on studies of the genes’ functions, we determined that Fhl2 is our 
primary candidate gene. We performed both RNA sequencing of skin transcripts and 
DNA sequencing of the region spanning this gene in Tsk2/+ and wild-type littermates. As 
of now, we have not found any nucleotide polymorphisms between Tsk2/+ and normal 
mice. We found that there are two transcripts of this gene and they are expressed 
differently in the various tissues. This can help us explain why there is only fibrosis in 
skin. We compared the expression levels of the two transcripts in each organ. The high 
expression level of one of the transcripts in the skin can help us understand the 
mechanism of skin fibrosis manifested by Tsk2/+ mice.  Understanding the mechanism of 
skin fibrosis in the mouse model will help us and other researchers understand the 
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CHAPTER 1.    BACKGROUND AND LITERATURE STUDY 
 
 
The immune system is a mechanism used to protect organisms from exogenous 
attack. Without the immune system, our bodies would be open to attack from many 
infectious organisms such as bacteria, viruses, parasites, among others[1, 2]. 
Approximately 50 million American people, around one-sixth of the U.S. population, 
suffer from different forms of immune disease[3, 4]. The immune system is the one of the 
most complex systems in humans. It uses cells, organs, proteins, and tissues to work in 
accordance with the nervous system to keep us healthy. In the immune system, 
leukocytes, also called white blood cells, are one of the most important cell types[1, 2]. 
Leukocytes are produced and stored in the bone marrow, thymus, lymph nodes, and 
spleen. They circulate throughout organs through the lymphatic system and blood 
vessels. As the leukocytes circulate throughout the body, the immune system works 
efficiently to seek out and solve problems. There are two basic types of leukocytes: 
phagocytes and lymphocytes. The responsibility of the phagocytes is to attack the 
invading organisms, and the lymphocytes’ responsibility is to remember and recognize 
the invaders and to help the body have a quick response. Lymphocytes are important 
immune recognition cells[5]. They can be divided into T cells, B cells, and NK cells. 
While lymphocytes are in the bone marrow, they mature to B cells. When part of a 
pluripotent stem cell or pre-T cell from the bone marrow migrates into the thymus, they 
differentiate and mature into immunocompetent T cells under the induction of 
thymosin[6]. These two types of lymphocytes serve different functions. B cells seek out 
their targets and send defenses to lock onto them, then T cells either destroy the foreign 
invaders that the B cells have identified (CD8+) or they provide help to the B cells in 
generating signals that give rise to antibody production (CD4+). Many immune diseases 
can be detected by looking at the ratio of T cells, B cells, and other cell subpopulations[5-
9]. 
 
 An immune disease is caused by an immunoregulatory imbalance that affects the 
body's immune response[1]. These diseases include structural or functional abnormalities 
of the immune system that are caused by genetic and environmental factors[10]. 
Environmental factors include viruses, bacteria, humidity, air, and food[11, 12]. These 
factors can cause immune diseases like HIV[13], rheumatoid arthritis[14], thyroiditis[15], 
and diabetes[16]. Congenital immune diseases are caused by genetic defects. Many 
immune diseases are caused by both environmental and genetic factors. For example, 
rheumatoid arthritis is affected by temperature, humidity, and genetics[17, 18]. 
Autoimmune diseases are caused mainly by the accumulation of immune cells and 
immunoglobulin produced by excessive immune reactions, thereby damaging normal 
tissues and causing lesions and functional impairment. Scleroderma and rheumatoid 
arthritis are both autoimmune diseases that have a hereditary component [19, 20]. By 
comparing the genomic background of normal and diseased people, we can search for 
mutated genes. Identifying the mutated genes is very helpful for the selection of 




A gene is a sequence of DNA and is the hereditary code for proteins. Genes are 
the building block of heredity: they pass from parents to children and hold the DNA and 
instructions for producing proteins[21]. Genes are transcribed to RNA, which in turn are 
translated to proteins that makeup living matter and are the catalysts of every single 
cellular process[22]. All organisms’ physical traits are determined by these proteins. The 
DNA that makes up a gene is a double-helix structure made up of Deoxyribonucleic acid, 
that was first proposed by Watson and Crick in 1953[23, 24]. DNA is composed of five 
organic elements – carbon, hydrogen, oxygen, nitrogen, and phosphorous – that are 
organized into highly ordered substructures called nucleotides[25-27]. There are four 
different nucleotides, Adenine (A)[28], Guanine (G)[29], Cytosine (C)[30], and Thymine 
(T) that form the basis for DNA, and are linked by β-N-glycosidic bond from their first 
carbons[28, 31]. Adenine bonds with Thymine and Cytosine bonds with Guanine. The 
change in a single nucleotide can cause protein denaturation, which can cause a disease. 
There are approximately 35,000 genes in the human body, and approximately 19,000 of 
them are coding genes[32]. There are also approximately 35,000 genes in mice[33]. 
Within this huge number of genes, even one nucleotide that has been added, deleted, or 
switched can cause a genetic disorder.  
 
The proteins encoded by genes have functions that include breaking down 
ingested toxins, transferring molecules, and building structures[34, 35]. Mutations in 
genes can affect protein expression or the protein’s structure, thus causing a loss or 
change in the function and/or excessive or insufficient expression[36, 37]. There are three 
types of genetic disorders that can cause a change of the structure and function of 
proteins; single gene mutations, multifactorial diseases and chromosomal abnormalities. 
A single gene disorder is caused by a nucleotide mutation, deletion and/or insertion into 
the coding gene[38]. The characteristics of each disease is related to the specific gene that 
is affected and the role its product plays in the body. A multifactorial disease is due to 
alterations in two or more genes as well as lifestyle or environmental factors. The 
inheritance of these diseases is not clear; they can be inherited or sporadic[39]. A 
chromosomal abnormality is a chromosomal disorder that occurs when part or all of a 
chromosome is deleted or altered[40]. Down syndrome and Turner syndrome are 
examples of such chromosomal disorder.  
 
To study genetic disorders, we must understand the gene mutation causing the 
disorder. A gene mutation is a permanent modification in the DNA sequence that results 
in the gene coding region differing from what is found in most normal people[41]. The 
change can be anywhere from a single nucleotide polymorphism to multiple large 
segments on a chromosome that affects multiple genes[42]. Polymorphisms are genetic 
alterations and they occur in more than one percent of DNA sequences in the human 
body. Polymorphisms determine a person’s physical traits, such as their eye color, blood 
type, or handedness[43, 44]. Polymorphisms are common results from natural variability 
in the DNA, and most of them do not negatively affect a person’s health, although certain 
mutations may increase the risk of various disorders[43]. There are two major categories 
of gene mutations: hereditary and acquired. Hereditary mutations are those inherited from 
a parent and they remain in a person’s cells throughout his or her life. These mutations, 
also called germline mutations, are present in the parent’s germ cells as well. An acquired 
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mutation is limited to certain cells after conception[45]. In this type of mutation, the 
change passes from these limited cells to their offspring cells. An acquired mutation is 
caused by environmental factors, such as radiation or an error in the copying of DNA 
during cell division. When the mutation is in the somatic cells, the mutation cannot be 
passed to the next generation. When the mutation is in the fertilized egg, the mutation 
will be delivered to the next generation, and the mutation will become a hereditary 
genetic disorder. Sometimes, the mutation occurs only in the fertilized egg and will be 
present in the reproductive cell but not any of the other cells. As the fertilized egg 
continues to divide, each cell will also contain the mutation[46]. Genetic disorders in 
which all of a child’s cells have the mutation but the parents’ do not and the disease is not 
present in other family members could be the result of de novo mutations. These gene 
mutations that lead to diseases are rather uncommon amongst the general population. 
 
Protein production is initiated with transcription, where DNA is turned into RNA, 
and proceeds with translation, where RNA is turned into a protein. The functions of a cell 
can be determined by the amounts and types of mRNA molecules found inside the 
cell[47]. The start of transcription is the main control point for gene expression[48]. 
Controlling the transcription initiation processes determines the types and the amounts of 
proteins present in the cell. In addition, how a cell processes RNA transcripts and new 
proteins can affect protein levels to a significant degree. A primary transcript synthesized 
by RNA polymerase will contain a sequence that does not appear in the RNA’s final 
mature form[49]. These sequences are defined as introns and are discarded before the 
mature mRNA exits the nucleus. The remaining regions of the transcript contain the 
protein coding region and are called exons[50, 51]. These regions are then spliced 
together, and the final product is mature mRNA. Each step allows the cell to self-regulate 
many of its functions through the adjustment of the amount and type of proteins it 
manufactures. The quantity of any protein in a cell reflects the balance between the 
synthesis and degradation biochemical pathways of said protein[48]. The gene expression 
level in each tissue is relative, thus we can find the mutated gene by comparing gene 
expression. 
 
The promoter and enhancer play very important role in balancing the gene 
expression level[52, 53]. The promoter is a short DNA sequence that is used to identify, 
bind and initiate RNA polymerase transcription, often located about 2000 base pairs 
directly upstream of the transcription initiation site[54]. To commence transcription, 
RNA polymerase and other required transcription factors bind to the promoter sequence. 
The promoter sequence defines the direction of transcription and indicates which DNA 
strand will be transcribed; this transcribed strand is called the sense strand. The TATA 
box is a promoter sequence approximately 25 to 35 base pairs above the transcription 
start site[55]. Certain transcription factors will bind to the TATA box to begin the 
production of an RNA polymerase transcription complex[54-56]. When there are changes 
in gene expression level, we not only need to sequence the gene, but also the promoter. 
Promoters sometimes have enhancers that act upon them in a cis-regulatory fashion to 
either increase or decrease transcription.  By interacting with promoters through DNA 
looping, enhancers are able to regulate gene expression’s temporal and spatial patterns. 
Enhancers can be located as much as 1,000,000 base pairs away and are 50-1500 base 
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pairs in size[57, 58]. Compared to the promoter, the enhancer is not easy to find, because 
it does not have an obvious feature and the range is relatively large. 
 
When we want to study a genetic disease, we should know the whole genome 
expression levels differences between the patient and normal people. Microarray 
technology is a great exploratory tool, and is commonly used in both scientific and 
clinical research[59]. It can help us look at the gene expression profile and can also be 
used to simultaneously measure thousands of gene expression levels. DNA microarray is 
a special microscope glass slide (also called gene chip) with thousands of small probes 
containing a known DNA sequence or gene at defined locations. For microarray analysis, 
researchers collect mRNA samples from experimental and control groups. The reference 
sample is collected from a healthy individual, while the experimental sample is taken 
from a diseased individual (samples are from people of the same age, gender, etc.). These 
mRNA samples are then converted to complementary DNA (cDNA) and labeled with 
fluorescent probes containing the color. The experimental and control samples are then 
hybridized with the microarray slide. Hybridization is the process of binding a cDNA 
molecule to a DNA probe on a slide. After hybridization, the expression levels of genes 
are scanned by the microarray fluorescent scanner. Data analysis is done using 
microarray software[59, 60]. There are two types of Microarray; one type (two-color 
technique) uses red and green fluorescent dyes to hybridize experimental and control 
sample separately and then load them on one chip. When gene expression levels in the 
experimental sample are higher than the control sample, they will show one color 
(normally red); when gene expression levels in the experimental sample are lower than 
the control sample, they will show another color (normally Green). We can judge the 
strength of the expression levels based on the gradient of the two colors. The data 
collected by the microarray can be used to create a gene expression profile. These high or 
low expressed genes will be our candidate genes. However, since microarray data only 
shows the difference in expression, not the fold change, it cannot be looked at as accurate 
because it may show a low difference while actually having a large fold change.  Another 
type of Microarray uses the one-color technique. The experimental and control samples 
are separately hybridized on two chips with one fluorescent color. There are multiple 
standard control probes on the chips to quantify the genes expression levels. Each probe 
is quantified comparing with standard control probes, thus avoiding errors in different 
batches. At the same time, each probe can determine the individual absolute expression 
levels according to the standard control probes. The digital expression levels of the 
experimental and control samples can be analyzed by fold changes[61, 62]. 
 
For these up or down expressed genes, an important step is to narrow down the 
region to identify the mutated genes. Using the recombinant inbred (RI) strain to find the 
quantitative trait locus (QTLs) that can help to narrow down the candidate genes[63-66]. 
RI strains are a very important and useful resources for mapping a complex trait. The RI 
principle is simple and can work on many species. We use two strains to crossover, 
beginning with the F2 generation, and paired to establish a new set of inbred lines 
through repeated sibling mating. The RI strain has two characteristics[64, 67]. First, as 
with the F2 progeny, each contains different chromosome segments randomly selected 
from two progenitor cells, and thus each new strain has a random different chimera 
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arrangement. Second, unlike the F2 progeny, each pair of chromosomes is homozygous 
for an extension of the mosaic of alternating chromosomes derived from two progenitor 
cells within each strain. The RI resource is very useful for mapping a gene of a basic 
phenotype and is particularly useful for complex phenotypes such as developmental 
processes, regulatory phenomena, and disease progression. The completion of the mouse 
genome sequence and extensive genotyping of RI strains greatly enhanced QTL mapping 
and candidate gene discovery in QTL studies[68]. The combination of RI strains and 
genomic information will enable the rapid development of QTL gene discovery[67]. QTL 
uses molecular marker to link the complex phenotypes with chromosomes specific region 
to identify the candidate genes. Usually, a single phenotypic trait is affected by many 
genes in multiple QTLs. The QTLs can be used to identify the action, interaction, and 
number of genes in these precise regions. When the gene or genes are identified as 
contributing to a phenotype on this region and have expression level changes. The gene 
or genes can be sequenced to compare with the normal gene or genes. Basically, QTL 
mapping is used to find the association between genes and the variation of a trait.  The 
difference between the mapping of QTL and a simple trait is that QTL needs to conduct 
correlations between many genes and many small changes in the trait, which turns out to 
be much more difficult to do. As the number of genes for a trait becomes larger, the 
effect of each gene on the variation of the trait gets smaller. The influence of the 
environment becomes important, at least in terms of the measurement of the influence of 
a genetic locus. By examining the up- and down-regulation of genes and the location of 
the genes on QTLs, we narrowed down the number of genes to a relatively small range, 
though finding the candidate gene out of all the genes in this range still very difficult. For 
some chronic diseases, it seems that the causative mutation does not exclusively appear in 
well-known candidate genes. 
 
GeneNetwork is an online software tool that can be used to search complex genes 
and molecular networks to understand their functions and phenotypes[69]. Utilizing sets 
of linked data to quantify the genes correlation, it can be used to study humans, mice, 
rats, fruit flies, and more. There are many sequences and extensive transcriptome data 
available on GeneNetwork[69-71]. It can be used to measure the extent to which genes 
are correlated with the same biological substrates in genetically similar individuals. 
Genetic correlations analyze gene expressions and traits within varying strains of interest. 
The QTL mapping module allows users to quickly analyze traits controlled by genetic 
variation and environmental factors online[70]. Genetic maps from the database can aid 
in finding genetic modifiers that cause phenotypic differences. An important association 
shows the presence of a QTL correlated with the tag that displays the association. Simple 
interval mapping can test the association between the trait values at multiple analysis 
points between each pair of adjacent marker loci and the expected genotype of the target 
QTL. The bootstrap method can be performed to estimate the confidence interval at the 
QTL location. Composite interval mapping and simple interval mapping is very similar. 
However, unlike simple interval mapping, within each analysis point composite interval 
mapping also analyzes other markers at different locations in the genome[70]. These 
markers have previously been shown to be associated with traits, so we can assume that 
they are close to background QTL. Paired scans evaluate all pairs of markers in the dual-
track model, including the main effects and interactions at each locus. These multiple 
 
6 
QTL models can help to find complex phenotypes. For all mapping methods, the 
empirical significance threshold can be determined by adding a displacement test. Some 
examples include the dominance of various traits in breeding or what would happen if 
only one trait is selected but other genetically related traits are expressed in unison[69-
71]. 
 
Genetically related assays can be applied to the same methods used to determine 
heritability. There are several types of genetic correlations[72-75]. One type of 
correlation is Matrix/PCA, which can compare the values of more than 100 features in 
the set. The correlation matrices can then be exported, and new composite phenotypes 
can be generated by using the principal component derivative of the feature set. QTL 
heatmaps are another type of genetic correlation that efficiently identify common and/or 
unique genetic determinants amongst large and complicated phenotypes[70]. This method 
can be used to analyze up to 100 traits simultaneously, sorted either by hierarchical 
clustering or their order within the genome[73]. Another type of genetic correlation, 
compare dependencies, looks for shared genetic correlations in a set of features by cross 
checking these traits with records across many databases. Lastly, network graphs 
examine the network of associations between large phenotypes. The diagrams are 
interactive, which allow users to select certain sets of features that can then be stored 
briefly for further analysis in data sets such as GeneNetwork[69, 71, 72, 74].  
 
An important step is to identify every possible genetic factor within this region. It 
is essential to obtain not only accurate genome information, but also every possible 
candidate gene within the genome sequences, though there are still gaps and errors in the 
sequence assembly. Based on previous knowledge of its biochemical functionality and 
mutant phenotypes, the candidate mutation gene was widely thought to contain alleles 
causing a mutation disorder or contributing to a complex phenotype closely related to 
said gene[71, 75].  
 
Candidate gene studies use markers derived from prior hypotheses regarding the 
phenotypic effect of one or multiple selected genes. The advantage of this gene approach 
is that the most relevant and crucial genes will be tested[76]. Researchers use various 
methods to detect such genes that are most likely to treat diseases. One method utilizes 
several candidate genes that perform similar functions to find the genetic pathway. 
Pathways are genes associated with drug metabolism (pharmacokinetics) and drug 
reactions (pharmacodynamics)[77-79]. Researchers utilize the candidate gene pathway 
strategy so that they can easily identify the effect of gene aggregation on the phenotype 
with less influence of the individual gene on the downstream phenotype. Its success, 
however, largely depends on the hypothesis used to select the gene to be studied[77, 79]. 
A risk of this method is that some genes that play an important role in pharmacokinetics 
and pharmacodynamics may be passed over. In the past, candidate gene studies across all 
traits have been severely lacking. Usually, diseases are linked to many different genes 
and thus makes it difficult to judge whether they result from mutations or pathway 




Candidate gene studies have often failed to determine the genetic basis of 
common characteristics, suggesting that this method has some limitations[81, 82]. First, 
the selection of candidate genes may not be suitable. Second, the selected SNP may 
provide limited coverage and could miss several mutations. Third, the gene in question 
may be located at the point of action of the selected candidate or upstream of the 
downstream signaling pathway. Fourth, most of the studies are underpowered; therefore, 
they face population stratification, phenotypic, and site heterogeneity issues. Lastly, and 
most notably, candidate gene studies are completely reliant on past data and prior 
hypotheses on disease, so it is impossible to discover genetic variants in new pathways. 
 
Once one or a small number of candidate gene have been selected, we will 
examine the difference between the candidate genes and normal genes. As we mentioned 
before, the change may be only on a single nucleotide or may have a large segment 
missing. Sequencing is an important method used to detect genetic mutations. The 
sequencing technology can make the biological signal into a digital figure, making the 
data more accessible to researchers[83, 84]. Sequencing is a method developed in 1975 
by Frederick Sanger, who would later go on to win the Nobel Prize, and is thus also 
commonly referred to as Sanger sequencing[85]. Sequencing is used to determine the 
exact sequence of a DNA molecule. The DNA molecule itself serves as a template for its 
own sequencing. DNA primers first synthesize a fragment of DNA, then the fragment is 
evaluated. We used ABI Model 3130XL Genetic Analyzers with four-color fluorescence-
based sequencing to detect the DNA sequence[86]. For the DNA synthesis reaction, the 
key lies in the addition of a small amount of the corresponding dideoxynucleotide 
triphosphates (ddNTPs) to bind A, G, T, C with the four fluorescence colors. The DNA 
samples go through the four-capillary array and read the fluorescence color from the 
capillary array detection, then a schematic representation of the in-capillary detection is 
made. By finding the nucleotide polymorphisms between the experimental and control 
group, we can calculate the changes in the amino acids. When we know the full amino 
acid sequence, we get the new protein structure by protein modeling. Based on the 
protein change, the protein function can also be changed.  
 
Progress in the research of the nucleotides or protein changes help people get to 
the next step in the study of immune-mediated diseases and gene therapy. It is the 
introduction of exogenous normal genes into target cells to correct or compensate for 
diseases caused by genetic defects and abnormalities for therapeutic purposes[87]. Gene 
therapy is currently only in the laboratory stage and is thus not yet universal[88, 89]. 
Currently, many labs want to use the genetic material of stem cells to treat a genetic 
disorder. There are several approaches to gene therapy that have been tested[87, 89].1) 
Replace a disease-causing mutated gene with a healthy copy. 2) Knock out a mutated 
gene that is not functioning correctly. 3) Insert a new gene into the body to help fight a 
disease. The gene or genes can synthesize unique proteins, that can be used to correct 
these genetic disorders. In the future, this technique can help doctors treat a disease by 
inserting a gene or protein into a patient instead of using drugs or surgery[89]. Although 
gene therapy shows promise as a treatment option for diseases, it is still very risky. 




Animal models are useful tools to help us study human diseases. The model 
usually is an animal with a disease or a phenotype similar to a human one[91]. Animal 
models are widely used in genetic mapping and transgenic studies for many reasons. The 
main reason for using animal models in genetic research is to obtain data that cannot be 
obtained from humans[92]. One example is gene therapy: genetic material can be put into 
animals, but it is not yet possible to test on humans. Genetic studies need heritable 
materials such as DNA and RNA. While we can easily obtain tissues such as the liver, 
heart, and brain from animals to extract RNA, it is extremely difficult to get them from 
humans[92]. Several benefits to using the mouse model include: a short generation time, 
a short life span, large population size, easy manipulation of environmental conditions, 
diseases or conditions that can be created that are similar to the human’s, and possible 
manipulation of genetic materials. However, there is also a disadvantage to using animal 
models. Depending on different situations, sometimes the differences between humans 
and animals are so large that the results from animal models are not reflective of those of 
humans[93].  Selection of a species of animal model should not be based on availability, 
familiarity, or cost, but rather on the biology, the suitability for the disease or trait, and 
the impact of the study on humans. There are many animal models that have been well 
developed. Mammal models have been most commonly used because of their obvious 
similarities in both structures and function to those of humans [94]. 
 
The mouse is an excellent model system for understanding the development of 
mammals, especially humans[95]. Mice and humans are very similar in development and 
physiology, and many comparisons can be drawn between the two. There is a lot of 
knowledge about human and mouse genomes. In most regions of the genome, the order 
of genes, and therefore, the linkage of genes, is conserved between mice and humans. 
These homologous or heterologous regions drive the advancement of human and mouse 
genome projects because information about one system can be directly translated to the 
other system[8, 95]. In addition, since a very large portion of the human and mouse 
genomes have been sequenced, direct sequence comparisons are now possible. Moreover, 
the mouse genome has been extensively characterized and its whole genome sequence 
has been completed, allowing for the execution of gene-targeted “knockouts” of every 
gene and transgenic over-expression in mice. We will use the mouse model to discuss the 




CHAPTER 2.    GENETIC STUDY OF HUMAN RHEUMATOID ARTHRITIS 





Rheumatoid arthritis (RA) is a common autoimmune arthritis. The disease 
involves pain, swelling, and damage in the joints. Genetic and environmental factors 
control the disease[96, 97]. For example, susceptible genes, humidity, and temperature all 
affect RA.  It is a systemic, chronic, inflammatory disorder that is presented in the wrists, 
ankles, and small joints of the hands and feet. There are around 1.5 million people that 
have the disease in the United States. RA normally starts between the ages of thirty and 
fifty, but having the disease at any age is possible. The etiology of RA is not yet 
completely known; it is a complex disease caused by many factors, with genetics and the 
environment being the most important factors[98]. The chronic multi-synovial 
inflammation in arthritis can cause extra-articular pathological changes[99]. RA occurs 
repeatedly and is distributed symmetrically in the body. There are several stages of RA. 
In the first stage, the inflammation is in the joint capsule, there is swelling in the synovial 
tissues, and the symptoms include pain, swelling, and stiffness in the joint. In the second 
stage, the cartilage is damaged by the inflammation of the synovial tissue. During the 
third stage, inflammation is found not only in the synovium and cartilage. It also causes 
bone erosion and decreases muscle strength[100]. During the last stage, the joints lose 
their function and patients have the possibility of crippling. No matter which stage, 
swelling and pain are always present. From the pathology, the major involvement of 
rheumatoid arthritis is in the joints, and includes the synovium, cartilage, bone, muscle, 
and joint ligaments[101]. Symptoms of systemic rheumatoid arthritis include fever, 
fatigue, pericarditis, subcutaneous nodules, pleurisy, and peripheral neuropathy. The 
inflammation also influences the other connective tissues, such as the serosa[102], 
heart[103], lung[104], and eyes[105].  
 
Studies of the genetic factors affecting arthritis have been conducted using animal 
models, and research on the genetic basis of arthritis has had significant results. A rat 
model was first used to report the susceptibility of multiple QTLs to regulate Collagen-
induced arthritis (CIA) in 1996[106]. In the study, CIA in rats and mice are both major 
histocompatibility complex (MHC)-linked, and a considerable portion of arthritis cases 
are caused by a non-MHC-linked molecular mechanism on other chromosomes. 
Identification of genes that regulate susceptibility to non-MHC-linked arthritis is essential 
for understanding the molecular mechanism of non-MHC-linked arthritis and selecting 
molecular targets for therapy[107]. Many non-MHC QTLs have been located on different 
chromosomes by various research groups. For example, Remmers et al. found non-MHC 
QTLs in chromosomes 1, 4, 7 and 10[106]. Otto et al. identified an instructive QTL on 
                                                 
 
1 Used with permission. Tian, C*, Liu, X*, et al. Ifi204 as the most favored candidate gene that 
regulates susceptibility to spontaneous arthritis in mice deficient in IL-1ra. Gene Reports. 2018, 




chromosome 8[107, 108]. They identified many QTLs on other chromosomes, scanned a 
genomic mouse model of arthritis and found that it was independent of proteoglycan-
induced arthritis and did not rely on a QTL associated with MHC QTL. Ibrahim’s group 
used (DBA/1×FVB/N) F11/12 AIL mice to improve arthritis severity and seizures as well 
as antibody responses in CIA by QTL[109]. (DBA/1×FVB/N) F2 generation has been 
used to identify the QTL region[109, 110]. 
  
The major histocompatibility complex is a generic name for the gene groups that 
encode the antigens of biocompatible complexes. This is a group of tightly linked gene 
groups that are located in a specific region of an animal or human chromosome and are 
highly polymorphic. The encoded molecules are expressed on different cell surfaces and 
participate in antigen presentation, restricting mutual recognition between cells and 
inducing immune responses. The names of the different species of mammalian MHC and 
their encoded products vary. The MHC is called the H-2 complex in mice. Human MHC 
is often referred to as human leukocyte antigens (HLA) genes or HLA complexes. Its 
encoded molecules are expressed on leukocytes. The distinction between genes is often 
referred to as HLA molecules or HLA antigens[111]. Progress has been made on the 
study of the MHC-linked molecular mechanism of arthritis. CIA was one of the mouse 
models of arthritis found to be associated with the MHC[112-114]. From the literature, 
collagen induced arthritis is MHC-linked in both rats and mice[115-117]. However, there 
is a portion of arthritis diseases that are not MHC-linked. Our goal is to study and 
improve the understanding of the non-MHC-linked molecular mechanism that leads to 
spontaneous arthritis disease[118-123]. Identification of genes that regulate via non-
MHC-linked arthritis can improve our understanding of this disease and help us to choose 
better molecular treatment (Figure 2-1). Many non-MHC-linked loci have been 
identified, yet the causal genes for these QTLs have yet to be identified [124, 125]. 
 
Many different mouse models have been used to study non-MHC-linked arthritis. 
In mice, an interleukin-1 receptor antagonist (IL-1ra) deficiency leads to spontaneous 
arthritis. This serves as an important model for studying human arthritis. The 
proinflammatory cytokine IL-1 is an important mediator of inflammation and arthritis in 
mice. IL-1 is present in the immune system in the body[120, 126]. In animal studies, 
researchers directly injected IL-1 into normal rabbit joints and this was shown to induce 
severe arthritis. Treating BALB/c mice with IL-1 enhances the development of arthritis. 
IL-1ra is an endogenous neuroprotectant that can inhibit IL-1. The action of IL-1ra 
binding to the IL-1 receptor can prevent the IL-1receptor from binding to IL-1.  
 
IL-1ra is a member of the Interleukin-1 gene family. It is a very important 
cytokine to regulate the biologic activity of IL-1. IL-1 is produced by monocytes, 
endothelial cells, fibroblasts, and other types of cells in response to infection. It is a 
general term for the two different proteins IL-1α and IL-1β, both of which bind to the 
same receptor in the immunoglobulin superfamily[127]. IL-1 is a regulatory and 
inflammatory cytokine. In the immune system, IL-1 production can often lead to 
inflammation. The role of IL-1 is not just inducing inflammation, it is also involved in 






Figure 2-1. MHC genomic region on mouse chromosome 17 and non-MHC QTL 
loci on other chromosomes marked by molecular markers on 9 out of 19 autosomal 
chromosomes. 
MHC genomic region on mouse chromosome 17 and the non-MHC QTL loci have been 






neuronal phenotypic development, and IGF/GH physiology. IL-1 has been widely 
reviewed, and there is an understanding of its biological activities and properties[126]. 
Our hypothesis is that the Ifi200 gene cluster regulates susceptibility to SAD in mice. 
Within the Ifi200 cluster we focused on the Ifi204 gene. Our hypothesis is based on the 
fact that expression levels of Ifi200 cluster genes decreased while resistance to SAD 
increased in the congenic strain with BALB/c background, and the Ifi200 cluster genes 
are the only group of genes relevant to SAD within the QTL region which showed the 
differential expression[97].  
 
 IL-1ra plays an important role in regulating the effects of IL-1, which in turn 
plays a significant role in the up-regulation and down-regulation of inflammation [128]. 
IL-1ra is a competitive and endogenous inhibitor produced by mononuclear and 
macrophages. It can bind to IL-1 receptors because IL-1ra has similar affinity to IL-1α 
and IL-1β. IL-1ra binds to the IL-1 receptor and blocks the activity of IL-1. IL-1ra can 
terminate the inflammatory response[129]. The IL-1ra level normally increases later than 
the IL-1 level in inflammatory response. Increasing the IL-1ra levels in mice can reduce 
inflammation in various diseases[128]. 
 
Spontaneous arthritis disease (SAD) has been used to study rheumatoid arthritis in 
humans. Horai and his coworkers showed that IL-1ra- deficient BALB/c mice develop 
spontaneous arthritis[130]. Zhou developed DBA/1 mice with a deficiency in IL-1ra, but 
found that the DBA/1 strain exhibits a resistance to arthritis [131]. The BALB/c and 
DBA/2 strains have the same MHC haplotype, but these two strains are genetically 
distanced from each other. The DBA/1 and C57BL/6J (B6) are susceptible to CIA, but 
CIA cannot be induced in BALB/c mice. It is well known that DBA/1 and B6 mouse 
strains have been widely used in CIA while BALB/c show resistance to CIA. SAD is 
dependent on non-MHC genes in BALB/c mice that lack IL-1ra. IL-deficient mice can be 
used to show the disease incidence of SAD in different mouse strains. Understanding the 
molecular mechanism that leads to SAD in IL-1rn-deficient mice will represent a 
breakthrough in the study of non-MHC-linked arthritis. Histopathological examination of 
the ankle joints of these mice revealed inflammatory cell infiltration and synovial 
proliferation in BALB/c-/-, but not in DBA/1-/- mice[132]. The bone structure and density 
are also changed in BALB/c-/-, but not in DBA/1-/- mice. BALB/c-/- mice are sensitive to 
nearly 100% incidence and high severity of arthritis at 7 weeks, but the DBA/1-/- mice are 
resistant to spontaneous arthritis until they are very old. BALB/c-/- mice develop 
spontaneous chronic inflammatory arthritis, whereas DBA/1-/- mice are resistant[97, 132].  
 
A classic genetic technique, whole genome linkage analysis was used to detect 
QTLs regulating the disease incidence and severity. Two different strains were used to 
obtain the F2 generation and the QTL differences were identified between the two 
parental strains[133]. F1 mice were created by intercrossing a resistant strain (DBA/1-/-) 
and a susceptible strain (BALB/c-/-) of spontaneous arthritis under IL-1ra deficiency. F2 
mice were used to map the QTL region that regulates IL-1ra deficient spontaneous 
arthritis. There are many QTL locations to be determined because spontaneous arthritis is 
a complex disease and is controlled by many genetic factors. Many pathways associated 
with IL-1ra are of importance. The whole-genome mapping shows the potential QTLs of 
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the disease are on chromosomes 1, 6, 11, 12 and 14. The QTL on chromosome 1 has a 
major genetic effect on spontaneous arthritis in F2 mice. The pathogenic genes are 
narrowed down within this QTL[133].  
 
The F2 generation was not only used to identify the QTLs, but also continued to 
generate two congenic mouse strains using BALB/c-/- and DBA/1-/- as the parental 
strains. These two congenic stains can help us to understand more of the molecular 
mechanisms with the parental strains[133]. Congenic strains are generated by transferring 
a DNA fragment from one genetic background to a specific inbred strain through 
repeated backcrossing. Backcrossing is a process where the mouse containing the donor 
allele is bred with the recipient inbred partner. Recipient inbreeds are inbred lines that 
provide the genetic background for the newly formed isogenic lines. The donor allele is 
the allele of interest. Subsequent hybridization is the backcross of the recipient's inbred 
line. Congenic strains are used because they differ by a specific chromosomal region. Our 
group developed a mouse DBA.B-1-/- congenic strain with a BALB/c-/- DNA fragment in 
the DBA/1-/- mouse background (by comparing the genetic markers, the genomic 
transferred region is between D1Mit400/506; chromosome 1, 163,306,348 bp to the distal 
end of the chromosome) and determined its susceptibility to spontaneous disease. But at a 
later point, the limbs of DBA.B-1-/- congenic mice can develop inflammation. Our group 
also developed a BALB.D-1-/- congenic mouse strain with a DBA/1-/- DNA fragment in 
the BALB/c-/- mouse background. By comparing genetic markers, the genomic 
transferred region is between D1Mit110 (chromosome 1, 167,758,517 bp) and D1Mit209 
(chromosome 1, 191,493284 bp) (Figure 2-2). At approximately eight weeks of age, 
limbs in BALB.D-1-/- congenic mice start to develop inflammation. The two congenic 
strains were relatively susceptible to spontaneous arthritis in varying degrees. BALB.D-1-
/- congenic mice delayed the onset and reduced the severity of disease compared to 
BALB/c-/-. Compared to congenic DBA.B-1-/- and DBA/1-/-, the incidence and severity in 
DBA.B-1-/- were higher than in DBA/1-/- mice[97, 131, 132, 134, 135]. 
 
Microarray gene expression analysis was used to analyze whole genome 
expression profiles. This technique has been used for more than a decade and is already 
very mature. This technology was used to compare the whole genome expression profiles 
between congenic BALB.D-1-/- and DBA.B-1-/- to the four other parental strains: 
BALB/c, DBA/1, DBA/1-/-, and BALB/c-/- IL-1ra deficient mice. The expression levels of 
the Ifi gene family had a similar change in all of the SAD susceptible mice. The Ifi gene 
family expression levels are correlated with the resistance or susceptibility to SAD[134]. 
The Ifi genes in BALB.D-1-/- are lower than in BALB/c-/-, and in DBA.B-1-/- they are 
higher than in DBA/1. The Ifi gene family is also in the QTL region on chromosome 
1[136]. The Ifi204 gene had the most different expression levels between the susceptible 
and resistant strains within the Ifi 200 family.  
 
The interferon-activatable 200 gene cluster is a family of interferons. Interferons 
(IFNs) are cytokines that regulate host resistance against infections by exerting 
antimicrobial, immunomodulatory and cell growth-regulatory functions. The biological 





Figure 2-2. Genomic region of the QTL on chromosome 1 and two congenic 
strains.  
The top part uses the F2 generation to represent the location on QTL mapping for arthritis 
that has been previously identified. Numbers on the top are the genetic distance along the 
chromosome. According to the genetic map, the QTL that regulate the SAD may be 
located in the region between 81cM and 100cM. The bottom part depicts the transferred 
genomic regions in the two congenic strains. Microsatellite markers are listed along the 
chromosome as molecular markers during the congenic breeding. Below the markers are 
the chromosomal components of the two congenic strains. Genomic components of 
BALB/c-/- are indicated by black boxes. While the genomic components of DBA/1-/- are 
indicated with red boxes. Congenic strain BALB.D1-1-/- contains a genomic region (red 
boxes) from DBA/1-/- into BALB/c-/- genomic background between D1Mit55 and 
D1Mit209.  In congenic strain DBA.B -1-/-, the genomic region from BALB/c-/- into 
DBA/1-/- strain is from D1Mit400/506 until the distal end. Based on the transferred 
genomic regions in these two congenic strains, the QTL is most likely within the region 





cluster) is encoded by several structurally related genes located on murine chromosome 1 
and three homologous genes (MNDA, IFI 16 and AIM2) located in the human 
chromosome, within a linkage group highly conserved between mouse and human. There 
are at least six members in the Ifi200 family, designated Ifi202a, Ifi202b, Ifi203, Ifi204, 
Ifi205, and Mndal. In human studies, IFI16 is connected to rheumatoid arthritis. The 
arthritis mouse models were used to study the Ifi200 gene cluster to better understand the 
arthritis diseases in humans. The Ifi204 gene is located from 173,747,293 to 173,766,943 
bp on Chromosome 1 in the genomic QTL region[137]. It has two transcripts, but only 
one can encode protein. The mRNA size of Ifi204 is 2302 bp and it consists of 9 
exons[138]. The Ifi204 gene encodes a 72 kDa polypeptide whose synthesis can be 
increased by treatment with IFN-α and β in several murine cell lines, with the sole 
exception of those derived from the B6 inbred strain[139]. The Ifi204 protein functions as 
a growth suppressor in sensitive cell lines, as determined by cell focus assays. Ifi204 is 
the most important interferon-activated gene in the Ifi200 cluster for the study of 
inflammation diseases in mice. The Ifi204 gene was sequenced between BALB/c-/- and 
DBA/1-/-strains, and it was shown that they had multiple polymorphisms between 
them[97, 140-143].  
 
 





BALB/c and DBA/1 wild-type mice were purchased from the Jackson Laboratory 
(Bar Harbor, ME). Animals that had an IL-1ra deficiency on the BALB/c background 
(BALB/c-/-) were initially provided by Dr. Yoichiro Iwakura (Tokyo Medical and Dental 
University, Tokyo, Japan)[130]. Animals that had an IL-1ra deficiency in the DBA/1 
background (DBA/1-/-) were generated at the University of Tennessee Health Science 
Center (UTHSC)[131]. We used congenic DBA.B-1-/- mice (BALB/c-/- fragment in 
DBA/1-/- background strain) and BALB.D-1-/- (DBA/1-/- fragment in BALB/c-/- 
background strain) mice. All mice were developed and bred in the Veterinary Medical 
Unit of the Memphis VA Medical Center. All experiments followed approved laboratory 
animal protocols and were approved by the VA Institutional Animal Care and Use 
Committee. 
 
 Arthritis disease phenotype BALB/c-/-, DBA/1-/-, BALB.D-1-/-, and DBA.B-1-/- 
mice were maintained in standard microisolator cages for 4 months. The severity of 
arthritis was graded on each ankle joint on a scale from 0 to 4 for the degree of redness 
and swelling on the left anterior limb, left posterior limb, right posterior limb, and right 
anterior limb, as viewed from behind the mice. The grades: 0 = no evidence of swelling, 
1 = mild swelling of the joint and/or redness of the footpad, 2 = obvious joint swelling, 3 
= severe swelling of the entirety, and 4 = limb burned out and deformed. The BALB/c 





Mouse Tissue Collection 
 
Mice were sacrificed and tissue samples collected when they were 4 months old 
and all tissues were stored separately in 1.5ml tubes. The heart, muscle, liver, spleen, 
lung, kidney, cerebrum, and cerebellum were put on dry ice immediately. One of the two 
legs was stored in RNAlater solution (Thermo Fisher, CA) at 4 °C for a few days. The 
other leg was stored in 70% ethanol in a 4 °C refrigerator. All the tissues except for the 
leg stored in 70% ethanol were stored in a -80 °C freezer for subsequent experiments.  
 
 
Analysis of Microarray Data 
 
Total RNAs were isolated from the spleen in three individuals from each group 
using the Trizol reagent (Invitrogen, CA) and purified using the RNAeasy Cleanup kit 
(Qiagen, CA). RNAs were quantified using NanoDrop-2000 (Thermo, DE) and quality 
was checked using the 2100 Bioanalyzer (Agilent, CA). The high-quality RNA was 
reverse transcribed to cDNA. Then, cDNA was transcribed to cRNA by using the 
Illumina® TotalPrep™ RNA Amplification Kit (Ambion, CA). For each strain, three 
individual mouse samples were pooled together. The Illumina mouse-6 v1.1 expression 
beadchips were used for the generation of whole genome expression profiles. Each chip 
well required 1.5 μg of cRNA sample. The beadchips were hybridized overnight in a 
multiple-step procedure according to the manufacturer's instructions. After washing and 
drying the chips, they were scanned on the BeadArray Reader (Illumina, CA). Raw data 
were analyzed using Illumina BeadStudio 2.3.41 (Illumina, CA).  
 
Raw data were normalized using BeadStudio software. The gene expression 
profiles of the two congenic strains were compared to the parental strains. The Diff Score 
from the quantile method is a proprietary algorithm that uses the bead standard deviation 
to build an error model; this used for the measurement of the significant difference in the 
expression levels of genes. The Diff Score was set up ± 10 at initial analysis to avoid 





50ng total RNA was used for TaqMan real-time PCR with the Ifi204 probe 
Mm00492602_m1. The TaqMan Real-Time PCR reactions were carried out with an ABI 
7900 Real-Time PCR System (software: Sequence Detection System 2.3 (ABI)) using 
ABI’s standard protocol for Real-Time PCR and PCR. Samples were normalized to 
GAPDH expression levels. Data for treatment groups are shown as ΔΔCT normalized to 









The expression levels of Ifi202b, Ifi203, Ifi204, Ifi205, and Mndal genes were 
confirmed by endpoint rt-PCR after being determined by microarray analysis (Table  
2-1). The genes expression levels were tested by using the spleen. Individual RNA 
samples were separately subjected to the assay. Reverse transcription (rt) and PCR were 
conducted using the One-step rt-PCR kit (Thermo Scientific, CA), as recommended by 
the manufacturer. Specific primers for selected genes are designed by Primer3. The rt-





All of the chromosomal regions of interest were sequenced. Ifi204 was identified 
between BALB/c-/- and DBA/1-/- mice. The primers were designed from Primer 3 online 
(http://bioinfo.ut.ee/primer3-0.4.0/). Products were amplified by PCR and rt-PCR. All of 
the PCR and rt-PCR products were cleaned by EXOSA-IT PCR CLEAN-UP 
PROTOCOL; 5 μl PCR or rt-PCR products and 2 μl ExoSAP-IT mix were incubated at 
37°C for 25 min, then at 80°C for 15min. 3 μl cleaned DNA samples, with 1 μl single 
primer and 8 μl water, was used for sequencing. Samples were loaded on ABI Model 
3130XL Genetic Analyzers (Thermo Fisher Scientific, CA). The data were analyzed by 





Splenocytes: Fresh spleen tissues were stored in 1 ml RPMI 1640, LX at RT when 
they were collected. Using a frosted-glass microscope slide, the spleen tissues were 
gently dissociated. Spleen cell suspensions were made by hemolysis with Gey’s solution 
(Gey’s stock solution: Stock A: 8.75 g NH4Cl, 0.46 g KCl, 0.27 g Na2HPO4·7H2O, 0.03 g 
KH2PO4, and 1.25 g glucose in 250 ml ddH2O; Stock B: 0.42 g MgCl2·6H2O, 0.14 g 
MgSO4·7H2O, and 0.45 g CaCl2·7H2O in 100 ml ddH2O; Stock C: 2.25 g NaHCO3 in 
100 ml ddH2O. Gey’s Working Solution: 20% stock A, 5% stock B, 5% stock C, and 
70% ddH2O). The cells were then filtered by 70 μm sterile cell strainer. Lastly, the cells 
were washed with PBS 3 times and stored in 200 μl PBS. Lymphocytes: Popliteal lymph 
nodes were collected from the outside of the thigh, between the skin and muscle. Cells 
were dissociated using the same technique employed for spleen tissues. 200 μl PBS was 
then added into the cells. Leukocytes: EL (erythrocyte lysis) buffer was used to eliminate 
erythrocytes and dead cells from the blood. Purified leukocytes were placed in 200 μl 
PBS. Fluorescently labeled antibodies specific for CD45 (APC-Cy7), CD3 (AlexaFluor 
700), CD4 (Pacific Blue), CD8 (PE), CD19 (peridinin chlorophyll-cyanine 5.5 [PerCP-
Cy5.5]), and CD25 (PerCP-Cy7) were obtained from BD Biosciences (San Jose, CA, 
USA). Intracellular staining for Foxp3 was performed using anti-mouse Foxp3 antibody 
labeled with FITC according to the manufacturer’s instructions (eBioscience, San Diego, 




Table 2-1. The Ifi202b, Ifi203, Ifi204, Ifi205, and Mndal cDNA designed primers. 
 
Name Forward-Primer Reverse-Primer Size(bp) 
Ifi202b-CD1 ccggtgtcattttcttacca ttggctctctgtagccactgt 480 
Ifi202b-CD2 agctgacacactctgccttg taggagcagcctctgacaca 538 
Ifi202b-CD3 tcaacagcagtggcatccta tcctcgaagaccatcactctg 544 
Ifi202b-CD4 taaaaagtaaaaagatgttccatgc tttcaccattgaattggggtta 550 
Ifi202b-CD5 attccagcgtgtctgaggtg ggaacttaagcatgcagactatga 550 
    
Ifi203-CD1 agtctccccaggaagacagc cctgaagtttctggaagctga 583 
Ifi203-CD2 caaacaagagtgtaccgtcttcaa actggaagattgtggcaagg 583 
Ifi203-CD3 agcaattccttcgagcagac cctggacattcttggatgct 596 
Ifi203-CD4 accatgcccagaaacatctc tgaaagccctggaatagcac 588 
Ifi203-CD5 tcatcaacagcatccagcag aaccaccactgccatttttc 603 
Ifi203-CD6 ctcacaagcaaaggggacat ggatagtgccaaaggcacac 577 
Ifi203-CD7 ttctaagaaatggtgctttctcat tcataagccttcttcatcttgc 572 
Ifi203-CD8 cggggcgtactattttcaac tgtaaacctgacaggatctgga 600 
Ifi203-CD9 aaacttcctcttgcacagca aatcattttcaaggttcatagcat 570 
Ifi203-CD10 tcacagtgcaccttccagag gaaagcaattgtgggcctta 556 
    
Ifi204-CD1 atgaacgaaactgggaggag aagttgttgctgagccttcc 272 
Ifi204-CD2 gcctacctactcaagccaagc cagtttgcccaatccagaat 300 
Ifi204-CD3 attctggattgggcaaactg cgccttgctctttttcactc 332 
Ifi204-CD4 gggacttctacagcccagaa ttgatctccaggatgccttt 449 
Ifi204-CD5 tgagccagtatttccatgtg ttccttagcaggctcctttg 496 
Ifi204-CD6 gcaaccaaagttagtgtgtgga actcacaaatgtcccccttg 436 
Ifi204-CD7 cctgtgtctctgatgtgaacg tctgtaattgaatcttatctccaca 462 
Ifi204-CD8 ggaagactcaccaatgtcagg gcataaaaattgcaaattgaaca 406 
    
Ifi205-CD1 ccccatttttcactttctcag ctgttgtgaaggacccacag 629 
Ifi205-CD2 cagcccagaaaaggaaaggt ccaccacttctatgcttcctg 657 
Ifi205-CD3 aggcatcctggagatcaatg tttttacagtagagaaatgaaatcaaa 624 
    
Mndal-CD1 tgtgtgtgtgtgtgtgtgctt cagtttttgcgatcgcttt 651 
Mndal-CD2 accgagaaggcaaaagttca gtattggtgactggcacctg 589 
Mndal-CD3 ccacccagcagttccttaaa ccactcccctccacttctat 680 
Mndal-CD4 ctttgagagcaaaggcatcc caaaatcagaaatcaggtatgaagg 557 
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Phenotype of Mice 
 
In the current study, DBA/1-/-, DBA.B-1-/-, BALB.D-1-/-, BALB/c-/-, DBA/1 wild-
type, and BALB/c wild-type mice were bred in the animal facility under the same 
conditions (Figure 2-3). The red arrows indicate the area around the ankle that is 
exhibiting signs of inflammation. The phenotypes of disease for DBA/1-/-, DBA.B-1-/-, 
BALB.D-1-/-, and BALB/c-/- were recorded. Mice were scored twice a week for the 
condition of the disease on each ankle joint, and the scores from each ankle were added 
together to calculate the cumulative clinical score for four months. The severity of 
arthritis in the strains is shown in Figure 2-4A, and incidences of disease are shown in 
Figure 2-4B. We knew that the phenotype of arthritic mice would be physically evident, 
therefore we began scoring the ankle joint of four strains of mice at 7 weeks of age so 
that we would not miss the beginning signs of arthritis. The DBA/1-/-, DBA.B-1-/-, 
BALB.D-1-/-, and BALB/c-/- mice were scored from 0 to 4 on each ankle joint following 
the literature. The mice were measured on day 35, 39, 42, 45, 49, 52, 56, 59, 63, 66, 70, 
73, 77, 80, 84, 87, 91, 94, 98, 101, 105, 108, 112, 115, 119, and 122.  BALB/c-/- and 
BALB.D-1-/- mice showed swelling and redness at the ankle joints, clear arthritic 
phenotypes on day 45; DBA.B-1-/- mice had mild swelling and inflammation on the hind 
ankle joints as early as 10 weeks, while DBA/1-/- mice had almost no change the whole 
time. These noticeable differences between the strains indicate that BALB/c-/- and 
BALB.D-1-/- had phenotypic traits of arthritis, DBA.B-1-/- had a mild presentation of the 
normal arthritic phenotype, and DBA/1-/- showed no phenotypic traits of arthritis. At the 
4th month, the scores for both genders of each strain were averaged; BALB/c-/- male and 
BALB/c-/- female scored 11.67 and 11.50; BALB.D-1-/- male and BALB.D-1-/- female 
scored 10.67 and 10.60; DBA.B-1-/- male and DBA.B-1-/- female scored 3.44 and 2.32; 
DBA/1-/- male and DBA/1-/- female scored 0.33 and 0.5. The males showed an earlier 
progression of severity. The incidences of disease in BALB/c-/- male, BALB/c-/- female, 
BALB.D-1-/- male, BALB.D-1-/- female, DBA.B-1-/- male, DBA.B-1-/- female, DBA/1-/- 
male, and DBA/1-/- female was 100%, 100%, 100%, 100%, 86%, 67%, 33%, and 50%, 
respectively, when they were 4 months old. These data, together with the visual changes 
noted above, suggest that DBA/1-/- is resistant to arthritis, and that a lack of IL-1ra leads 
to resistance as well. Introduction of the BALB/c-/- gene region into DBA.B-1-/- results in 
a mild arthritis phenotype; BALB/c-/- and BALB.D-1-/- both have the disease. The organs 
were weighed when we sacrificed them at 4 months of age (Table 2-2). In the four 
strains, the males were larger than the females. Most organ weights were similar in all 
four strains, but the spleens in females and males of BALB/c-/-, 0.1412 g and 0.1471 g 
respectively, were larger than the other three strains. The spleen of the male DBA/1-/- was 
0.1439 g, but the spleens of the other strains, besides BALB/c-/-, were ~0.11-0.12 g. The 





Figure 2-3. The phenotype of DBA/1-/-, DBA.B-1-/-, BALB.D-1-/-, and BALB/c-/- 
strains. 
Four strains of mice were bred in the UTHSC animal facility under the same conditions. 
The red arrows indicate the hind ankle joints. The ankle joints from hind limbs in the 
BALB/c-/- and BALB.D-1-/- strains have very severe swelling and redness at 4 months of 
age. The DBA.B-1-/- mice have mild inflammation when they are 4 months of age. The 






Figure 2-4. Arthritis relative severity and incidence in male and female BALB/c-/-, 
DBA/1-/-, BALB.D-1-/-, and DBA.B-1-/- mice. 
(A) The severity of joint arthritis in both genders of four strains. The days are listed 
below the horizontal axis and the severity scores are listed to the left of the vertical axis. 
The BALB/c-/- mice reach maximum levels of disease severity earlier than the other 
strains. The congenic BALB.D-1-/- have severe swelling and redness, but later and with 
less severity than BALB/c-/- mice. BALB.D-1-/- have a later and less severe onset as a 
result of the fragment of DBA/1-/- DNA. The DBA.B-1-/- mice begin to have mild arthritis 
when they are ten weeks old. The severity of arthritis slowly increased over time until the 
end, when it was higher. The males showed quicker progression of severity among these 
three strains. The DBA/1-/- mice have almost no arthritis the entire time (n＞6).  (B) The 
incidence of ankle joint inflammation in the BALB/c-/-, DBA/1-/-, BALB.D-1-/-, and 
DBA.B-1-/- mice. The days are listed below the horizontal axis and the incidences are 
listed to the left of the vertical axis. The BALB/c-/- and BALB.D-1-/- mice have 100% 
incidence at a very early stage. At nine weeks DBA.B-1-/- mice began to have incidence 
of disease. DBA/1-/- showed incidence around thirteen weeks. The incidence in DBA/1-/- 
is skewed because scoring one mouse as having swelling or redness can change the 
incidence rate by a great deal. The DBA/1-/- and DBA.B-1-/- mice have lower percentages 
than the BALB/c-/- and BALB.D-1-/- mice (n＞6).  
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strains. The weights of the other organs show no major differences. These data were 
interpreted to mean that arthritis or IL-1ra was not causing the change in the spleen 
weight, thus we do not know the reason for heavier spleen than that of other strains. 
 
 
Expression Profile Among Different Strains 
 
DBA.B-1-/- contains a genomic fragment from BALB/c-/- on a DBA/1-/- 
background. Through biomarker testing, we know that it is located somewhere between 
marker D1Mit506 and the distal end on chromosome 1. BALB.D-1-/- contains a genomic 
fragment from DBA/1-/- on a BALB/c-/- background. Through biomarker testing, we know 
that it is located between markers D1Mit55 and D1Mit426 on chromosome 1. The whole 
genome gene expression similarities were compared between the two congenic mice 
(DBA.B-1-/- and BALB.D-1-/-) and their parental mice (BALB/c, DBA/1, DBA/1-/-, and 
BALB/c-/-) by using the mouse-6 v1.1 expression beadchip from the Illumina. The 
beadchip includes 30774 probes that cover 29940 mouse genes. The R (correlation) of 
expression levels of probes between DBA.B-1-/- and BALB.D-1-/- was 0.9895. (Figure  
2-5A, B). The expression levels of both DBA.B-1-/- and BALB.D-1-/- were highly 
correlated to that of DBA/1-/-, while DBA.B-1-/- showed more correlation than that of 
BALB.D-1-/-. Because DBA.B-1-/- was deficient in IL-1ra and under the genomic 
background of DBA/1-/-, its expression profile was more similar to DBA/1-/- than to any 
other strain. Surprisingly, the similarity between DBA.B-1-/- and DBA/1 was less than 
that between DBA.B-1 and BALB/c and BALB/c-/-, implying the possibility that the QTL 
fragment from BALB/c makes the gene expression profiles of the DBA.B-1-/- similar to 
that of BALB/c[97]. 
 
 
Gene Expression Profiling Between BALB.D-1-/- and DBA/1 Wild Type 
 
Greater than 97% of all genes expressed by BALB.D-1-/- and DBA/1 wild type 
mice showed similar expression levels. All gene expression levels were also identified in 
the QTL region, and the expressions were at similar levels in the two strains. There were 
264 probes down-regulated and 472 probes up-regulated in BALB.D-1-/- compared with 
the expression levels of DBA/1 wild type (Figure 2-6A, B). There were 344 known 
genes in these 472 up-regulated probes. By comparing the known genes in the probes 
with the expression levels of DBA/1 wild type by searching on PGMapper, sixty-one out 
of the 344 known genes were shown to be associated with arthritis. The Darc and Fcgr4 
were located in the QTL regions. There were 189 known genes in the 264 down regulated 
probes. Of these known genes, twenty-six genes were classified as arthritis related genes 
by PGMapper. Three genes, Kmo, Fcr1a, and Ephx1, were within the QTL regions. 
GeneNetwork was used to analyze the correlation of the sixty-one up-regulated genes, 
twenty-six down-regulated genes, and the interleukin family with the UTHSC Affy 
MoGene 1.0 ST spleen program. For all of these up- and down-regulated genes, no strong 
correlation between these genes and the IL-1 family was found. Therefore, there was no 
candidate gene that could increase the resistance to SAD, as revealed through differential 





Figure 2-5. Correlation of whole genome gene expression levels between DBA.B-1-
/-, BALB.D-1-/-, and their four parental strains.  
(A) Similarity between two congenic mice DBA.B-1-/- and BALB.D-1-/-. The similarity 
between the two strains is 98.95%. (B) Comparison of the similarities between the two 
congenic strains and their four parental strains.  Strain names are listed under their 
respective bars on the horizontal axis. R values are listed to the left of the vertical axis. 
The gene expression profile of DBA/1 wild type has the lowest similarity with both 
congenic mice, while DBA/1-/-, which has a mutation of IL-1rn and is under the DBA/1 
genomic background, has the highest similarity to both congenic strains. The BALB.D-1-
/- has more similarity with BALB/c background mice (BALB/c wild type and BALB/c-/-) 






Figure 2-6. Up and down regulated genes in BALB.D-1-/- mice in comparison to 
that of DBA/1 wild type mice.  
(A) Downregulated genes in BALB.D-1-/- mice compared with DBA/1 wild type. The 
gene names are shown below the horizontal axis. Numbers to the left of the vertical axis 
are the fold changes. There are 264 probes downregulated and 189 of them are known 
genes. Twenty-six of them are related to arthritis and three of them (Kmo, Fcr1a, and 
Ephx1) are on QTL region. (B) Upregulated genes in BALB.D-1-/- mice compared with 
DBA/1 wild type. The gene names are shown below the horizontal axis. Numbers to the 
left of the vertical axis are the fold changes. There are 472 probes upregulated and 344 of 
them are known genes. Sixty-one of them are related to arthritis and two of them (Darc 




Gene Expression Profiling Between BALB.D-1-/- and DBA/1-/- 
 
There was approximately 99% similarity between BALB.D-1-/- and DBA/1-/- 
mice.  Both lack the IL-1rn gene. The gene expression levels in BALB.D-1-/- and DBA/1-
/- showed more similarities compared to BALB.D-1-/- and DBA/1 wide type mice. There 
were 241 probes down-regulated and 310 probes up-regulated in BALB.D-1-/- (Figure  
2-7A, B). 235 of the 310 up-regulated probes were known genes. From PGMapper, forty-
three known genes were related to arthritis. There were 212 known genes in the 242 
down-regulated probes. Twenty-nine of these known genes were related to arthritis 
according to PGMapper. Forty-three upregulated and twenty-nine downregulated probes 
and IL-1rn family genes were identified using the UTHSC Affy MoGene 1.0 ST Spleen 
program. BALB.D-1-/- compared with DBA/1-/- was very similar to the DBA wild type 
mice. There were none directly related to the IL-1 family. 
 
After eliminating duplicate probes, there were 101 probes left to analyze. Similar 
to the DBA wild type mice, the data analysis of the gene network showed no strong 
correlation between these genes and the IL-1rn family. Thus, there was no candidate gene 
to account for the increased susceptibility to SAD.  
 
 
Gene Expression Profiling Between BALB.D-1-/- and BALB/c Wild Type 
 
Between the BALB.D-1-/- and BALB/c wild type mice, the similarity between 
them were around 98.8%. There were seventy probes up-regulated and thirty-one probes 
down-regulated (Figure 2-8A, B). Among the seventy up-regulated probes, all were from 
known genes and among the thirty-one down-regulated probes, thirty were from known 
genes. In these changing genes, Siglec1 was only one associated with arthritis. Ifi202b 
was one of the up-regulated genes and was found in the QTL region. Ifi203 was one of 
the down-regulated genes and was also located in this QTL region. In these ninety-two up 
and down regulated probes, there was no correlation to the Interleukin-1 family by 




Gene Expression Profiling Between BALB.D-1-/- and BALB/c-/- 
 
The similarity between BALB.D-1-/- and BALB/c-/- was 99%. There were twelve 
down-regulated probes and no up-regulated probes. Eight of the twelve down-regulated 
probes were known genes (Figure 2-9). These nine genes are LOC100040462 (Mndal), 
LOC639001, Ifi203, LOC665425, Lefty1, Trbc6, LOC638301, Ifi204, and Ifi202b. There 
was no relationship between these genes and arthritis using PGMapper. The Ifi202b, 
Ifi203, Ifi204, Mndal, and Lefty1 genes are located in the QTL region on chromosome 1. 
In comparing these genes with the IL-1 family, there is no strong correlation between the 
IL-1rn and the interferon-activatable protein family members. Searching the genetic 






Figure 2-7. Up and down regulated genes in BALB.D-1-/- mice in comparison to 
that of DBA/1-/- mice. 
(A) Downregulated genes in BALB.D-1-/- mice compared with DBA/1-/-. The gene 
names are shown below the horizontal axis. Numbers to the left of the vertical axis are 
the fold changes. There are 241 probes downregulated and 212 of them are known genes. 
Twenty-nine of them are related to arthritis. (B) Upregulated genes in BALB.D-1-/- mice 
compared with DBA/1-/-. The gene names are shown below the horizontal axis. Numbers 
to the left of the vertical axis are the fold changes. There are 310 probes upregulated and 






Figure 2-8. Up and down regulated genes in BALB.D-1-/- mice in comparison to 
that of BALB/c wild type mice. 
(A) Downregulated genes in BALB.D-1-/- mice compared with BALB/c wild type. The 
gene names are shown below the horizontal axis. Numbers to the left of the vertical axis 
are the fold changes. There are thirty-one probes downregulated and thirty of them are 
known genes. None of them are related to arthritis. (B) Upregulated genes in BALB.D-1-/- 
mice compared with the BALB/c wild type. The gene names are shown below the 
horizontal axis. Numbers to the left of the vertical axis are the fold changes. There are 
seventy probes upregulated and all of them are known genes. Only one of them (Siglec1) 
is related to arthritis. Ifi202b is one of the upregulated genes and Ifi203 is one of the 






Figure 2-9. Down regulated genes in BALB.D-1-/- mice in comparison to that of 
BALB/c-/- mice. 
There are twelve probes downregulated and no probes upregulated when BALB.D-1-/- is 
compared with BALB/c-/- mice. The gene names are shown below the horizontal axis. 
Numbers to the left of the vertical axis are the fold changes. There are twelve probes 
downregulated and nine of them are known genes. None of them are related to arthritis, 
but there are five of them (Ifi202b, Ifi203, Ifi204, Mndal, and Lefty1) that are located in 




region, but the T-cell receptor beta chain gene was positively associated with the Ifi 
family. The location of Ifi202b, Ifi203, Ifi204, Mndal, and Lefty1 genes in the QTL 
region indicate that these could be the candidate genes. 
 
 
Gene Expression Profiling Between DBA.B-1-/- and DBA/1 Wild Type 
 
Comparing DBA.B-1-/- to DBA/1 wild type mice, there was around 97% 
similarity between DBA.B-1-/- and DBA/1 wild type. Compared to the expression levels 
of DBA/1 wild type, there were 255 up-regulated probes and thirty-six down-regulated 
probes in DBA.B-1-/-(Figure 2-10A, B).  From these probes, 194 of 255 up-regulated 
probes were known genes and twenty-eight of thirty-six down-regulated probes were 
known genes. The data of DBA.B-1-/- and its parental strain were very different from 
BALB.D1-1-/- and its parental strain, where the number of down regulated genes was 
much larger than that of up-regulated genes. Forty of the up-regulated probes were 
located on chromosome 1 and five of them are within the transferred genomic region. 
They are:  Dermatopontin (dpt); Integrator complex subunit 7 (ints7); CDNA sequence 
BC055324 (bc055324); Interferon activated gene 203 (Ifi203); and Fc receptor, IgG, low 
affinity IV (fcgr4). By searching PubMed using PGMapper, there was only the HtrA 
serine peptidase 1 (htra1) down-regulated gene related to arthritis, but this gene was on 
chromosome 7. There were no genes located in the QTL region. 
 
 
Gene Expression Profiling Between DBA.B-1-/- and BALB/c Wild Type 
 
Between the DBA.B-1-/- and BALB/c wild type mice, the similarity was more 
than 97.5%. There were 305 probes with down-regulated expression levels and 336 
probes with up-regulated expression levels when DBA.B-1-/- was compared with BALB/c 
wild type mice (Figure 2-11A, B). The number of up and down regulated genes were 
many greater than that found in BALB.D1-1-/- when it was compared to BALB/c.  These 
data are reasonable considering the fact that DBA.B-1-/- is under the background of a 
different genome. 164 of 336 up-regulated probes were known genes in DBA.B-1-/-, and 
seventy-one of them were reported as relevant to arthritis by PGMapper. Ten genes were 
located on chromosome 1; however, only one gene, Epoxide hydrolase 1 (ephx1), was 
located in the QTL region. In these 305 down-regulated probes, there were 214 known 
genes. Fifty of these known genes were relevant to arthritis according to PGMapper. 
Eleven genes were on chromosome 1 and three of them were located within the QTL 
region. They were Olfactomedin-like 2B (olfml2b), Selectin platelet (selp), and Low 
affinity immunoglobulin gamma Fc region receptor IV (fcgr4). 
 
These four genes on QTL, along with IL-1rn family genes were analyzed for their 
gene correlation using the same whole genome expression profiles of spleen used above 
for DBA/1. One probe was found for each of the twelve genes. GeneNetwork indicated 
that the expression levels of all four genes are positively correlated with the expression 






Figure 2-10.  Up and down regulated genes in DBA.B-1-/- mice in comparison to 
that of DBA/1 wild type mice. 
(A) Downregulated genes in DBA.D-1-/- mice compared with DBA/1 wild type. The gene 
names are shown below the horizontal axis. Numbers to the left of the vertical axis are 
the fold changes. There are thirty-six probes downregulated and twenty-eight of them are 
known genes. One of them (htra1) is related to arthritis. (B) Upregulated genes in 
DBA.D-1-/- mice compared with DBA/1 wild type. The gene names are shown below the 
horizontal axis. Numbers to the left of the vertical axis are the fold changes. There are 
255 probes upregulated and 194 of them are known genes. Forty of them are related to 






Figure 2-11. Up and down regulated genes in DBA.B-1-/- mice in comparison to that 
of BALB/c wild type mice. 
(A) Downregulated genes in DBA.D-1-/- mice compared with BALB/c wild type. The 
gene names are shown below the horizontal axis. Numbers to the left of the vertical axis 
are the fold changes. There are 305 probes downregulated and 214 of them are known 
genes. Fifty of them are related to arthritis. There are eleven genes on chromosome 1 and 
three of them (olfml2b, selp, and fcgr4) are in the QTL region. (B) Upregulated genes in 
DBA.D-1-/- mice compared with BALB/c wild type. The gene names are shown below 
the horizontal axis. Numbers to the left of the vertical axis are the fold changes. There are 
336 probes upregulated and 164 of them are known genes. Seventy-one of them are 
related to arthritis. There are ten genes on chromosome 1 and only one of them (ephx1) is 




Gene Expression Profiling Between DBA.B-1-/- and BALB/c-/- 
 
The similarity of DBA.B-1-/- and BALB/c-/- mice was around 98%. In expression 
levels, there were 231 probes down-regulated and 158 probes up-regulated when DBA.B-
1-/- was compared with BALB/c-/- (Figure 2-12A, B).  
 
There were 153 known genes in these 231 down-regulated probes. Thirty-three of 
those known genes were connected to arthritis by using the PGMapper. Among the 158 
up-regulated genes, 109 were known genes. Twenty-seven of these genes were arthritis-
relevant. However, none of these up or down-regulated genes are located in the QTL 
region on chromosome 1. This result is significantly different from the data which 
compared BALB.D-1-/- to BALB/c-/-, where only a few genes, mainly Ifi family members, 
were down regulated in BALB.D1-1-/-.   Probes for Ifi204, Ifi205, and Fcgr4 were 
identified from the spleen genome expression profile. They were used to construct a gene 
network with genes of the IL-1rn family. The gene network indicated that Ifi204 and 
Ifi205 are weakly positively correlated to the genes of the IL-1rn family while hsph1 is 
not. None of these genes have a relationship to arthritis. Among these differentially 
expressed genes, the Ifi cluster is located within the transferred QTL genomic region. 
 
 
Gene Expression Profiling Between DBA.B-1-/- and DBA/1-/- 
 
There was about 97% similarity between DBA.B-1-/- and DBA/1-/-; both of them 
lack the IL-1rn gene. Comparing the expression levels of DBA.B-1-/- to DBA/1-/-, there 
were only three down-regulated probes and five up-regulated probes (Figure 2-13). In 
these three down-regulated genes, one was heat shock 105kDa/110kDa (hsp105/110hDa). 
Another one was immunoglobulin kappa variable 2-112 (Igkc2-112). There was no useful 
information about the third one. In the five up-regulated genes, three of them are for 
interferon-activatable proteins (Ifi). LOC100040462 is a predicted new gene for 
interferon-activatable proteins called myeloid nuclear differentiation antigen like 
(Mndal). LOC100044430 is predicted as Ifi205, and LOC638301 is predicted as Ifi204, 
because the probes and the genes have the same sequence. The Ifi family genes had a 




Interferon-activatable Protein Gene Expression Levels in BALB.D-1-/- and  
DBA.B-1-/- Compared with the Four Parental Strains 
 
Ifi gene expression levels of the BALB.D-1-/- strain were compared with the four 
parental strains. The Ifi gene family expression levels in the BALB.D-1-/- strain were 
lower than BALB/c-/- and BALB/c, but there was no significant difference between the 
other two strains, DBA/1-/- and DBA/1 (Figure 2-14A). A lower expression level in the 
candidate genes would be expected because BALB.D-1-/- has the genetic fragment from 
DBA/1-/-. The differences in expression levels of the Ifi family genes between DBA.B-1-/- 





Figure 2-12. Up and down regulated genes in DBA.B-1-/- mice in comparison to that 
of BALB/c-/- mice. 
(A) Downregulated genes in DBA.D-1-/- mice compared with BALB/c-/-. The gene 
names are shown below the horizontal axis. Numbers to the left of the vertical axis are 
the fold changes. There are 231 probes downregulated and 153 of them are known genes. 
Thirty-three of them are related to arthritis. None of them is in the QTL region on 
chromosome 1. (B) Upregulated genes in DBA.D-1-/- mice compared with BALB/c wild 
type. The gene names are shown below the horizontal axis. Numbers to the left of the 
vertical axis are the fold changes. There are 158 probes upregulated and 109 of them are 
known genes. Twenty-seven of them are related to arthritis. None of them is in the QTL 






Figure 2-13. Up and down regulated genes in DBA.B-1-/- mice in comparison to that 
of DBA/1-/- mice.  
Up- and downregulated genes in DBA.D-1-/- mice compared with DBA/1-/-. The gene 
names are shown below the horizontal axis. Numbers to the left of the vertical axis are 
the fold change. There are only 3 downregulated probes and 5 upregulated probes. Two 
of the downregulated genes (hsp105/110hDa and igk2-112) are known. Three of the 






Figure 2-14. Gene expression levels of Ifi family congenic strain BALB.D-1-/- and 
DBA.B-1-/- in comparison with four parental strains. 
(A) Ifi family gene expression in BALB.D-1-/- compared with four other strains. The 
strains are shown below the horizontal axis. Numbers to the left of the vertical axis are 
the fold changes. Ifi protein, Ifi202b, Ifi203, Ifi204, and Ifi205 expression levels in 
BALB.D-1-/- are downregulated in comparison with that of BALB-/- and BALB/c (except 
the Ifi202b is upregulated when BALB.D-1-/- is compared with BALB/c), but no 
significant difference compared to the other two strains, DBA/1-/- and DBA/1. (B) Ifi 
family gene expression in DBA.B-1-/- compared with four parental strains. The strains are 
shown below the horizontal axis. Numbers to the left of the vertical axis are the fold 
change. Ifi protein gene expression was similar to-Ifi204, and similar to Ifi205; 
expression levels in DBA.B-1-/- are upregulated in comparison with that of DBA/1-/- and 
DBA/1, but no significant difference in comparison to the other two strains, BALB-/- and 




significant difference between any of the genes when comparing with BALB/c and 
BALB/c-/- because DBA.B-1-/- has the genetic fragment from BALB/c-/- that contains the 
Ifi family genes (Figure 2-14B). DBA.B-1-/- has higher expression levels of Ifi204 in 
comparison to DBA/1-/- and DBA/1 because it has the genetic fragment from BALB/c-/-.  
 
 
The Potential Involvement of Interferon-activatable Protein Genes in the Regulation 
of Susceptibility to SAD 
 
DBA/1-/- is resistant to SAD, whereas BALB/c-/- is susceptible to SAD. The 
increase in expression levels of the Ifi family genes in the DBA.B-1-/- strain resulted in a 
decrease in resistance to arthritis compared to DBA/1-/- mice. The decreased Ifi family 
gene expression levels in the BALB.D-1-/- strain also showed increased resistance 
compared to the BALB/c-/- mice. Our multiple comparisons confirmed that the increased 
Ifi gene cluster expression levels in DBA.B-1-/- constitute the major change that 
potentially leads to increased susceptibility to SAD, and the conversely – decreased Ifi 
gene cluster expression levels in BALB.D-1-/- – constitute the major change that 
potentially leads to increased resistance to SAD. The BALB/c and BALB/c-/- (susceptible 
to SAD) strains had higher Ifi gene expression levels than the DBA/1 and DBA/1-/- strains 
(resistant to SAD). Based on gene expression levels and QTL analysis, the Ifi200 gene 
family was determined to be our candidate gene family for SAD. Among differentially 
expressed genes between congenic strains and parental strains, three genes in the Ifi 
family cluster were differentially expressed and are located in the transferred genomic 
fragments in the congenic strains. These genes are in the QTL genomic fragment on 
chromosome 1, which is found between 173,747,293 (Ifi204) bp and 174,031,810 
(Ifi205) bp. The transferred region from BALB/c-/- to DBA/1-/- background in the 
congenic DBA.B-1 strain is from 163,306,348bp (D1mit506) to the distal end of 
chromosome 1. The transferred region contains several hundreds of genes and other 
genetic elements. None of the probes of other genes showed a significant change in the 
expression level between DBA.B-1 and DBA/1-/-, while three probes of the Ifi family 
were upregulated in DBA.B-1-/-. Research has shown that interferon-activatable protein is 
an immune suppressor in viral infection[97, 128].    
 
 
The Ifi204 as the Most Favorable Candidate Gene for SAD 
 
The Ifi200 genes are located next to each other and are known to be located in the 
identified QTL region. Rnpep is located outside of the QTL, therefore, it is eliminated as 
a candidate for SAD. Lefty1 is within the QTL, but there is no indication of it having a 
role in arthritis. In comparison to Ifi200 genes, Lefty1 is of a lower priority.  
 
In order to explore whether all of the genes in Ifi200 or one or two other genes 
regulate SAD, we examined the expression levels of these genes in congenic DBA.B-1-/-  
and DBA/1-/- strains (Figure 2-15A). To our surprise, among these genes, only the 
expression levels of Ifi204 were at meaningful levels. The other genes were detected at 





Figure 2-15. Comparison of expression levels of genes in Ifi family. 
(A) Relative expression levels of Ifi family genes compared between DBA.B-1-/- and 
DBA/1-/-. The gene names are shown below the horizontal axis. Numbers to the left of the 
vertical axis are the scores of relative expression. Ifi202b gene expression in DBA.B-1-/- 
is lower than DBA/1-/-. Ifi204 and Ifi205 gene expressions are similar between DBA.B-1-
/- and DBA/1-/-. Ifi203, LOC100044430-Ifi205, and LOC638301-Ifi204 gene expressions 
in DBA.B-1-/- are higher than in DBA/1-/-. Ifi204 gene expression is twice as high in 
DBA.B-1-/- than in DBA/1-/-. (B) Relative expression levels of Ifi family genes compared 
between DBA.B-1-/- and DBA/1-/-. The gene names are shown below the horizontal axis. 
Numbers to the left of the vertical axis are the scores of relative expression. Ifi202b gene 
expression in BALB.D-1-/- is higher than in BALB/c-/-. Ifi204 and Ifi205 gene 
expressions are similar between BALB.D-1-/- and BALB/c-/-. Ifi203, LOC100044430-





further examined the expression levels of these genes in congenic BALB.D1-1-/- and 
BALB/c-/- strains (Figure 2-15B). Among these genes, only the expression of Ifi204 was 
at a meaningful level. The other genes were detected at very low levels. In order to 
answer the question concerning whether it is possible that the low expression levels of 
other Ifi cluster genes are the results of cross hybridization among genes in the Ifi200 
cluster, we compared the sequences of the probe of Ifi204 with the sequences from other 
genes in the Ifi200 cluster. Our blast search showed a high similarity of genes among the 
Ifi200 cluster[97].  
 
 
The Potential Connection Between Ifi204 and Differentially Expressed Genes within 
QTL Regions and Arthritis Relevant Genes 
 
By comparing congenic to parental strains, we identified differential genes within 
QTL regions and genes that are relevant to arthritis. Our final question was, what was the 
relationship between Ifi204 and these differentially expressed genes? Any potential 
association was explored between Ifi204 and these genes. The genes being compared 
were Dpt, Ints, bc055324, fcgr4, and htra1 from the comparison between DBA.B-1-/- and 
DBA/1 wild type; ephx1, olfml2b, selp, and fcgr4 from the comparison between DBA.B-
1-/- and BALB/c wild type; Fcgr4 and Ifi205, from the comparison between DBA.B-1-/- 
and BALB/c-/-; hsp105/110hDa, Igkc2-112, and Mndal from the comparison between 
DBA.B-1-/- and DBA/1-/-.  
 
A graphic gene network created using the literature was made, based on gene 
expression levels. The expression level of Ifi204 is only weakly positively connected to 
that of Fcgr4, with an R value of 0.405, suggesting that the expression level of this gene 
is not strongly influenced by Ifi204 (Figure 2-16A). This network indicated that the 
majority of these genes were studied or were reported with Ifi204, suggesting that their 
functions are potentially connected to that of Ifi204 (Figure 2-16B). In particular, Htra1 
was linked to arthritis through the destruction of the extracellular matrix causing a 
degradation in cartilage[144]. As seen in the figure, Htra1 is strongly connected to Dpt 
with a very high positive correlation value, and two of them were found to both be highly 
enriched in hip cartilage[145]. Htra1 and Dpt are also connected to Ifi204 with a high 
positive correlation value, as seen in figure 2-16B. This suggests that Dpt may play an 
important role in the development of arthritis. Both Htra1 and Dpt may be involved in the 
Ifi204 molecular pathway[97]. 
 
 
The Sequence of the Genes in BALB/c-/- and DBA/1-/- 
 
From gene mapping and microarray data, the number of candidate genes were 
narrowed. We focused on the Ifi cluster on chromosome 1 between 173,680,000 to 
174,100,000 bp to identify the differences in Ifi202b, Ifi203, Ifi204, Ifi205, and Mndal 
genes between BALB/c-/- and DBA/1-/- strains (Figure 2-17, Table 2-3). RNA sequencing 
was used to reduce the genomic interval. Each gene was searched online and known each 





Figure 2-16. Graphic gene network between Ifi204 and genes within the QTL 
region and genes relevant to the immune system.  
(A)  Graphic gene network based on expression correlations. The 18 nodes in the graph 
show the selected traits below. All nodes are displayed. The 14 edges between the nodes 
are shown, filtered from the 153 total edges. (B) Graphic network based on literature 
reports. The 18 nodes in the graph show the selected traits below. The 33 edges between 
the nodes are shown, filtered from the 153 total edges and drawn as curves, showing 





Figure 2-17. Ifi200 cluster is located on chromosome 1 between in 173.7Mb and 
174.1Mb.  
The Ifi200 gene cluster is located on chromosome 1 in a genomic region of a QTL for 
non-MHC arthritis. This is the same position for Ifi204, Mndal, Ifi203, Ifi202b, and 
Ifi205 genes on chromosome 1.  
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Ifi202b gene had one transcript; the size of the gene was 1659 bp and the protein size was 
445 aa. It had one consensus CDS, CCDS35794. Ifi203 had nine transcripts. All of them 
had different gene sizes, but only five of them could encode proteins. The Ifi203-201 
gene transcript size was 3754 bp and the protein size was 445 aa; the Ifi203-202 gene 
transcript size was 3610 bp and the protein size was 409 aa; the Ifi203-209 gene 
transcript size was 3605 bps and the protein size was 457 aa; the Ifi203-203 gene 
transcript size was 3482 bp and the protein size was 409 aa; the Ifi203-205 transcript size 
was 3054 bp and the protein size was 871 aa. These five transcripts had CCDSes and the 
rest of the four transcripts did not encode proteins. The Ifi205 gene had two transcripts. 
Only the Ifi205-201 transcript could be translated to a protein (404 aa) and the gene size 
was 2296 bp. The Mndal gene had 10 transcripts, but only 5 could translate to protein. 
The Mndal-204 transcript size was 2026 bp and the protein size was 538 aa; the Mndal-
201 transcript size was 1907 bp and the protein size was 538 aa; the Mndal-202 transcript 
size was 1646 bp and the protein size was 485 aa; the Mndal-208 transcript size was 762 
bp and the protein size was 184 aa; the Mndal-207 transcript size was 931 bp and the 
protein size was 129 aa. The rest of the transcripts could not translate proteins. Ifi204 had 
two transcripts, but only one could translate a protein. The Ifi204-201 gene transcript was 
2296 bp and the protein size was 619 aa. Its consensus CDS ID was CCDS35792 (Figure 
2-18). Ifi204-201 gene was sequenced and found several different polymorphisms 
between BALB/c-/- and DBA/1-/-. At 292 bp and 293 bp, DBA/1-/- was AA and BALB/c-/- 
was TG; at 197 bp, DBA/1-/- was G and BALB/c-/- was C; at 190 bp DBA/1-/- was T and 
BALB/c-/- was G. The Ifi 204 protein structure changed between BALB/c-/- and DBA/1-/- 
(Figure 2-19).  The change from AA to TG changed the amino acid from lysine to 
methionine.  The T to C change changed the amino acid from tyrosine to histidine. The G 
to C change made the amino acid change from serine to threonine. The fourth 
polymorphism amino acid change could not be determined because the nucleotide 
sequence was unclear. The Ifi 204 protein structure is likely to be different as encoded by 
BALB/c-/- versus DBA/1-/- because of these amino acid changes. 
 
 
The Ifi204 Expression Levels in Different Strains 
 
Ifi204 gene expression levels were obtained from 4-month old DBA/1-/-, DBA.B-
1-/-, BALB.D-1-/-, and BALB/c-/-, DBA/1 wild type and BALB/c wild type male and 
female mice (Figure 2-20). In both DBA/1 and BALB/c wild type mice, the Ifi204 
expression levels of females were lower than that observed in males. In DBA/1-/- and 
BALB/c-/- strains, there were contrasting expression levels among each gender. In the 
DBA/1-/- strain, the expression levels in females were higher than that of males, but male 
expression levels were higher than that of females in the BALB/c-/- strain. In the congenic 
strains, the expression levels in males were higher than that observed in females in the 
DBA.B-1-/- strain, and females were found to have higher expression than males in the 
BALB.D-1-/- strain. Between the two congenic strains, males and females did not have 
any significant difference, so we could not use these data for analysis. The data from real-
time PCR and microarray had differences indicating that the two experiments used 
different loci to test. In the DBA/1 background, there were contrasting expression levels 





Figure 2-18. Ifi204 gene sequencing and designed primers on cDNA. 
Eight pairs of primers are designed in Ifi204. Each color represents a pair of primers. The 
primers overlapped each other, so there is no missing nucleotide between the first and last 






Figure 2-19. BALB/c-/- and DBA/1-/- have multiple polymorphisms on Ifi204 gene 
sequencing. 
The Ifi204 gene sequence in DBA/1-/- strain is shown on the top, and the bottom 
representation is the BALB/c-/- strain. Comparing the sequences in these two strains, there 
are several polymorphisms on the gene, causing the protein structure to be changed. (A) 
At 292 bp and 293 bp, DBA/1-/- was AA and BALB/c-/- was TG, the amino acid changed 
from Lys to Met; (B) at 190 bp DBA/1-/- was T and BALB/c-/- was C, the amino acid 
changed from Tyr to His; (C) at 197 bp, DBA/1-/- was G and BALB/c-/- was C, the amino 






Figure 2-20. Ifi204 gene expression levels in both genders of each strain. 
Ifi204 gene expression levels of 4-month old male and female DBA/1-/-, DBA.B-1-/-, 
BALB.D-1-/-, BALB/c-/-, DBA/1 wild type, and BALB/c wild type mice expression levels 
were measured from spleen tissue. (n=3). (* means p > 0.05) (A) Ifi204 gene expression 
levels in DBA/1 background of both genders. The strains are shown below the horizontal 
axis. Numbers to the left of the vertical axis are the ratios of relative expression. In 
DBA/1 and DBA.B-1-/- strains, female gene expression is lower than that of male. In 
DBA-/- strain, female gene expression is higher than that of male. (B) Ifi204 gene 
expression levels in BALB/c background of both genders. The strains are shown below 
the horizontal axis. Numbers to the left of the vertical axis are the ratios of relative 
expression. In BALB/c and BALB/c-/- strains, female gene expression is lower than that 




were the same within the same gender in the BALB/c background. This is likely a result 
of differential gender effects of the IL-1ra knockout in the different mice strains studied. 
 
 
Foxp3+ Regulatory T Cells in Each Strain 
 
Flow cytometry was used to determine the numbers, frequencies, and phenotypes 
for specific types of lymphocytes. The percentage of lymphocytes expressing CD3, CD4, 
CD8, CD25, and Foxp3 were compared for each strain. CD19 and CD3 were used to 
analyze the concentration of B cells and T cells. In the  BALB/c-/- strain, the B cells were 
45% and T cells were 36% of total lymphocytes. In the DBA/1-/- strain, the B cells were 
62.9% and T cells were 24.7% of total lymphocytes. The congenic BALB.D-1-/- strain 
had 43.2% B cells and 44.9% T cells of total lymphocyte. The T cells in the BALB/c-/- 
strain and the BALB.D-1-/- strain had a higher percentage than did the DBA/1-/-strain, and 
the B cells in the BALB/c-/- strain and the BALB.D-1-/- strain had a lower percentage than 
did the DBA/1-/- strain. For T cell subsets, CD4 and CD8 markers were analyzed. 
Cytotoxic (CD8+) T cells were 26.4% and helper (CD4+) T cells were 64.8% in the 
BALB/c-/- strain, cytotoxic T cells were 24.0% and helper T cells were 63.5% in the 
DBA/1-/- strain, and cytotoxic T cells were 22.4% and helper T cells were 71% in the 
BALB.D-1-/- strain. Cytotoxic T cells and helper T cells had similar percentages in the 
three strains. Treg cell percentages in BALB/c-/-, DBA/1-/-, and BALB.D-1-/- were 25.7%, 
37.6%, and 26.4%, respectively, in lymphocytes. The DBA/1-/- strain had a higher 
percentage than the other two strains. The DBA/1-/- strain was arthritis-resistant and the 
BALB/c-/- and BALB.D-1-/- strains were susceptible to arthritis (Figure 2-21). 
 
 
The Effect of Arthritis on the Ankle Joint Area 
 
SAD is observed in mouse ankle joints. This conclusion was based on the 
previous observation that changing the genotype results in a different phenotype in the 
ankle joint area in each strain. The ankle joint’s degree of severity in arthritis presentation 
is most prevalent when the mice are growing. We scored and calculated the four limbs, 
following the scale and the data given above. The severity of swelling and redness in the 
ankle joint of hind legs was more serious in BALB/c-/- than found in DBA/1-/-. 
Inflammation affects the cartilage and synovium. Ankle joints will lose function when the 
synovial tissue is eroding. The inflammation can also affect the joint bones and result in 
bone erosion.  μCT is the best tool for testing our hypothesis. As Figure 2-22 shows, the 
DBA/1-/- strain did not have arthritis as shown by the very smooth bone surface. In the 
BALB/c-/- strain, the bone surface is obviously rough. We enlarged the ankle joint apart 
from the whole leg so that we could display the difference between the two strains more 
clearly. The whole bone volume and bone mineral density were measured for both the 
males and females in the four strains. In whole bone volume, males were slightly greater 
than that observed in females, but they were similar among each strain. We believed that 
arthritis could not change whole bone volume. In bone mineral density, males were 




Figure 2-21. Analysis of foxp3 in lymphocyte cells of BALB. D-1-/- compare with 
BALB/c-/- and DBA/1-/-. 
Cells were harvested at 4 months. Representative flow cytometry histograms show CD3, 
CD19, CD4, CD8, CD25, and foxp3 expression on splenocytes from BALB/c-/-, DBA/1-/-, 
and BALB.D-1-/- female mice (n=3). (A) Percentages of T cells and B cells in each strain. 
In the  BALB/c-/- strain, the B cells were 45% and T cells were 36% of total lymphocytes. 
In the DBA/1-/- strain, the B cells were 62.9% and T cells were 24.7% of total 
lymphocytes. (B) Percentages of Helper T cells and cytotoxic T cells in the three strains. 
Cytotoxic T cells were 26.4% and helper T cells were 64.8% in the BALB/c-/- strain, 
cytotoxic T cells were 24.0% and helper T cells were 63.5% in the DBA/1-/- strain, and 
cytotoxic T cells were 22.4% and helper T cells were 71% in the BALB.D-1-/- strain. (C) 
Percentages of T regulator cells (Tregs) in the three strains. Treg cell percentages in 












Figure 2-22. The structure of ankle joint bones shows in BALB/c-/-, DBA-/-, 
BALB.D-1-/-, and DBA.B-1-/-. 
(A) Images from μCT show that the DBA/1-/- mice have very smooth bone surfaces and 
the BALB/c-/- mice have obvious irregularities on the surface of the ankle joint areas. (B) 
Comparison of whole bone volume differences between BALB/c-/-, DBA-/-, BALB.D-1-/-, 
and DBA.B-1-/- mice. The strains are shown below the horizontal axis. Numbers to the 
left of the vertical axis are the bone volume in cubic millimeters. In all four strains, the 
male expresses a slightly higher volume than the female, but there are no significant 
differences between strains. (C) Comparison of bone mineral density differences in 
BALB/c-/-, DBA-/-, BALB.D-1-/-, and DBA.B-1-/- mice. The strains are shown below the 
horizontal axis. Numbers to the left of the vertical axis are bone density in mgHA/mm3. 
Males have higher bone mineral density than females in all four strains. DBA/1-/- has 
higher bone mineral density than that of BALB/c-/-.  
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higher than BALB/c-/- in both genders. Arthritis could erode the bone and decrease the 
bone density. The two congenic strains, DBA.B-1-/- and BALB.D-1-/-, were scored 





Using an F2 mouse population from a resistant strain, DBA/1-/-, and a strain 
susceptible to spontaneous arthritis, BALB/c-/-, we were able to study spontaneous 
arthritis in the absence of IL-1ra QTLs-regulated mapping. From the different QTL 
location numbers, we discovered spontaneous arthritis is controlled by many genetic 
factors. The QTLs on chromosome 1 had been found to have a major genetic effect on 
spontaneous arthritis. Through the QTLs, the region can be narrowed down, and we can 
thereby reduce the work needed to find the candidate genes. The QTLs on chromosome 1 
were very useful in our study. The candidate genes were confirmed in this region, but the 
genomic region of the QTL was still at too large of a range – more than 300 genes were 
on this region. Different gene expression levels were identified between the congenic and 
parental mice on this region. From the online database, the gene function and correlation 
can be searched. We obtained a list of candidate genes through bioinformatics, gene 
expression profiles, and molecular pathway analysis. 
 
IL-1ra has been linked to many diseases: respiratory diseases, aneurysm 
formation, and periostitis, among others. There were no diseases found in BALB/c-/-, 
DBA/1-/-, and the two congenic mice strains. Diseases might appear in a small number of 
mice, but it was not a common phenomenon. CIA involves late steps in the molecular 
pathway, but IL-1ra is involved in earlier steps. Because the IL-1ra-deficient arthritis was 
heritable and spontaneous, the BALB/c-/- and DBA/1-/- genomic background were very 
useful for understanding the QTLs. The homozygous disease mouse model is a useful 
tool for studying diseases falling under a uniform genomic background, but many of 
these studies result in failed human trials. The use of multiple animal strains can help us 
to understand the range and variability in disease regulation of different genes or genetic 
loci of interest. Parental strains and their congenic mice could enhance our study of the 
molecular mechanism, and so provide a useful tool for searching the candidate genes. 
 
The QTL region conferring susceptibility to spontaneous arthritis is on 
chromosome 1 and functions in both directions. The two congenic mice BALB.D-1-/- and 
DBA.B-1-/- were created from the DBA/1-/- and BALB/c-/- parental strains. A DNA 
fragment covering the QTL loci was transferred from the DBA/1-/- strain onto the 
BALB/c-/- strain background to build the BALB.D-1-/- congenic strain. The fragment of 
DNA from the same QTL loci from BALB/c-/- strain was transferred onto the DBA/1-/- 
strain to build the DBA.B-1-/- congenic strain. In the BALB.D-1-/- congenic strain, the 
onset of the disease was delayed and it was less severe than found in the BALB/c-/- 
parental strain. The DBA.B-1-/- congenic strain showed an increased possibility of 
suffering from arthritis in comparison to DBA/1-/-. The two congenic strains can be used 
to confirm the function of the QTL and help us to understand the sequence of the 
genomic region of the QTL. Most studies only transfer the fragment in one direction, 
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transferring one piece of genomic DNA from one strain to another strain, but not 
transferring the section of DNA from the same location on the second strain to the first. 
In our study, we exchanged DNA fragments from both strains. They were useful models 
for studying the interaction of the QTL region and the whole genome in the congenic 
strains. The genomic DNA from a QTL loci in the two congenic strains can either 
increase or decrease the susceptibility to arthritis in comparison to their parental strains. 
The exchange of the DNA fragments in the congenic strains can help inform our 
understanding of the molecular mechanisms of the genes in the QTL region. The data 
from the four strains prove that the genotype and molecular pathways interact. By using 
the two congenic strains, we can confirm the function of the QTL region and clearly 
define the genes that regulate the susceptibility to spontaneous arthritis. 
 
The phenotype of the mouse strains was studied by scoring the ankle joints at 
different periods throughout growth and by imaging the bone with a μCT after collection. 
The two parent strains were on opposite ends of the scoring spectrum, as BALB/c-/- 
showed signs of severe arthritis early, and DBA/1-/- showed no signs. The congenic 
strains had less extreme results, with BALB.D-1-/- having less severe joint swelling and 
redness than its parent strain, and DBA.B-1-/- having more than its parent. The male 
BALB/c-/- and BALB.D-1-/- mice had higher severity than the females. A study using 
mouse models to investigate osteoarthritis found that sex hormones play a significant role 
in the progression of arthritis in mice, with it being more severe in males. This study 
concluded that estrogen plays a protective role in osteoarthritis and may explain why 
males had it with greater severity. They did not establish a correlation between 
testosterone and osteoarthritis. The role of sex hormones could also be applicable to SAD 
and may explain why the severity progressed quicker in the males than in the females. 
Arthritis is affected by genetics and the environment. This means that although the 
DBA/1-/- strain does not have the genetic background to cause arthritis, it is susceptible to 
the disease because of its environment. However, the severity of arthritis would be much 
lower than the genetically influenced disease. The substantial influence genetics has on 
arthritis is demonstrated by the incidence rate in Figure 2-4. BALB.D-1-/- has delayed 
incidence and severity compared to its parent BALB/c-/- because of the transferred 
genomic region from DBA/1-/-.  DBA.B-1-/- has a higher chance of getting the disease, 
and at an earlier age, in comparison to its parent DBA/1-/- as a result of the genomic 
region from BALB/c-/-. Swelling and inflammation are evident in the images of the 
BALB/c-/- and BALB.D-1-/- mice in Figure 2-3. Using congenic strains allows us to 
prove that the genes affecting arthritis are found in the region that we predicted. As 
discussed above, transferring the genomic pieces from DBA/1-/- and BALB/c-/- to the 
other strain affects the incidence and severity of arthritis; allowing us to conclude that the 
candidate gene(s) are in this region. When watching the affected mice, it was obvious that 
they walked slower and more cautiously so as to not put pressure on their hind legs. The 
study indicated erosion of the soft tissue and synovium as a result of the inflammation 
from arthritis, and after collection, it was found that the bones of the arthritic mice have 
irregular surfaces, compared to the smooth surfaces of the healthy mice. The whole bone 
volume did not show any major differences between the four strains; however, the bone 
mineral density showed differences between BALB/c-/- and DBA/1-/- and between 
genders. This indicates that arthritis decreases the bone mineral density. Besides being a 
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direct effect of arthritis, the bone mineral density may decrease as a result of physical 
inactivity due to pain from joint damage. Physical inactivity can cause a decrease in bone 
mineral density because of a decrease in muscle strength that subsequently leads to less 
loading of the bone. Studies have shown that bone loss in rheumatoid arthritis is a direct 
result of the disease and is most prominent in areas surrounding the affected joints. The 
severe erosion seen in Figure 2-22A is likely a result of these bones surrounding the 
affected ankle joints. The tissue weights of the strains were similar when we collected 
them at the same age. Normally, autoimmune system diseases like arthritis do not affect 
the weight of organs because it is localized.  
 
In our microarray data, a high correlation (R=0.9895) of gene expression was 
found between the two congenic strains. Since the expression levels between the strains 
are mostly the same, it allows us to identify the differences that could explain the genes’ 
varying susceptibility to SAD. The similarities are also found between the parents and the 
congenic strains. As Figure 2-5 shows, the smallest correlation is still relatively high 
(0.97), meaning we can compare the parent and congenic strains to identify differences 
that could cause either a resistance or a susceptibility to arthritis. Using two congenic 
strains allowed us to compare them to the other four strains (DBA/1-/-, BALB/c-/-, DBA/1 
wild type, and BALB/c wild type) and narrow down the possible candidate genes by 
examining overlapping upregulated genes between the comparison genes.  
 
The function of the T-cell receptor beta chain and the Ifi cluster genes in SAD 
susceptibility were confirmed by their expression levels in the BALB.D-1-/- strain. The 
decreased expression levels of these genes in BALB.D-1-/-, in comparison to BALB/c-/-, 
resulted in an increased resistance to SAD.  In the strains that are resistant to SAD, DBA 
wild type and DBA/1-/-, the expression levels of these genes were similar and were also 
lower than found in the BALB/c wild type and BALB/c-/- strains, which are susceptible to 
SAD. BALB/c-/- and BALB.D-1-/- had very few genes with differences in up- or 
downregulation because most of the genes are from the BALB/c-/- background. This is 
also true for the comparison between DBA.B-1-/- and DBA/1-/-. The congenic strains 
compared to the donor allele strains showed many differences in the up- and 
downregulated genes, since the majority of the congenic strains’ genes came from the 
background. When comparing the congenic strains to their respective donor strains and 
the wild type of the donor strain, the congenic strains had fewer differences in 
comparison with the donor strain. All of the wild type strains had more differences in up- 
and downregulated genes in comparison with the congenic strains than the IL-1ra 
deficient strains showed, because the congenic strains were also IL-1ra deficient. The 
data showed an Ifi200 cluster that contained candidate genes for SAD resistance in the 
BALB.D-1-/- strain. The Ifi200 cluster genes between BALB.D-1-/- and BALB/c-/- were 
expressed differentially and located in the transferred genomic fragment in the BALB.D-
1-/- strain. The genes were located on chromosome 1 from D1Mit110 to D1Mit209. The 
microarray data displays differences between the two strains. The Ifi family genes may 
not have the greatest difference between the strains, but from our data and that of other 
studies, there is a large fold change, and therefore the Ifi200 cluster contained candidate 
genes for SAD resistance. It has been published that Ifi proteins are immune suppressors. 
For example, Ifi202b, Ifi203, Ifi204, Ifi205, and Mndal are known as interferon-inducible 
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lupus susceptibility genes[146]. Since we believed that the Ifi200 gene family plays an 
important role in arthritis, the number of transcripts per gene and the protein size of each 
transcript were important to use as experimental search parameters. 
 
To choose a gene to focus on within the Ifi200 family, we needed to compare the 
relative expression levels of the family of genes made up by the congenic strains and 
their parents.  We hypothesized that the Ifi200 gene family influences the inflammation 
found in arthritis, so searching the genes within this family, that had higher expression in 
the arthritis susceptible strains, is a productive strategy. By comparing the congenic strain 
to its parent and to the donor allele strain, we were able to determine which genes were 
different in the DNA region of interest between the arthritis susceptible strain and the 
resistant strain. Since BALB.D-1-/- has the DBA/1-/- DNA region, it would not be 
expected to have different gene expression levels than DBA/1-/-, but we can examine the 
differences between it and BALB/c-/- to find possible candidate genes. Ifi203, Ifi204, and 
Ifi205 had negative differential expression scores between these two strains, thus we 
focused on them as the possible candidate genes. Ifi202b did not have the positive 
correlation that the other Ifi family genes had. A comparison between DBA.B-1-/- and its 
parent strain and donor allele strain should also show differences similar to the BALB.D-
1-/- comparisons. From the narrowed results from the BALB.D-1-/- comparisons, the 
differential expression scores were identified for Ifi205 and Ifi204 in DBA.B-1-/-, DBA/1 
wild type, and DBA/1-/-. Expression levels of the Ifi family genes between the congenic 
strain and its background strain were also determined. The candidate gene that is 
positively correlated with the susceptibility of arthritis should be higher in DBA.B-1-/- 
than in DBA/1-/- and lower in BALB.D-1-/- than in BALB/c-/-. Data from Ifi203, Ifi204, 
and Ifi205 all agreed with this line of prediction. Ifi202b did not have a positive 
correlation. Ifi204 had the highest overall expression in the arthritis susceptible strains, 
hence we chose to focus on this one as the most favorable candidate gene.  
 
Taken together, our data support the current evidence that Ifi204 is the candidate 
gene obtained for the regulation of susceptibility to SAD in mice. There are many aspects 
of the experimental evidence supporting our conclusion. Our data indicated that 
expression levels of Ifi204 varied inversely with the resistance to SAD in the congenic 
strain with the BALB/c-/- background; additionally, the expression levels of Ifi204 also 
varied inversely with the resistance to SAD in the congenic strain DBA.B-1-/-. 
Furthermore, the human homolog to mouse Ifi204, IFI16, has recently been linked to 
arthritis, and the expression level of Ifi204 is the only gene in the Ifi200 cluster which 
was found to be at a detectable or functional level. Finally, the Ifi200 cluster genes are 
the only group of genes relevant to SAD within the QTL region, which showed 
differential expression. This study will significantly enhance our understanding of the 
roles of the Ifi204 gene in inflammatory diseases, because the role of the Ifi204 gene in 
mice was recently found to be very similar to its human homolog IFI16, which is linked 
to arthritis, as noted above[97]. 
 
The Ifi200 family is composed of interferon-activated genes, and thus its role in 
infection and innate immune responses has been studied. Flow cytometry was used to 
examine if the genes in the Ifi family interact with the T-cell receptor beta chain family to 
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downregulate SAD. The possible interaction between these two families of genes was of 
interest because the T-cell receptor beta chain family is known to a have a role in 
controlling susceptibility to arthritis. Flow cytometry results in Figure 2-21 show that the 
arthritic mice (BALB/c-/- and BALB.D-1-/-) have higher percentages of T cells than does 
DBA1-/-, but lower percentages of cells expressing FoxP3. FoxP3 is a transcription factor 
that helps regulate immune responses by activating or repressing anti-inflammatory 
genes. This explains why the strains with severe inflammation have lower levels of 
FoxP3, but higher levels of T-cells than the strain resistant to arthritis. Within the smaller 
percentage of T cells in the DBA1-/- strain, there is a high percentage of Treg cells. FoxP3 
helps Treg cells to suppress immune responses by a positive feedback mechanism. 
DBA1-/- would be expected to have a high percentage of Treg cells and FoxP3, because 
its phenotype does not present with the inflammation that coincides with immune 
responses.      
   
Our study again emphasized the power of whole genome analysis, as well as the 
importance of quality and accuracy in microarray analysis. Because the microarray chip 
contains more than 30,000 probes of mouse genes, any error in the technique could create 
a large number of genes with false positive differential expressions. The large number of 
differentially expressed genes between DBA.B-1-/-, BALB.D-1-/-, and the other three 
parental strains suggested that the small number of differentially expressed genes 
between DBA.B-1-/- and DBA/1-/- are most likely to be the true differentially expressed 
genes. Furthermore, the precise agreement on the expression level of genes in the Ifi 
cluster between DBA.B-1-/- versus DBA/1-/- and DBA.B-1-/- versus DBA/1 wild type 
confirms the accuracy of this analysis. 
 
One should note that both LOC638301 and LOC100044430 were withdrawn, 
most likely due to the inaccuracy of their sequences. However, their probes on the 
Illumina mouse-6 v1.1 were highly similar to that of Ifi204 and Ifi205. Because of the 
high similarity to the sequences of Ifi family genes, their probes were most likely to 
detect the expression of Ifi204 and Ifi205, with certain mismatches to other genes. 
Because differential expression of the Ifi family in our study was not exclusively based 
on these two probes, we felt that the data were truly representative in terms of the 
connection between the expression level of Ifi family genes and spontaneous arthritis 
disease. Zhang et al. indicated in their study that Mndal was absent from DBA/2. With 
the close genome background between DBA/2 and DBA/1, one would assume that Mndal 
in the DBA/1 strain is also absent[147]. Considering the similarity among genes in the 
Ifi200 family cluster, we speculate that the increased level of the expression level of 
Mndal, in this case, could reflect (1) a partial rather than complete deletion, or (2) cross-
reactivity to other genes in the Ifi family cluster. Thus, these probes represent probes for 
the Ifi200 family, and we detect their expression levels at the whole family level, rather 
than at the level of individual genes in the cluster[97]. 
 
 Using real-time PCR to test the expression level of Ifi204 between BALB/c-/-, 
DBA/1-/-, BALB.D-1-/-, DBA/1-/-, BALB/c wild type and DBA/1 wild type, there is a 
noticeable difference between Ifi204 gene expression level in DBA/1-/- and BALB/c-/- 
strains, but the variation among the sexes within each strain is unexplainable at this 
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moment. There is a definite relationship between Ifi204 expression and arthritis, as seen 
in the comparison between the congenic strains and their parents.  DBA/1-/- had lower 
expression levels of Ifi204 than its congenic strain DBA/1-/-, and the congenic strain 
BALB.D-1-/- had lower expression levels than its parent BALB/c-/-.  This is to be 
expected if Ifi204 plays a large role in SAD, because the DBA congenic strain had 
arthritis while DBA/1-/- did not, and BALB/c-/- had arthritis whereas the disease was 
lessened in its congenic strain. 
 
Ifi204 plays a regulatory role in SAD. We sequenced the Ifi204 gene in the 
DBA/1-/- and BALB/c-/- strains. There were several nucleotide polymorphisms in the 
coding region between the two parental strains. This not only made the expression levels 
different, but also changed the protein structure between the two strains. Multiple 
nucleotide changes can have substantial effects on the protein, as just one change in 
nucleotide can change the amino acid and thus the secondary and tertiary structure of the 
protein. 1)The nucleotide from AA to TG change caused the expressed amino acid to 
change from lysine to methionine. This is an exchange of a hydrophilic side chain to a 
hydrophobic one. Charged amino acids can form ionic bonds, whereas hydrophobic ones 
cannot. 2)The T to C nucleotide swap changed the amino acid from tyrosine to histidine. 
This changed a hydrophobic amino acid to a positively charged amino acid. The 
introduction of a positively charged amino acid could disrupt hydrophobic interactions, 
which was shown to severely impact the phenotype or raise susceptibility to disease. 
3)The G to C change switched the amino acid from serine to threonine. This did not 
cause a change in the amino acid’s charge.  The changes in amino acids could have an 
effect on the protein’s structure and/or function. A change from a charged to an 
uncharged amino acid, and vice versa, will change the pH of the protein. The difference 
in proteins may be an important factor in causing the resistance of DBA/1-/- mice and the 
susceptibility of BALB/c-/- mice to SAD. Because of the way primers function 
experimentally, we have the complete nucleotide sequence at the beginning for Ifi204. 
This would not change the start position for transcription but could have an effect on the 






CHAPTER 3.    GENETIC STUDY OF HUMAN SCLERODERMA USING THE 





Scleroderma is a connective tissue disease characterized by hardening and 
thickening of the skin and multiple other organs caused by an accumulation of collagen. 
When the condition affects the internal organs, it is called systemic scleroderma, diffuse 
scleroderma or systemic sclerosis. The disease is mainly divided into the following two 
categories, localized scleroderma (morphea) and systemic sclerosis (SSc)[148-150]. 
Localized scleroderma can be further divided into subgroups depending on the shape and 
distribution of the skin lesions. These subgroups are teardrop-shaped scleroderma, 
scalded scleroderma, ribbon scleroderma, and generalized scleroderma. Localized 
scleroderma only affects the skin of the face, hands, and feet. Scleroderma is an 
autoimmune disorder, characterized by vascular alterations, production of antinuclear 
antibodies (ANAs)[151], and the excessive accumulation of extracellular matrix (ECM) 
proteins (mostly collagen) in the skin and some other internal organs[152]. There are two 
types of scleroderma: the extremities type and the diffuse type. The etiology and 
pathogenesis are unknown, but it is related to genetic factors, infectious factors, abnormal 
metabolism of connective tissue, vascular abnormalities, and immune abnormalities. 
Systemic sclerosis is a prototypic idiopathic fibrosing disease[149]. Fibrosis is the 
development of excess extracellular matrix in organs or tissues. It can occur as part of the 
reparative process or can be idiopathic in origin. The abnormal deposition of ECM is 
stored in the skin, lung, heart, and gastrointestinal tract[152, 153]. However, many of the 
basic mechanisms of disease pathogenesis remain elusive. Therefore, there are few 
effective therapies for preventing fibrosis. Mouse models are useful tools to determine 
the pathogenesis of the human disease. 
 
There are several animal models for studying scleroderma. There are individual 
gene deficiencies or overexpression that cause the vasculopathy and lung fibrosis in SSc. 
The genes include Fos-related antigen-2 (Fra2)[151], endothelin-1 (Edn1)[154, 155], and 
Friend leukemia integration 1 transcription factor (Fli1)[156]. Besides the genetic 
models, there are also non-genetic models of SSc[157], such as the bleomycin-induced 
scleroderma model[158-160] that have been used to study the initiating events of fibrosis. 
Two main genetic mouse models used to study the skin effects of SSc are the tight skin 1 
(Tsk1/+) mouse and the tight skin 2 (Tsk2/+) mouse. Both mouse models are 
heterozygotes because the homozygote is embryonic lethal, but these two types of mouse 
models have different molecular mechanisms. There is a tandem duplication of the 
fibrillin-1(Fbn1) gene in chromosome 2 of Tsk1/+[161]. The Tsk2/+ mutation mouse 
model is an ENU-induced dominant mutation on chromosome 1. The cutaneous 
phenotype is similar to the tight skin 1 (Tsk1/+) mutation. Blankenhorn’s group found the 
candidate gene collagen type III alpha 1 chain (Col3a1) in 2015[162]. Col3a1 is located 
on chromosome 1 between 45,311,538 and 45,349,706[163]. It only has one major 
transcript that encodes proteins. Collagens are a big group of proteins; the collagen 
proteins can enhance and support many tissues in the body[164, 165]. Col3a1 can be 
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found in the skin, intestine, lung, and blood vessel wall. The data cannot support Col3a1 
as the only cause of skin fibrosis, since there is no effect on the other organs[166, 167]. 
Col3a1 may not be the only gene that causes the disease.  
 
 Our hypothesis is that ENU caused single nucleotide mutations in one or more 
genes in the Tsk2 locus interval that determines the disease phenotype. Using a 
combination of high-throughput screening and a bioinformatics approach correlating 
published data and our own data, we tested this hypothesis to identify the gene(s) 
underlying the Tsk2/+ phenotype. Tsk2/+ is a mutation that first appeared in the offspring 
of a male from the 101/H strain that had been administered the mutagenic agent, 
ethylnitrosourea, in 1986[168, 169]. Now, the Tsk2/+ mutation mice are under the 
C57BL/6 background. Tsk2/+ mice have many symptoms similar to the human disease; 
the dermis is tight, the macromolecule deposition dysregulates in the dermal extracellular 
matrix, and the autoimmune response is disordered. Collagen and extracellular matrix 
deposition are increased in the dermis of Tsk2/+ mice[170]. The cutaneous phenotype is 
present in the whole skin and is measured in the interscapular region. Type I and type III 
collagen are synthesized by fibroblasts in the dermis and deposited in the extracellular 
matrix. Increased collagen expression by dermal fibroblasts results in the fibrotic 
condition of the ECM. This is a characteristic of many fibrotic diseases. We will use this 
Tsk2/+ mouse model to study the genetic factors that regulate fibrosis in the dermis. The 
location of the mutagenized genes is known; however, the molecular mechanism of the 
genetic defect is unclear. The genes are located on chromosome 1 from 42.5 to 52.5 
megabases (Mb)[169]. Microarray data can narrow the number of Tsk2/+ candidate 
mutation genes in this region. The Fhl2 gene exhibited a high expression level in Tsk2/+ 
mice; this allowed us to concentrate our focus on this candidate gene. The full name of 
Fhl2 is gene four and a half LIM domain 2. This gene can encode one of the proteins in 
the four-and-a-half-LIM-only family[171]. Fhl2 is located on chromosome 1 from 
43,123,074 to 43,196,984. This gene has 2 transcripts that can encode a protein and is 
composed of six exons. The protein works as a regulator in the development and 
differentiation of the cell, as well as in numerous signaling pathways[172-174]. This gene 
is also connected to bone formation and bone mineral density. Our research goal is to find 
a connection between this gene and skin. 
 
 





Tsk2/+ mice were crossed on the C57BL/6 (B6) background and obtained from 
Dr. Arnold Postlethwaite (University of Tennessee Health Science Center, Memphis, 
TN). The wild type C57BL/6J strain mice were purchased from the Jackson Laboratory. 
Both strains of mice were housed at the animal facility in the Coleman Building, 
University of Tennessee Health Science Center (UTHSC). The animal facility room 
conditions were 12 hr light / 12 hr dark per day, the temperature was 22 ± 2 °C, and 
 
60 
relative humidity was controlled between 30% to 60%. All animal experimental 
procedures for this study followed the protocol set by the IACUC of UTHSC. 
 
The tight skin disease phenotype in Tsk2/+ mice and B6 mice were bred in 
standard microisolator cages. The mice had been measured for their body weight (g), 
body length (cm), tail length (cm) and skin score (cm) when they were anesthetized, on 





Ear pieces (about 2 mm2) of the 3-4-week-old Tsk2/+ mice were taken by using 
sterilized ear punch (with anesthesia) the first time the mice were marked. The tissue was 
immediately used for DNA extraction or frozen at -80°C. DNA was isolated by 
“HotSHOT” genomic DNA preparation protocol. The ear pieces were put in 75 μl 
Alkaline Lysis Reagent (25 mM NaOH: 0.2 mM EDTA, pH 12) incubated at 95°C for 10 
min to 1 h, then 75 μl Neutralization Buffer (40 mM Tris-HCL, pH 5) was added. PCR 
was used to genotype mice. Primers used: Col3a1-dna-T, forward primer: 
5’CCCACAGATGAATTGGGAA; reverse primer 5’CAACAGACATGGCTTGCATT; 
expected product size: 323 bp. Col3a1-dna-N, forward primer: 
5’CCCACAGATGAATTGGGAT; reverse primer 5’CAACAGACATGGCTTGCATT; 
expected product size: 323 bp (IDT, CA). mRNAs were also collected for rt-PCR to 
distinguish between the Tsk2/+ and B6 mice. The rt-PCR primers were used forward 
primer Col3a1-T-F: 5’ -ACGTAGATGAATTGGGAA- 3’ with reverse primer Col3a1-
T/N-R: 5’-ACGTAGATGAATTGGGAT- 3’ and forward primer Col3a1-T-N: 5’-
ACGTAGATGAATTGGGA- 3’ with same reverse primer Col3a1-T/N-R. 
 
 
Collection of Mouse Tissues 
 
Mice were collected at 4, 6, and 10 weeks of age and all tissues (heart, muscle, 
liver, spleen, lung, kidney, and one piece of skin) were stored separately in 1.5 ml tubes 
and immediately put on dry ice. One piece of skin was stored in RNAlater solution 
(Thermo Fisher, CA) at 4°C until the skin completely absorbed the solution. After, all 





RNA: A piece of tissue that had been stored in the -80°C freezer was cut on dry 
ice before it melted. The tissue samples were put in 1 ml TRIzol and then the solution 
was homogenized. 0.2 ml of chloroform per 1 ml of TRIzol sample was then added. After 
being centrifuged, the top phase of the solution was moved to a new tube with 0.5 ml of 
100% isopropanol. The mix solution was kept in a fridge for 40 min and then centrifuged 
to produce the RNA pellet. Next, they were washed with 75% ethanol three times. Water 
and sodium acetate:ethanol (4:96)  was added to purify the RNA at -20°C overnight. The 
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next morning, the RNA was washed and measured, the concentration was assessed by 
nanodrop 2000 spectrophotometry (Thermo Scientific, CA). The RNA samples’ quality 
was verified by agarose gel electrophoresis, which should have 3 bands (5S, 18S, and 
28S). RNAs were stored at -80°C until the experiment. 
 
DNA: DNA was extracted using the DNeasy Blood & Tissue Kit (Qiagen, CA). 
The DNA samples’ integrity was also verified by agarose gel electrophoresis; most 
fragments should be larger than 5 kb and have no distinct smear band. The concentration 
and contamination were also measured by nanodrop 2000 spectrophotometry (Thermo 





The RNAs were isolated from B6 and Tsk2/+ mouse spleen samples. Three 
individual RNA samples had been pooled as one group in each well. The SuperScript 
Choice System (Invitrogen, CA) reverse transferred the RNA samples to cDNA, and then 
we used Enzo® BioArray HighYield RNA transcript labeling kit to produce cRNA. The 
cRNA samples were loaded on GeneChip mouse genome U74Av2 array (Affymetrix, 
CA) and hybridized at 45°C overnight, following the manufacturer's protocol. The 
genechip was washed and stained by Affymetrix Fluidics Station 400 and scanned by 






RNA samples were used to measure the gene expression of Col3a1 and Fhl2 
between B6 and Tsk2/+. The expression levels were used to confirm the data from the 
Microarray. The RNA samples were isolated from the skin, muscle, heart, kidney, liver, 
and lung. Each RNA sample was tested for the expression levels separately. One-step 
RT-PCR kit from Thermo scientific was used and we followed the manufacturer’s 
protocol. Specific primers were designed by the Primer3 online service. The reaction was 
performed in a total volume of 12.5 μL, the total RNA volume was 1 ng, and the volume 
of the forward and reverse primers was 50 nM in the reaction. cDNA synthesis and pre-
denaturation were performed in 1 cycle of 50°C for 30 min, and 95°C for 15 min. PCR 
amplification was performed in 35 cycles at 94°C for 30 s, 60-54°C for 40 s, and 72°C 
for 1 min. The final extension was 72°C for 5 min. The PCR products were analyzed on a 





All of the chromosomal regions of interest were sequenced.  The exon, intron, and 
promotor were identified between B6 and Tsk2/+ mice (Table 3-1). DNA or mRNA 
samples were amplified to their PCR products.  All of the PCR and rt-PCR products were  
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Table 3-1. The Fhl2 gene primer. 
 
Name Forward-Primer Reverse-Primer Size(bp) 
Fhl2-
cd1(1417) 
cattaaagcaacccaatgaagc aggacaagtccttgcagtcg 290 
Fhl2-
cd1(1566) 
cagctcctgctgcactcc gcagtcaaagcgttcagtca 298 
    
Fhl2-CD1 attaaagcaacccaatgaagc ctgctgcccttgtattccat 496 
Fhl2-CD2 atggaatacaagggcagcag gccgccttcaaatatccttt 505 
Fhl2-CD3 aatggcacaacgactgcttt aaggaagtcacaaagctgcaa 481 
    
Fhl2-DNAx1 caaatggggacgtgcatag gagctggggtcctgaggt 452 
Fhl2-DNAx2 ggtctgtggtagcgtcatca tctcctatcgccagaacctg 451 
Fhl2-DNAx3 tttccctgaaacttttgagca gcagctctgctctgctttgt 451 
Fhl2-DNAx4 gcttgtccacaggcaaatct gcccagcactgaagtatcaa 456 
Fhl2-DNAx5 aggagccattgagagcagaa caagagaacagatgcgcaag 436 
Fhl2-DNAx6 agccacaggtccctccat agacgtccatgttgttccag 400 
Fhl2-DNAx7 gtacagcgggctcaaacatt ggatcttgtccccactgaga 442 
Fhl2-DNAx8 cgcagagattcggatgtttt gagggagaaaagtcggtgct 461 
    
Fh2-ax-1 gtgcagcagcatcagggta attcggctctcctatgctca 355 
Fh2-ax-2 ctgtgcctgcctttctatcc gcagtcaaagcgttcagtca 350 
Fh2-ax-3 aggagtgtggaacacccatc caagagagtaccgccctgag 346 
Fh2-ax-4 ccaacagggaggcagtaaca agtgccgatccttgtaggac 356 
Fh2-ax-5 ctgtgcaccgactgctattc aggggtaggggttgagacag 349 
Fh2-ax-6 tccacttaaaactcccaacca acaggtgaagcaggtctcgt 317 
Fh2-ax-7 gccctgctatgagaagcagt tgaagtcctggaagtgtcacc 397 
Fh2-ax-8 ctggtttccactccgaaaac tgctcccggtaagtaacacc 352 
Fh2-ax-9 actgcctgacctgcttctgt cccacctagctgtggtttgt 415 
Fh2-ax-10 tggaaaccagtccctcaaac tgtactttgtgccacccaga 353 
Fh2-ax-11 tcaagcacagtgtgtgggact gcatttgcacatatacacattca 354 
    
Fhl2-Fdna 1 cagctgctacagctctctgc taagggaacccagcggact 353 
Fhl2-Fdna 2 cagagggagccaactgaatgt tccagggctagttgctatgc 358 
Fhl2-Fdna 3 agtcactacccaggccttc aatgaaccaaaccgatgacc 353 
Fhl2-Fdna 4 ccaaggtggacagcacttct tatcctcatgcccaggaaag 326 
Fhl2-Fdna 5 tgactgcgtggcagttattc gactggtgctcagcttcctc 352 
Fhl2-Fdna 6 atccctcaattgcaagatgg cgtggtggaacctcagaact 352 
Fhl2-Fdna 7 cagcaaaacaaaacaaaacagg ggagagtgagcaagctgagg 313 
Fhl2-Fdna 8 tggagagatggctcagaggt aagagtaacaaaacgccgattc 349 
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cleaned with EXOSA-IT PCR CLEAN-UP PROTOCOL. 5 μl PCR or rt-PCR products 
and 2 μl ExoSAP-IT mix were incubated at 37°C for 25 min followed by 80°C for 15 
min. 3 μl cleaned DNA samples, 1 μl single primer, and 8 μl water was used for 
sequencing. Samples were loaded on ABI Model 3130XL Genetic Analyzers (Thermo 




Quantitative Real-Time PCR 
 
The TaqMan Reverse Transcription Reagents (Roche, AG) were used to amplify 
the individual samples, following the manufacturer’s instructions. The cDNA samples 
were mixed with the TaqMan Universal PCR Master mix. TaqMan gene expression 
assays containing FAM-labeled primer/probe sets specific for Fhl2(Mm00515778_m1) 
and GAPDH(Mm03302249_g1) were obtained from Applied Biosystems. The real-time 
PCR reactions were performed in a total reaction volume of 25 μL by using FastStart 
TaqMan Probe Master (Roche) reagent, and results were analyzed using the ABI 7900 
real-time PCR-detection system (Applied Biosystems). Relative expression was 





Western blotting was used to determine Fhl2 expression level differences between 
the normal control B6 mice and Tsk2/+ mutation mice. Protein from samples of the same 
region of skin was isolated by using RIPA Lysis Buffer (Santa Cruz Biotechnology, TX). 
The protein concentration was tested by nanodrop 2000 (Thermo Fisher, CA). All 
samples were diluted by Sample Buffer, Laemmli 2x Concentrate (SIGMA, MO) to a 
ratio of 1:1 and boiled at 95°C for 10 min. The gradient polyacrylamide gel that was used 
contained 6% stacking gel on top and 10% the separating gel on bottom. The 6% 
Stacking Gel: 2.9 ml ddH2O, 0.75 ml 40% Acrylamide, 1.25 ml 0.5 M Tris, pH 6.8, 50 μl 
10% SDS, 50 μl 10% APS, and 5 μl TEMED. The 10% Separating Gel: 3.8 ml ddH2O, 2 
ml 40% Acrylamide, 2 ml 1.5 M Tris, pH 8.8, 80 μl 10% SDS, 80 μl 10% APS, and 8 μl 
TEMED. The samples in each well were loaded with 1x electrophoresis buffer (25 mM 
Tris, 0.25 M glycine, 5 mM SDS), with 100 Volts, and were run for 1.5 hr. Proteins were 
then transferred to polyvinylidene difluoride membranes (Millipore Sigma, MA) in a 
transfer buffer containing 0.2 M glycine, 25 mM Tris, and 20% methanol, pH 8.3 at 4°C, 
100V, for 1.25 hr. After transfer, membranes were blocked in 5% BSA in TBST buffer 
(10 mM Tris and 0.9% NaCl, and 0.1% Tween20) for 2 hr at room temperature (RT). 
After blocking, the membranes were washed with 1x TBST three times. Membranes had 
been cut to a suitable size and then incubated with the selective antibody against Fhl2 (1st 
antibody,1:2000) overnight at 4°C. On the second day, after washing the membranes 
three times, the membranes were incubated in the 2nd antibody (1:5000; Abcam, UK) for 
1 hr at RT. They were then washed three times, and the membranes were exposed on the 
Classic Autoradiography film (MIDSCI, MO) for 5 min in the dark room. The Fhl2 
protein was 32 kDa. The membranes were stripped with Restore Western Blot Stripping 
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Buffer (Thermo, CA) and added GAPDH as a control for the protein quantity.  ImageJ 








In the current study, the Tsk2/+ mutation and C57BL6/J B6 mice were bred in the 
animal facility under the same conditions. Body size, body shape, and hair color were 
similar between the Tsk2/+ and normal mice as compared with the naked eye. The only 
significant difference between the Tsk2/+ mutation and B6 normal was the tightness of 
the skin (Figure 3-1). The phenotype of tight skin in Tsk2/+ mice is physically evident 
and can be felt upon pinching the skin of young mice as early as three weeks of age. The 
Tsk2/+ mice and age-matched controls were evaluated by body length, tail length, body 
weight, and skin score at several time points. The mice were measured on days 21, 28, 
32, 35, 40, 42, 45, 49, 53, 56, 59, 63, 66, 70, 73, 80, 87, 94, 101.  At these selected time 
periods, the body length and the tail length of the male and female Tsk2/+ and B6 mice 
did not show any distinct changes (Figure 3-2A, B). The males were heavier than the 
females of all ages in both B6 and Tsk2/+. Within the same gender, the Tsk2/+ mice were 
reported to weigh less than their normal B6 littermates (Figure 3-2C). Pictures were 
taken at the 4 and 6-week time points; in the pictures, the interscapular skin was grasped 
to measure the skin tightness. An obvious difference could be felt between the two 
strains. In the photos, the tightness of the skin was marked with a red circle, and there are 
different circle sizes between the B6 and Tsk2/+ mice. Measuring of the skin was done 
by the same person to ensure that the same method and location of grabbing were used, 
providing consistency for the data. The skin of the one and two-week-old mice is too 
difficult to grasp because they are too small. According to the literature, the disease 
phenotypes begin to show around three weeks. Both genders of Tsk2/+ and B6 have been 
measured at all time points. The skin measurements have significant differences; the B6 
skin can be grasped ~ 1.7cm, but the Tsk2/+ only can be grasped ~ 0.7cm (Figure 3-2D). 
 
 
Verification of Tsk2/+ Mice 
 
Four pairs of primers were used to identify the Tsk2/+ and normal mice by PCR 
and rt-PCR. The pair of primers for PCR were Col3a1-dna-T and Col3a1-dna-N and the 
primers for rt-PCR were Col3a1-T and Col3a1-N to confirm the Tsk2/+ and B6 
genotypes (data not shown) using PCR. The mRNA samples were used to confirm that 
the Col3a1 gene is the mutated gene. The mRNA samples 1-3 from 4wks-B6 skin and 
samples 4-6 from 4wks-Tsk/2+ were amplified by rt-PCR using the Col3a1-T-F and 
Col3a1-T/N-R pair of primers. Col3a1-T can amplify the 4wks-Tsk2/+ skin RNA, but 
cannot amplify the 4wks-B6 skin RNA. Both of the Tsk2/+ and B6 skins’ RNA can be 
amplified by Col3a1-N (Figure 3-3A, B). Both Tsk2/+ and B6 can be amplified by 





Figure 3-1. The phenotype of Tsk2/+ and B6 skin tightness when they are 4 and 6 
weeks of age. 
(A) Comparison of the body size, body shape and hair color between Tsk2/+ and B6 
mice. (B, C) Comparing the difference in how much skin is able to be grasped at four 
weeks old.  (D, E) Comparing the difference in how much skin can be grasped at six 
weeks old.  (F, G) The skin score is measured using a ruler when skin is grasped on the 
back. The body, tail shape, and hair from Tsk2/+ and B6 skin are similar. The 





Figure 3-2. Comparison of body length, body weight, tail length, and skin 
tightness score in male and female Tsk2/+ and B6 mice. 
 
(A, B) The body length and tail length are compared between the Tsk2/+ and B6 mice in 
both genders. The times (days) are shown below the horizontal axis. Numbers to the left 
of the vertical axis are the lengths (cm). The body length increases for both strains until 
about forty-five days, and then it stabilizes. The tail length of both strains increases 
steadily throughout their lifetime. The Tsk2/+ and B6 body length and tail length of both 
the males and females do not show obvious changes. (C) The body weight is compared 
between the Tsk2/+ and B6 mice in both genders. The times (days) are shown below the 
horizontal axis. Numbers to the left of the vertical axis are the weights (g). The Tsk2/+ 
mice were reported to weigh less than their normal B6 littermates in both genders. The 
males of both strains weighed more than the females. The body weights of the two strains 
steadily grow throughout their lifetime. D) The skinscore is compared between the 
Tsk2/+ and B6 mice in both genders. The times (days) are shown below the horizontal 
axis. Numbers to the left of the vertical axis are the lengths (cm). The skin score is stable 
throughout the mice’s lifetime.  The B6 skin can be grasped ~ 1.7cm, but the Tsk2/+ only 






Figure 3-3. Identifying and comparing the Tsk2/+ and B6 by Col3a1 candidate 
mutation gene and Col3a1 gene expression levels between Tsk2/+ and B6 tissues. 
(A, B) Identifying the SNP between 4 weeks Tsk2/+ and B6 with skin mRNA. The 
Col3a1-T can amplify the Tsk2/+, but cannot amplify the B6. Both Tsk2/+ and B6 can be 
amplified by Col3a1-N. No. 1-3 are 4 weeks B6 skin mRNA samples and No. 4-6 are 4 
weeks Tsk2/+ skin mRNA samples. (C) The Col3a1 gene expression levels compared 
between Tsk2/+ and B6 mice in different tissues. There is no difference between Tsk2/+ 
and B6 mice in skin, heart, and kidney. No. 1-3 are 4 weeks B6 skin mRNA samples and 




expression level between B6 and Tsk2/+ by primer Col3a1-12 (forward: 
CGTAAGCACTGGTGGACAGA, reverse: TGGGGTTTCAGAGAGTTTGG; bp: 489) 
in the skin, heart, and kidney tissues. There is no obvious difference between Tsk2/+ and 
normal (Figure 3-3C). 
 
 
Microarray Analysis of Tsk2/+ Mice 
 
Tsk2/+ is under the B6 background, and there were a small number of genes 
changing the expression levels. However, the expression levels of more than 99% of the 
genes compared between these two mice are similar. In analyzing the expression levels of 
genes in B6 and Tsk2/+, the expression levels of eighty-two probes were found to be 
upregulated and 177 probes were downregulated in Tsk2/+ compare with B6 (Figure  
3-4). A previous study found that the candidate gene is located on chromosome 1 from 
42.5 to 52.5 Mb. In this region, there were twelve probes downregulated and four probes 
upregulated. The downregulated probes were 1500015O10Rik, Kdelc1, Tgfbrap1, Eroc5, 
Gulp1, Pou3f3, Gpr45, Uxs1, EG212225, Bivm, Tpp2, and Mrps9 and the upregulated 
probes were Col3a1, Slc40a1, Slc39a10, and Fhl2. 
 
 
Comparison of Two Genes 
 
From the Ensemble database, the positions of Fhl2 and Col3a1 were both on 
chromosome 1, Fhl2 was from 43,123,074 to 43,196,984 and Col3a1 was from 
45,311,538 to 45,349,706 bp (Figure 3-5A). From the online gene expression database, 
we searched the BioGPS website (http://biogps.org/#goto=welcome) and compared the 
gene expression levels of Col3a1 and Fhl2 in most tissues and organs in mice (Figure 3-
5B). Unfortunately, there is no skin or dermis expression on this list, but most major 
organs and tissues could be found. Fhl2 gene expression in epidermis, muscle, heart, 
kidney, liver, and lung is 11.0915±4.5248, 46.2905±3.489572, 21857.0475±6050.6809, 
194.9005±27.0645, 15.6560±6.9381, and 54.7640±35.6580 and the Col3a1 gene 
expression is 1434.9770±841.9238, 1280.4620±364.6521, 389.3040±167.1120, 
26.5730±18.3918, 15.2225±8.9442, and 540.1390±101.6706 (Table 3-2). The Fhl2 gene 
is highly expressed in the heart but is not as highly expressed in the other organs. There 
are eight organs or tissues where the expression level of Col3a1 is more than 2000, but 
the heart is the only organ with an expression level more than 2000 in Fhl2. 
 
 
Transcript of the Genes 
 
On the Ensemble online database, there were basic data for the Col3a1 and Fhl2 
genes (Table 3-2). The Col3a1 gene had seven transcripts and Fhl2 gene had three 
transcripts. For the Col3a1 gene, there were three transcripts, Col3a1-201, Col3a1-205, 
and Col3a1-204, that encoded proteins, but only Col3a1-201 had a CCDS.  For Fhl2, all 






Figure 3-4. Up and down regulated genes and networks in Tsk2/+ mice in 
comparison to that of B6 mice. 
(A) Upregulated genes in Tsk2/+ mice compared with B6 wild type. The gene names are 
shown above the horizontal axis. Numbers to the left of the vertical axis are the fold 
changes. The expression levels of eighty-two probes are upregulated. (B) Downregulated 
genes in Tsk2/+ mice compared with B6 wild type. The gene names are shown below the 
horizontal axis. Numbers to the left of the vertical axis are the fold changes. The 






Figure 3-5. Fhl2 and Col3a1 are located on chromosome 1 and they are expressed 
in different tissues. 
(A) Fhl2 and Col3a1 are located on chromosome 1. Genes have been marked by red 
arrows. Fhl2 is located on chromosome 1 from 43,123,074 to 43,196,984 and Col3a1 on 
chromosome 1 from 45,311,538 to 45,349,706 bp. (B) Col3a1 and Fhl2 have different 
expression levels in different tissues or organs. The organ names are shown below the 
horizontal axis. Numbers to the left of the vertical axis are the expression level units. The 
Fhl2 gene expression is high in the heart, where the expression level is more than 21000, 
but there are no more than 1500 in other organs. The Col3a1 is expressed more than 1000 




Table 3-2. The Fhl2 and Col3a1 gene expression levels in each tissue or organ. 
 
Samples Fhl2 Stdev.S Col3a1 Stdev.S 
NK_cells.1 149.8985 7.2570 5.4795 0.6272 
RAW_264_7.1 14.0245 4.9179 5.5145 0.6767 
T-cells_CD4+.1 14.0400 0.5459 5.8075 0.1633 
T-cells_CD8+.1 34.9440 3.5652 5.6920 0.0000 
T-cells_foxP3+.1 19.7865 3.2308 4.9720 0.0905 
Adipose_brown.1 17.8120 0.4384 1573.9835 810.9461 
Adipose_white.1 39.0065 8.6486 953.7960 384.0452 
Adrenal_gland.1 128.4775 25.1285 43.4440 9.0708 
Amygdala.1 157.6655 3.7781 5.2995 0.3019 
Bladder.1 314.5495 55.9597 4003.3750 566.4618 
Bone.1 75.1865 15.6532 320.3745 111.4351 
Bone_marrow.1 32.2440 10.5203 4.9880 0.1131 
Cerebellum.1 11.0695 2.3511 5.6920 0.0000 
Cerebral_cortex.1 326.5605 70.4611 5.7255 0.0474 
Cerebral_cortex_prefrontal.1 388.4195 83.9993 5.5580 0.5162 
Ciliary_bodies.1 9.0995 1.2268 15.2210 4.2978 
Common_myeloid_progenitor.1 23.1110 5.2312 5.8075 0.1633 
Cornea.1 11.5340 6.7854 8.2780 3.3729 
Dorsal_root_ganglia.1 25.1470 6.6015 125.7045 43.3520 
Dorsal_striatum.1 45.6030 6.5535 9.8780 6.8476 
Embryonic_stem_line_Bruce4_p13.1 101.0710 22.5355 5.4795 0.6272 
Embryonic_stem_line_V26_2_p16.1 115.9515 25.4495 7.3240 2.3080 
Epidermis.1 11.0915 4.5248 1434.9770 841.9238 
Eyecup.1 36.6610 27.0949 210.4600 19.5416 
Follicular_B-cells.1 20.0530 6.9565 5.1365 0.1421 
Heart.1 21857.0475 6050.6809 389.3040 167.1120 
Hippocampus.1 161.0325 31.4754 5.3640 0.4639 
Hypothalamus.1 59.6850 18.4385 5.3640 0.4639 
Intestine_large.1 187.3630 6.8038 289.0980 21.8652 
Intestine_small.1 289.4680 62.9509 209.2300 104.5302 
Iris.1 19.3375 9.5622 74.6680 36.8912 
Kidney.1 194.9005 27.0645 26.5730 18.3918 
Lacrimal_gland.1 12.9745 5.1074 20.5510 20.6871 
Lens.1 43.1585 36.3517 4.9720 0.0905 
Liver.1 15.6560 6.9381 15.2225 8.9442 
Lung.1 54.7640 35.6580 540.1390 101.6706 
Lymph_nodes.1 9.0635 0.8407 255.2065 242.4238 
MIMCD-3.1 911.8575 63.0152 5.5695 0.1732 
Mammary_gland__lact.1 62.0655 16.7789 4538.4560 184.6129 
Microglia.1 17.5020 0.0000 71.9650 93.7242 
Min6.1 8.7460 1.5401 25.5350 11.9473 
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Table 3-2.  Continued. 
 
Samples Fhl2 Stdev.S Col3a1 Stdev.S 
Neuro2a.1 11.1510 4.6655 4.9945 0.1223 
Nih_3T3.1 1437.8815 155.7070 30.8070 26.5123 
Nucleus_accumbens.1 27.0160 4.8663 5.8100 0.1598 
Olfactory_bulb.1 121.1285 0.1054 5.3640 0.4639 
Osteoclasts.1 7.4330 0.3168 5.4795 0.6272 
Ovary.1 201.6885 0.4646 1626.7425 1414.1690 
Pancreas.1 32.3720 21.4098 239.1720 22.0349 
Pituitary.1 41.6095 30.1178 5.8245 0.1393 
Placenta.1 808.1875 52.2220 847.4510 60.2130 
Prostate.1 171.2190 1.1087 206.6360 19.3719 
Retina.1 10.3610 3.5879 5.4345 0.3642 
Retinal_pigment_epithelium.1 17.0395 8.9626 5.6920 0.0000 
Salivary_gland.1 38.5275 26.7845 849.0865 1135.8391 
Skeletal_muscle.1 46.2905 3.4896 1280.4620 364.6521 
Spinal_cord.1 33.4055 4.5163 5.6920 0.0000 
Spleen.1 18.1760 0.9532 21.9085 9.1945 
Stem_cells__HSC.1 17.2505 1.7727 5.5995 0.1308 
Stomach.1 388.9085 87.7640 605.5300 213.3200 
Testis.1 70.7280 15.3796 15.3590 6.0712 
Thymocyte_DP_CD4+CD8+.1 23.5500 3.6656 5.3275 0.4122 
Umbilical_cord.1 823.8050 236.2373 27661.4400 2335.1692 
Uterus.1 183.2825 21.4911 3108.8535 594.1910 
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and Fhl2-201 had CCDSs (they both have two). Thus, Fhl2 has two transcripts that 
encode proteins (Table 3-3). 
 
 
Fhl2 Transcripts in Different Tissues 
 
Through the previous searching, there were two transcripts with CCDSs in the 
Fhl2 gene. The Fhl2 gene was composed of 6 segments of exons. The first exons on Fhl2-
201 and Fhl2-202 were completely different, but the remaining five exons were the same. 
These two transcripts had different promoters. Fhl2-201 was 1566 bp and Fhl2-202 was 
1417 bp (Figure 3-6). Two transcripts were identified per the expression levels in 
different tissues. The Fhl2-201 transcript was expressed in the skin and kidney, but not 
expressed in the muscle, heart, liver, and lung. The Fhl2-202 transcript was expressed 
only in the heart, but not in the skin, muscle, kidney, liver, or lungs (Figure 3-7). 
 
 
Fhl2 Gene Expression in Different Tissues at Different Ages 
 
Real-time PCR was used to determine the Fhl2 gene expression levels in different 
tissues in 4, 6, and 10-week-old female mice. In the skin, the Fhl2 expression level from 
Tsk2/+ mice was higher than that of B6 at all time points. At 4 and 6 weeks, the Fhl2 
expression level in Tsk2/+ were around 1.5-fold over that of B6. At 10 weeks, Tsk2/+ 
expression level was 2.5-fold. The B6 mouse skin expression remained around 1-fold at 
4, 6, and 10 weeks (Figure 3-8A). The expression of Tsk2/+ increased significantly at 10 
weeks compared to 4 and 6 weeks. In muscle, Fhl2 expression levels in Tsk2/+ were 
slightly higher than B6 at 4 and 6 weeks. In heart and lung, Fhl2 expression levels in 
Tsk2/+ were slightly higher than B6 at 4, 6, and 10 weeks. In the kidney, Fhl2 expression 
levels in Tsk2/+ were slightly higher than B6 at 4 and 6 weeks, but not at 10 weeks. 
Tsk2/+ were twice as high at 4 weeks and were also 1.6-fold higher than B6 at the same 
age (Figure 3-8B). 
 
 
Sequencing the Fhl2 Gene 
 
We searched for polymorphisms in the Fhl2 gene that would establish it as the 
likely candidate gene. We employed mRNA sequencing to reduce the genomic interval 
(Figure 3-9A). We also sequenced the captured genomic DNA (Figure 3-9B), promoter 
(Figure 3-9C), and introns connecting to each exon (Figure 3-9D). We used the B6 
genome sequence as the control group to analyze the polymorphisms within the interval 
in the Tsk2/+. We read many kilobases in the Fhl2 gene and genomic interval. We 
wanted to find a polymorphism that would cause an overexpression or degeneration as a 
result of changes in the protein structure, or protein denaturation as a result of intron 
changes. We have not yet found a polymorphism in the Fhl2 gene between B6 and 
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Figure 3-6. There are two transcripts of the Fhl2 gene. 
In the Fhl2 gene, there are 6 exons used to assemble the gene. The highlighted regions are 
the first exons of each transcript. The first exon is different in the two transcripts, except 






Figure 3-7. Comparing transcripts Fhl2-201 and Fhl2-202 in different tissues. 
Fhl2-201 and Fhl2-202 expression levels are compared in the skin, muscle, heart, kidney, 
liver, and lung between B6 and Tsk2/+. No. 1-3 are 4 weeks female B6 skin mRNA 
samples and No. 4-6 are 4 weeks female Tsk2/+ skin mRNA samples. (A) Fhl2-201 is 
expressed in the skin and expression in Tsk2/+ is higher than B6. There is no Fhl2-202 
expression in the skin. (B) In the muscle, there is no expression of either transcripts. (C) 
Fhl2-202 is expressed in the heart. There is no Fhl2-201 expression in the heart. (D) 
Fhl2-201 is expressed in the kidney, and expression is not different between Tsk2/+ and 
B6. There is no Fhl2-202 expression in the kidney. (E) In the liver, there is no expression 






Figure 3-8. The Fhl2 gene expression in Tsk2/+ and B6 mice tissues at 4, 6, and 10 
weeks. 
(A) The Fhl2 gene expression levels in Tsk2/+ and B6 female skin at 4, 6, and 10 weeks. 
The strains are shown below the horizontal axis. Numbers to the left of the vertical axis 
are the ratio of relative expression. At 4 and 6 weeks, Tsk2/+ were around 1.5-fold more 
than normal. At 10 weeks, the Tsk2/+ expression level was 2.5-fold more than normal. 
(B) The Fhl2 gene expression level in Tsk2/+ and B6 female muscle, heart, kidney, and 
lung at 4, 6, and 10 weeks. The strains are shown below the horizontal axis. Numbers to 
the left of the vertical axis are the ratio of relative expression. In the muscle TSK, is 
higher than B6 at 4 and 6 weeks. There is no overall difference between TSK and B6 in 




Figure 3-9. Fhl2 gene sequencing and designed primers on mRNA, genomic DNA, 
promoter and intron. 
The pairs of primers were designed for sequencing the Fhl2 gene. Each color represents a 
pair of primers. The primers overlapped each other, so there were no missing nucleotides. 
(A) The mRNA of Fhl2; (B) the genomic DNA covered the Fhl2 gene; (C) the promoter 
of the Fhl2; (D) the introns beside the Fhl2 exons. (E) The sequences of B6 and Tsk2/+. 
















Fhl2 Protein Levels in Skin 
 
As evidenced by the phenotype, Tsk2/+ shows very tight skin and obvious ECM 
fibrosis. We believe these phenotypic traits are caused by an excess of the Fhl2 protein. 
Under the same experimental conditions, we measured Fhl2 protein levels in the skin of 
Tsk2/+ and B6 littermates. We used all parts of the skin to measure the protein levels, 
including the dermis and epidermis. Higher Fhl2 protein levels in Tsk2/+ compared to the 
B6 mice verified that Tsk2/+ produces overexpression at the gene level compared to B6. 
The protein expression was tested from four-week-old mice skin by western blot, and it 
was found that the Fhl2 protein expression in Tsk2/+ mice is significantly more than that 
observed in B6 mice of the same age (Figure 3-10). We duplicated the samples to ensure 
that it was not an individual difference. We used ImageJ software to quantify the strength 
of the band. 
 
 
Gene Regulation of the Expression of Fhl2 in the Spleen 
 
The genetic factors that regulate the expression of Fhl2 were measured on 
GeneNetwork. With 2000 permutation testing, we found that the gene for regulating Fhl2 
was on chromosome 5, and that the QTL on chromosome 5 was significant. The 
significant LRS was 17.14 and suggestive LRS was 10.71. The QTL can reach the level 
of 15 on Chromosome 5 (Figure 3-11A). The peak region of QTL on chromosome 5 was 
between 55.00 to 64.00 Mb (Figure 3-11B). There were twenty-two genetic elements, 
and eight of them were known genes. These were Pcdh7, G6pd2, Arap2, Gm336, Centd1, 
Dthd1, Nwd2, and Rell1. From these gene networks, we gained understanding regarding 
the upstream gene location and genetic pathway – from chromosome 5, from 55 to 65 
Mb. The upstream gene of Fhl2 should be in this region. 
 
 
Gene Network of Fhl2 in Mouse Spleen 
 
The UTHSC Affy MoGene 1.0 ST Spleen (Dec10) RMA in GeneNetwork was 
used to search the expression level data. The probe for Fhl2 and whole genome 
expression profiles were compared in the spleen. From the top fifty probes, gene 
expression levels correlated to Fhl2, and nineteen of them were known genes. There were 
positive or negative correlations to Fhl2. The expression of Fhl2 was positively correlated 
to translocate demilune cell and parotid protein1 (Dcpp1), kinocilin (Kncn), follistatin 
(Fst), Lim homeobox protein 3 (Lhx3), amelogenin X chromosome (Amelx), predicted 
gene 5246 (Gm5246), keratin 31 (Krt31), synaptotagmin-like 5 (Sytl5), trace amine-
associated receptor 8A (Taar8a), CCR4-NOT transcription complex, subunit 8 (Cnot8), 
defensin, alpha, related sequence 2 (Defa-rs2), transmembrane channel-like gene family 1 
(Tmc1), H1 histone family, member O, oocyte-specific (H1foo), olfactory receptor 1505 
(Olfr1505), calcyon neuron-specific vesicular protein (Caly), C1q and tumor necrosis 
factor related protein 3 (C1qtnf3), extended synaptotagmin-like protein 3 (Esyt3), and 






Figure 3-10. Western blot analysis of skin from Tsk2/+ and B6 mice. 
Protein samples were collected from the skin of Tsk2/+ and B6 mice when they were 4 
weeks old. Samples were duplicated with the Fhl2 antibody. The bands of the 4 week old 
B6 mice were lighter than those of the Tsk2/+ mice. The intensity of the bands was 
measured using Image J software. From the bar graph, the Tsk2/+ mice had significantly 






Figure 3-11. Detection of QTL for Fhl2 gene expression levels using RI strains. 
(A) QTL detection that the upstream gene is on the chromosome 5. The numbers on top 
of each figure indicate the chromosome number. Numbers on the left vertical axis 
indicate the LRS values. The pink lines on the top indicate the threshold for the 
significant level. Light grey lines indicate the threshold for the suggestive level. (B) On 
chromosome 5, the region is between 55.00 Mb to 64.00 Mb. The location is shown 
below the horizontal axis. Numbers to the left of the vertical axis are the LRS values. The 
pink lines on the top indicate the threshold for the significant level. Light grey lines 




protein 1, binding protein 3(Hp1bp3) (Figure 3-12). There is only Taar8a gene on 





Collagen is very abundant in the body and is the protein that plays the most 
important role in the fibrotic process of SSc. Previous studies have shown that Tsk2/+ 
mice develop skin tightness, display ECM anomalies, and produce high ANAs levels. 
Tsk2/+ mice have a normal life expectancy in comparison to the wild type mice. Male 
Tsk2/+ mice were bred with B6 females because Tsk2/+ females cannot breed. We 
examined and quantified the disease signs during aging and in different tissues and 
determined a causative role for the collagen accumulation in the fibrotic trait. Tsk1/+ 
mice develop a hunched posture as they age. The Tsk2/+ mice do not have a posture 
change. To evaluate disease progression, we needed to find a reliable method to 
determine and quantify disease severity. To eliminate the variability inherent in the 
physical skin grabbing method, measuring the interscapular skin tightness was used to 
quantify the disease. Tsk2/+ mice have noticeably tighter scapular skin than their 
littermates after 3 weeks; it was difficult to gather the skin into a fold. No difference was 
found between organ size and shape of the two mice strains when they were collected at 
4, 6, and 10 weeks. The body length, tail length, body weight, and skin tightness were 
measured for comparing the Tsk2/+ and B6 mice. The body length and tail length did not 
show a significant difference between Tsk2/+ and B6 mice. This is expected because this 
is a skin disease and should not affect the body or tail length. For the body length, males 
were longer than the females in both strains, but there was no tail length difference 
between male and female. Weight increased with age in both male and female. Males 
were heavier than the females in both strains. Both genders of the Tsk2/+ mice were 
lighter than their B6 littermates. The reason for this is unknown, but we speculate that it 
may be due to the physically smaller bones and lower bone density of Tsk2/+ mice 
compared to normal B6 mice[167]. The skin scores were measured by grabbing the 
interscapular skin at different ages. The mice were measured the first time when they 
were 3 weeks old. phenotype between Tsk2/+ and B6 was obviously different, and this 
was an important basis to use to distinguish them. The capability to grasp the skin was 
measured by placing the pulled skin against a ruler. B6 mice skin can be grasped ~ 1.7 
cm and the Tsk2/+ mice skin can only be grasped ~ 0.7 cm. Upon contact with the skin, 
you can tell the difference between the two mice strains. The skin of the B6 mice was 
elastic and one could grab a substantial amount of skin. On the other hand, the skin of 
Tsk2/+ mice was tight and one was unable to grab very much skin to pull. The skin has 
some small variation before 7 weeks and is relatively stable during growth. Our goal was 
to find the mutation gene in Tsk2/+ mice. 
  
The mutation gene for Tsk2/+ was reported as Col3a1 the Jiménez group[168]. 
The Tsk2/+ mice were identified by a single nucleotide change on Col3a1 gene by the 
Blankenhorn group in 2015[167]. There were three DNA sequence differences that were 
Tsk2/+-specific. All three single nucleotide polymorphisms were at different regions. 





Figure 3-12. Gene network among Fhl2 genes, which are upregulated or 
downregulated in mice, constructed using expression profiles from spleen BXD 
mouse strains.  
The Fifty most related genes were collected to compare with Fhl2, nineteen of them are 
known genes. The Taar8a gene is the only one related to Fhl2 and on the chromosome 5 





and gene expression in the skin. These two SNPs cannot cause the mutation. The third 
SNP was in the Col3a1 exon. Thymine changed to adenine at 45,378,353 on chromosome 
1. This changed the amino acid from cysteine to serine in the Procollagen III amino 
terminal propeptide segment. Four pairs of primers for PCR and rt-PCR were designed by 
Primer 3 to identify the Tsk2/+ and normal mice. The pairs of primers for PCR were 
Col3a1-dna-T and Col3a1-dna-N. The Primers for rt-PCR were Col3a1-T and Col3a1-N. 
The Col3a1-dna-T and Col3a1-dna-N had the same reverse primer, only the forward 
primers were different. The Col3a1-dna-T forward primer and the Col3a1-dna-N forward 
primer had only a single nucleotide difference. The last single nucleotide of the Col3a1-
dna-T forward primer was A and the Col3a1-dna-T forward primer was T. Tsk2/+ and B6 
strains were confirmed by using PCR (data not shown). On the mRNA level, samples 1-3 
from 4wks-B6 skin and samples 4-6 from 4wks-Tsk/2+ were amplified by rt-PCR by 
using the Col3a1-T-F and Col3a1-T/N-R pair of primers. In this instance, when we 
amplified the segment of DNA, Col3a1-dna-N can amplify both B6 and Tsk2/+, while 
Col3a1-dna-T can only amplify Tsk2/+. Our data verified there is an SNP on Col3a1. 
Verifying the B6 and Tsk2/+ mice by PCR and rt-PCR experiments can prove that there 
is a single nucleotide polymorphism in Tsk2/+ in Col3a1 gene.  
 
The single nucleotide polymorphism of thymine to adenine in Col3a1 was one 
difference between B6 and Tsk2/+. The changing of this single nucleotide causes the 
amino acid to change from cysteine to serine, and this changed the protein structure. 
Cysteine and serine are both neutral-polar amino acids with similar structures. The only 
difference in structure between the two amino acids is a change from a sulfhydryl (SH) to 
a hydroxyl (OH) group. We believe that this a negligible difference that makes only a 
limited change in protein structure or function. The Col3a1 expression levels were not 
different between B6 and Tsk2/+ mice in skin, heart, and kidney. There is only one 
transcript of the Col3a1 gene. If Col3a1 is the mutation gene, why is there fibrosis only in 
the skin, not other tissues or organs? According to an online database, bladder, 
mammary, osteoblast, and umbilical had very high expression levels. Why was there not 
any report of these tissues having fibrosis? If Col3a1 is the only mutated gene, then 
fibrosis should be found throughout the body, not just in the skin. However, fibrosis has 
not been reported in other organs; thus, in our hypothesis, there must be at least one other 
mutation gene influencing susceptibility to tight skin disease. Based on this, there is 
another regulatory gene that could be found by examining upregulation in Tsk2/+. The 
upregulated genes were of interest because we knew that the collagen level increased in 
tight skin and that this was caused by overexpression. In our microarray data, there were 
eighty-two probes upregulated in Tsk2/+ and four probes upregulated on chromosome 1 
between 42.5 and 52.5 Mb. The four genes were Col3a1, Slc40a1, Slc39a10, and Fhl2. 
Based on our many years of research, Fhl2 was chosen as our candidate gene.  
 
Of the four upregulated genes, the Col3a1 and Fhl2 have had expression levels 
tested in different tissues, because Col3a1 had been previously reported as a candidate 
gene, and Fhl2 is located on the QTL region. Col3a1 and Fhl2 are both located on 
chromosome one. These two genes are expressed in different tissues, and within the 
tissues in which they are expressed, their expression levels are different. Since Col3a1 
only has one transcript, fibrosis would be expected to be found in the tissues where there 
 
87 
is high expression, but it is not. The high expression of Fhl2 in the heart can be explained 
by Fhl2 having two transcripts and only one of them being the cause of tight skin.  
 
Fhl2 is located on chromosome 1 from 43,123,074 to 43,196,984. In our research, 
there were two protein coding transcripts: Fhl2-201 and Fhl2-202. Fhl2-201 was 
determined to be 1566 bp and Fhl2-202 was 1417 bp. The difference in these two 
transcripts is that they have different first exons. The first exons are completely different 
fragments between the two transcripts, not just that Fhl2-201 is 149 bp longer than Fhl2-
202. The rest of the five exons were identical. The two transcripts displayed different 
expression ratios in different tissues and organs, and many tissues and organs only 
showed expression of one of the transcripts. Although the first exon is different, these 
two transcripts produce the same protein, but the promoters are different. So, although the 
same protein is being expressed by these transcripts, the amount of protein produced will 
be different because of the promoters. A mutation in the promoter of Fhl2-201 could be 
the cause of upregulation in Tsk2/+, causing tight skin. The expression levels of the two 
transcripts are relatively independent. In our experiments, the two transcripts, Fhl2-201 
and Fhl2-202, were tested for expression levels in skin, muscle, heart, kidney, liver, and 
lung. From the results of our experiments, skin and kidney only showed Fhl2-201 
transcript expression. As shown in Table 3-1, the expression of Fhl2 is very low in the 
kidney and likely does not cause fibrosis. The heart had mainly Fhl2-202 transcript 
expression and subtle Fhl2-201 transcript expression. In muscle, liver, and lung, both 
transcripts had no or very low expression. It is clear that the expression level of the Fhl2-
201 transcript in the skin is much higher for the Tsk2/+ mice than that of the B6 mice. 
The heart expresses Fhl2-202 but not Fh12-201, so the high expression of the gene does 
not affect the heart. These results explain why fibrosis is only found in the skin, and why 
expression of Fhl2-201 is low or nonexistent in the other organs compared to high 
expression in the skin.     
 
 In our study, we thought there was a single or only a few single nucleotide 
polymorphisms on the Fhl2 gene. We designed many primers to amplify the segments in 
order to sequence them and identify the polymorphisms. We sequenced the genomic 
DNA, cDNA, promoter, and two side introns connecting each exon. We have not yet 
found a polymorphism between B6 and Tsk2/+. We will increase the scope of sequencing 
to find the polymorphisms. Since a polymorphism was not found, upstream genes were 
identified as other possibilities to study. Taar8a was found upstream of Fhl2 and is on 
chromosome 5. This can be beneficial in the quest to understand the molecular 
mechanism and pathway of Tsk2/+.   
 
Real-time PCR was used to detect the expression levels in different tissues and 
organs. Probes were ordered from Applied Biosystems, so we did not know which part of 
the gene they selected. The Fhl2 gene expression levels in Tsk2/+ mice were higher than 
that of B6 mice, and the expression variability increased with age. The Fhl2 gene 
expression levels were tested in different tissues at 4, 6, and 10 weeks in female mice. In 
the skin, the Fhl2 expression levels of Tsk2/+mice were higher than that of B6 mice at all 
the same time points. At 4 and 6 weeks, Tsk2/+ were around 1.5-fold more than normal. 
At 10 weeks, the Tsk2/+ expression level was 2.5-fold more than normal. In the muscle, 
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heart, kidney, and lung tissues, the Fhl2 expression levels were slightly higher in Tsk2/+ 
than B6. The expression of Fhl2-202 in Tsk2/+ and B6 tissues or organs were the same. 
The Fhl2-201 gene expression levels were different among Tsk2/+ and B6 tissues and 
organs. In the skin, the Fhl2 gene mainly expresses the Fhl2-201 transcript, so there was a 
clear difference between Tsk2/+ and B6 in real-time PCR. In muscle, heart, kidney, and 
lung, we found that the Fhl2 expression levels in Tsk2/+ were higher than B6, but the 
difference very minor. Both Fhl2-201 and Fhl2-202 were present in these tissues or 
organs, but Fhl2-202 accounted for a more dominant role. Fhl2-201 is suspected as being 
the mutated gene and not Fhl2-202 as supported by these data because the RT results 
showed that there was no difference in Fhl2-202 between Tsk2/+ and B6, but there is a 
difference in Fhl2-201. Through Western blot experiments, we measured Fhl2 protein 
levels to substantiate our position. The protein levels of Fhl2 in Tsk2/+ skin were higher 
than that found in B6 skin. 
 
This study identified Fhl2 as a possible candidate gene for Tsk2/+, but the 
research on this gene and its role in the disease is not yet complete. Even if this gene is 
not the mutated gene, it has very important implications in the molecular mechanism and 
pathway for this disease. We have not yet found the SNP between the Tsk2/+ and B6 







CHAPTER 4.    CONCLUSION 
 
 
Diseases of the immune system are a very important issue. They are always very 
complicated because they have multiple influencing factors. Currently, there are at least 
80 known autoimmune diseases, of which rheumatoid arthritis and systemic sclerosis are 
two. Arthritis and systemic sclerosis are serious, debilitating autoimmune diseases that 
collectively affect over fifty-five million people in just the United States. Rheumatoid 
arthritis is a systemic, chronic, inflammatory disorder that is expressed in the wrists, 
ankles, and small joints of the hands and feet that can cause pain and swelling. Systemic 
sclerosis is a localized or diffuse skin thickening and fibrosis caused by the body’s 
immune system attacks its own tissue. This disease is a debilitating, chronic autoimmune 
disease that is potentially fatal, but the underlying cause is unknown. Limited cutaneous 
and diffuse cutaneous are the two main types of system sclerosis. In past six years, I used 
our two disease mouse models to improve the understanding of the human diseases. This 
study aimed to evaluate the molecular mechanisms of these two diseases by studying 
wild type and mutated genes in mouse models.  Understanding the molecular 
mechanisms that lead to these diseases is of great importance for discovering therapeutic 
remedies and possibly preventing or curing the RA and systemic sclerosis.   
 
Spontaneous arthritis was studied in mice because of the strong similarities found 
between arthritis in humans and in mice.  We discovered the candidate genes in our IL-
1rn deficient spontaneous arthritis mouse models to understand the pathogenesis and 
treatment of inflammatory arthritis. The model is of interest because it is spontaneous in 
onset and involves a signaling pathway implicated in human arthritis. Fully 
understanding the model may provide insight into what triggers disease and ultimately 
how to prevent arthritis. To better understand the pathogenesis of SAD, we bred 
susceptible, resistant and congenic mice: BALB/c-/-, DBA/1-/-, BALB.D-1-/-, and DBA.B-
1-/-. Our study produced useful data on the genetic regulation of spontaneous arthritis 
under the BALB/c-/- and DBA/1-/- genomic background. The QTLs and the information 
on candidate genes provide a basic analysis of the molecular mechanisms of spontaneous 
arthritis. We located a genetic factor that regulates SAD on chromosome 1. The 
expression levels of Ifi200 cluster genes were decreased while the resistance to SAD is 
increased in the congenic strain BALB.D1-1-/-, in comparison to its recipient parental 
strain BALB/c-/-. The expression level of Ifi204 is the only gene in the Ifi200 cluster 
which showed a significant difference at a detectable or functional level, suggesting 
Ifi204 within the QTL region is most likely the causal gene for the regulation of SAD 
between mice with BALB/c-/- and DBA/1-/- genomic background. We sequenced the 
coding gene between BALB/c-/- and DBA/1-/- mice and found several polymorphisms. 
The function of the protein may be changed by alterations in the protein structure that is 
modified by the polymorphisms. In future studies, we will compare the specific protein 
structure between BALB/c-/- and DBA/1-/- by first getting a complete sequence of the 
genes to compare. The difference in protein structure can help us understand why the two 
strains do or do not have arthritis when they lack IL-1rn. Through this research we were 
able to determine a genetic component that regulates susceptibility to SAD, and then 
identify Ifi204 as a candidate gene in the causal pathway of spontaneous arthritis.  The 
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theory that Ifi204 is a favorable candidate gene is supported by the results. They show 
that the expression levels of Ifi204 decreased while resistance to SAD increased, but the 
expression levels increased in relation to a decrease in SAD resistance.  This data can be 
used to further study Ifi204 and its relationship with spontaneous arthritis in hopes of 
developing a drug that targets Ifi204.   
 
Systemic sclerosis (SSc) or scleroderma is a prototypic idiopathic fibrosing 
disease. These fibrotic diseases are influenced by many environmental and genetic factors 
and have been extensively studied. However, many of the basic mechanisms of disease 
pathogenesis remain elusive. There are only a few effective therapies for preventing 
fibrosis. We used a mouse autoimmune disease model called tight skin 2 (Tsk2) to study 
genetic factors that regulate fibrosis in dermal tissues. Tsk2/+ is a mouse model 
containing a mutation that causes tight skin and excessive deposition of dermal ECM 
proteins, a presentation very similar to that of systemic sclerosis in humans, and thus 
making it a perfect animal model to study the molecular mechanism of the disease.  
Studies indicated that excess collagen production was the result of an increased number 
of collagen expressing dermal fibroblasts, as well as elevated collagen expression on a 
per cell basis. We focused on identifying the mutated gene in the disease locus of the 
Tsk2/+ mouse. The mutation has been localized to mouse chromosome 1 between 42.5 
and 52.5 megabases (Mb), and considerable effort has been expended in the study of the 
molecular mechanisms of the disease. We used data from microarray expression profiles 
to select candidate genes. A single nucleotide polymorphism was found in COL3A1 
between the diseased model (Tsk2/+) and the normal model (B6) that results in a change 
in protein structure. From the microarray data and gene mapping, Fhl2 gene was found to 
be the potential candidate gene. We confirmed Fhl2 gene expression levels were different 
in Tsk2/+ and normal mice skin by PCR, rt-PCR and real time PCR. There are two 
transcripts of the Fhl2 gene and each transcript is expressed in different tissues which 
explains why only the skin has fibrosis. We hypothesized that there would be one or more 
nucleotide polymorphisms between Tsk2/+ and B6 in this gene, but one has not been 
found.  We intend to increase the scope to find the polymorphism(s). In future studies, we 
will increase our sequencing region and carefully examine the data to make sure we do 
not miss any potential heterozygotes in Tsk2 mice. We will search the molecular pathway 






LIST OF REFERENCES 
 
 
1. Chandra, R.K., Nutrition and the immune system: an introduction. Am J Clin 
Nutr, 1997. 66(2): p. 460S-463S. 
2. Springer, T.A., Adhesion receptors of the immune system. Nature, 1990. 
346(6283): p. 425-34. 
3. Grode, L., et al., Prevalence, incidence, and autoimmune comorbidities of celiac 
disease: a nation-wide, population-based study in Denmark from 1977 to 2016. 
Eur J Gastroenterol Hepatol, 2018. 30(1): p. 83-91. 
4. Harrison, C.A. and D. Taren, How poverty affects diet to shape the microbiota 
and chronic disease. Nat Rev Immunol, 2018. 18(4): p. 279-287. 
5. Siegel, I., T.L. Liu, and N. Gleicher, The red-cell immune system. Lancet, 1981. 
2(8246): p. 556-9. 
6. Kerschensteiner, M., et al., Activated human T cells, B cells, and monocytes 
produce brain-derived neurotrophic factor in vitro and in inflammatory brain 
lesions: a neuroprotective role of inflammation? J Exp Med, 1999. 189(5): p. 
865-70. 
7. Knight, J.A., Review: Free radicals, antioxidants, and the immune system. Ann 
Clin Lab Sci, 2000. 30(2): p. 145-58. 
8. Rosenthal, A.S., Determinant selection and macrophage function in genetic 
control of the immune response. Immunol Rev, 1978. 40: p. 136-52. 
9. Adams, D.O. and T.A. Hamilton, The cell biology of macrophage activation. 
Annu Rev Immunol, 1984. 2: p. 283-318. 
10. Deighton, C. and L.A. Criswell, Recent advances in the genetics of rheumatoid 
arthritis. Curr Rheumatol Rep, 2006. 8(5): p. 394-400. 
11. Coteur, G., N. Corriere, and P. Dubois, Environmental factors influencing the 
immune responses of the common European starfish (Asterias rubens). Fish 
Shellfish Immunol, 2004. 16(1): p. 51-63. 
12. Zemskov, A.M., et al., [Immune reactivity and environmental factors]. Fiziol 
Cheloveka, 1997. 23(6): p. 98-105. 
13. Alfsen, A., Environmental factors in HIV/AIDS epidemic development: new 
perspectives for gender equity and global protection against HIV transmission. 
Ann N Y Acad Sci, 2004. 1023: p. 164-74. 
14. Traylor, M., et al., Genetic and environmental risk factors for rheumatoid 
arthritis in a UK African ancestry population: the GENRA case-control study. 
Rheumatology (Oxford), 2017. 56(8): p. 1282-1292. 
15. Duntas, L.H., Environmental factors and thyroid autoimmunity. Ann Endocrinol 
(Paris), 2011. 72(2): p. 108-13. 
16. Rewers, M. and J. Ludvigsson, Environmental risk factors for type 1 diabetes. 
Lancet, 2016. 387(10035): p. 2340-2348. 
17. Joe, B., Quest for arthritis-causative genetic factors in the rat. Physiol Genomics, 
2006. 27(1): p. 1-11. 
18. Oliver, J.E. and A.J. Silman, Risk factors for the development of rheumatoid 
arthritis. Scand J Rheumatol, 2006. 35(3): p. 169-74. 
 
92 
19. Duncan, M.R., et al., Cultured fibroblasts in avian scleroderma, an autoimmune 
fibrotic disease, display an activated phenotype. J Autoimmun, 1992. 5(5): p. 
603-15. 
20. Shiozawa, S., et al., An approach to identify new genes in autoimmune diseases: 
lessons from rheumatoid arthritis. Rev Immunogenet, 2000. 2(1): p. 133-9. 
21. Blencowe, B.J., Exonic splicing enhancers: mechanism of action, diversity and 
role in human genetic diseases. Trends Biochem Sci, 2000. 25(3): p. 106-10. 
22. Smith, M.L. and G.V. Glass, Meta-analysis of psychotherapy outcome studies. 
Am Psychol, 1977. 32(9): p. 752-60. 
23. Watson, J.D. and F.H. Crick, Molecular structure of nucleic acids; a structure for 
deoxyribose nucleic acid. Nature, 1953. 171(4356): p. 737-8. 
24. Hershey, A.D. and M. Chase, Independent functions of viral protein and nucleic 
acid in growth of bacteriophage. J Gen Physiol, 1952. 36(1): p. 39-56. 
25. Hartwell, L.H., Macromolecule synthesis in temperature-sensitive mutants of 
yeast. J Bacteriol, 1967. 93(5): p. 1662-70. 
26. Hubscher, U., DNA polymerases in prokaryotes and eukaryotes: mode of action 
and biological implications. Experientia, 1983. 39(1): p. 1-25. 
27. Grantham, R., Viral, prokaryote and eukaryote genes contrasted by mRNA 
sequence indexes. FEBS Lett, 1978. 95(1): p. 1-11. 
28. Koo, H.S., H.M. Wu, and D.M. Crothers, DNA bending at adenine . thymine 
tracts. Nature, 1986. 320(6062): p. 501-6. 
29. Shafer, R.H., Stability and structure of model DNA triplexes and quadruplexes 
and their interactions with small ligands. Prog Nucleic Acid Res Mol Biol, 1998. 
59: p. 55-94. 
30. Duncan, B.K. and J.H. Miller, Mutagenic deamination of cytosine residues in 
DNA. Nature, 1980. 287(5782): p. 560-1. 
31. Cathcart, R., et al., Thymine glycol and thymidine glycol in human and rat urine: 
a possible assay for oxidative DNA damage. Proc Natl Acad Sci U S A, 1984. 
81(18): p. 5633-7. 
32. Ezkurdia, I., et al., Multiple evidence strands suggest that there may be as few as 
19,000 human protein-coding genes. Hum Mol Genet, 2014. 23(22): p. 5866-78. 
33. Guenet, J.L., The mouse genome. Genome Res, 2005. 15(12): p. 1729-40. 
34. Prockop, D.J., et al., The biosynthesis of collagen and its disorders (first of two 
parts). N Engl J Med, 1979. 301(1): p. 13-23. 
35. Prockop, D.J., et al., The biosynthesis of collagen and its disorders (second of two 
parts). N Engl J Med, 1979. 301(2): p. 77-85. 
36. Kogan, S.C., M. Doherty, and J. Gitschier, An improved method for prenatal 
diagnosis of genetic diseases by analysis of amplified DNA sequences. 
Application to hemophilia A. N Engl J Med, 1987. 317(16): p. 985-90. 
37. Kim, J., J.J. Kim, and H. Lee, An analysis of disease-gene relationship from 
Medline abstracts by DigSee. Sci Rep, 2017. 7: p. 40154. 
38. Cargill, M., et al., Characterization of single-nucleotide polymorphisms in coding 
regions of human genes. Nat Genet, 1999. 22(3): p. 231-8. 
39. Smithies, O., Animal models of human genetic diseases. Trends Genet, 1993. 
9(4): p. 112-6. 
 
93 
40. Rowley, J.D., Letter: A new consistent chromosomal abnormality in chronic 
myelogenous leukaemia identified by quinacrine fluorescence and Giemsa 
staining. Nature, 1973. 243(5405): p. 290-3. 
41. Sharma, S., et al., Homology and enzymatic requirements of microhomology-
dependent alternative end joining. Cell Death Dis, 2015. 6: p. e1697. 
42. Rodgers, K. and M. McVey, Error-Prone Repair of DNA Double-Strand Breaks. 
J Cell Physiol, 2016. 231(1): p. 15-24. 
43. Leimar, O., The evolution of phenotypic polymorphism: randomized strategies 
versus evolutionary branching. Am Nat, 2005. 165(6): p. 669-81. 
44. Gordon, W.G., J.J. Basch, and M.P. Thompson, Genetic polymorphism in caseins 
of cow's milk. VI. Amino acid composition of alpha-s-1-caseins A, B, and C. J 
Dairy Sci, 1965. 48(8): p. 1010-3. 
45. Wang, M. and G. Caetano-Anolles, The evolutionary mechanics of domain 
organization in proteomes and the rise of modularity in the protein world. 
Structure, 2009. 17(1): p. 66-78. 
46. Siepel, A., Darwinian alchemy: Human genes from noncoding DNA. Genome 
Res, 2009. 19(10): p. 1693-5. 
47. Audic, S. and J.M. Claverie, The significance of digital gene expression profiles. 
Genome Res, 1997. 7(10): p. 986-95. 
48. Chomczynski, P., A reagent for the single-step simultaneous isolation of RNA, 
DNA and proteins from cell and tissue samples. Biotechniques, 1993. 15(3): p. 
532-4, 536-7. 
49. Orphanides, G., T. Lagrange, and D. Reinberg, The general transcription factors 
of RNA polymerase II. Genes Dev, 1996. 10(21): p. 2657-83. 
50. Murray, V. and R. Holliday, Mechanism for RNA splicing of gene transcripts. 
FEBS Lett, 1979. 106(1): p. 5-7. 
51. Breathnach, R., et al., Ovalbumin gene: evidence for a leader sequence in mRNA 
and DNA sequences at the exon-intron boundaries. Proc Natl Acad Sci U S A, 
1978. 75(10): p. 4853-7. 
52. Winick, M. and A. Noble, Quantitative changes in DNA, RNA, and protein during 
prenatal and postnatal growth in the rat. Dev Biol, 1965. 12(3): p. 451-66. 
53. Roeder, R.G. and W.J. Rutter, Multiple forms of DNA-dependent RNA polymerase 
in eukaryotic organisms. Nature, 1969. 224(5216): p. 234-7. 
54. Sawadogo, M. and R.G. Roeder, Interaction of a gene-specific transcription 
factor with the adenovirus major late promoter upstream of the TATA box region. 
Cell, 1985. 43(1): p. 165-75. 
55. Parker, C.S. and J. Topol, A Drosophila RNA polymerase II transcription factor 
contains a promoter-region-specific DNA-binding activity. Cell, 1984. 36(2): p. 
357-69. 
56. Furth, P.A., et al., Temporal control of gene expression in transgenic mice by a 
tetracycline-responsive promoter. Proc Natl Acad Sci U S A, 1994. 91(20): p. 
9302-6. 
57. Gossen, M. and H. Bujard, Tight control of gene expression in mammalian cells 




58. Wu, H., et al., Tissue-specific RNA expression marks distant-acting 
developmental enhancers. PLoS Genet, 2014. 10(9): p. e1004610. 
59. Schena, M., et al., Quantitative monitoring of gene expression patterns with a 
complementary DNA microarray. Science, 1995. 270(5235): p. 467-70. 
60. Li, X., et al., Clinical utility of microarrays: current status, existing challenges 
and future outlook. Curr Genomics, 2008. 9(7): p. 466-74. 
61. Brown, M.P., et al., Knowledge-based analysis of microarray gene expression 
data by using support vector machines. Proc Natl Acad Sci U S A, 2000. 97(1): p. 
262-7. 
62. Lababidi, S., Challenges in DNA microarray studies from the regulatory 
perspective. J Biopharm Stat, 2008. 18(1): p. 183-202. 
63. Bailey, D.W., Recombinant-inbred strains. An aid to finding identity, linkage, and 
function of histocompatibility and other genes. Transplantation, 1971. 11(3): p. 
325-7. 
64. Paigen, B., et al., Atherosclerosis susceptibility differences among progenitors of 
recombinant inbred strains of mice. Arteriosclerosis, 1990. 10(2): p. 316-23. 
65. Nadeau, J.H. and W.N. Frankel, The roads from phenotypic variation to gene 
discovery: mutagenesis versus QTLs. Nat Genet, 2000. 25(4): p. 381-4. 
66. Van Ooijen, J.W., LOD significance thresholds for QTL analysis in experimental 
populations of diploid species. Heredity (Edinb), 1999. 83 (Pt 5): p. 613-24. 
67. Gill, K. and A.E. Boyle, Genetic analysis of alcohol intake in recombinant inbred 
and congenic strains derived from A/J and C57BL/6J progenitors. Mamm 
Genome, 2005. 16(5): p. 319-31. 
68. Darvasi, A., et al., Detecting marker-QTL linkage and estimating QTL gene effect 
and map location using a saturated genetic map. Genetics, 1993. 134(3): p. 943-
51. 
69. Parker, C.C., et al., Systems Genetic Analysis in GeneNetwork.org. Curr Protoc 
Neurosci, 2017. 79: p. 8 39 1-8 39 20. 
70. Williams, R.W. and L. Lu, Integrative genetic analysis of alcohol dependence 
using the GeneNetwork Web resources. Alcohol Res Health, 2008. 31(3): p. 275-
7. 
71. Williams, R.W., et al., The genetic structure of recombinant inbred mice: high-
resolution consensus maps for complex trait analysis. Genome Biol, 2001. 2(11): 
p. RESEARCH0046. 
72. Chesler, E.J., et al., Genetic correlates of gene expression in recombinant inbred 
strains: a relational model system to explore neurobehavioral phenotypes. 
Neuroinformatics, 2003. 1(4): p. 343-57. 
73. Jones, B.C., et al., Genetic correlational analysis reveals no association between 
MPP+ and the severity of striatal dopaminergic damage following MPTP 
treatment in BXD mouse strains. Neurotoxicol Teratol, 2014. 45: p. 91-2. 
74. Kimura, M. and G.H. Weiss, The Stepping Stone Model of Population Structure 
and the Decrease of Genetic Correlation with Distance. Genetics, 1964. 49(4): p. 
561-76. 
75. Lu, H., et al., Iris transillumination defect and its gene modulators do not 




76. Witte, J.S., W.J. Gauderman, and D.C. Thomas, Asymptotic bias and efficiency in 
case-control studies of candidate genes and gene-environment interactions: basic 
family designs. Am J Epidemiol, 1999. 149(8): p. 693-705. 
77. Yamaoka, K., T. Nakagawa, and T. Uno, Statistical moments in 
pharmacokinetics. J Pharmacokinet Biopharm, 1978. 6(6): p. 547-58. 
78. Dunne, A., Statistical moments in pharmacokinetics: models and assumptions. J 
Pharm Pharmacol, 1993. 45(10): p. 871-5. 
79. Forrest, A., et al., Pharmacodynamics of intravenous ciprofloxacin in seriously ill 
patients. Antimicrob Agents Chemother, 1993. 37(5): p. 1073-81. 
80. Moore, P.S., et al., Molecular mimicry of human cytokine and cytokine response 
pathway genes by KSHV. Science, 1996. 274(5293): p. 1739-44. 
81. Tabor, H.K., N.J. Risch, and R.M. Myers, Candidate-gene approaches for 
studying complex genetic traits: practical considerations. Nat Rev Genet, 2002. 
3(5): p. 391-7. 
82. Xu, Z. and J.A. Taylor, SNPinfo: integrating GWAS and candidate gene 
information into functional SNP selection for genetic association studies. Nucleic 
Acids Res, 2009. 37(Web Server issue): p. W600-5. 
83. Church, G.M. and W. Gilbert, Genomic sequencing. Proc Natl Acad Sci U S A, 
1984. 81(7): p. 1991-5. 
84. Hyman, E.D., A new method of sequencing DNA. Anal Biochem, 1988. 174(2): p. 
423-36. 
85. Sanger, F., The Croonian Lecture, 1975. Nucleotide sequences in DNA. Proc R 
Soc Lond B Biol Sci, 1975. 191(1104): p. 317-33. 
86. Ensenberger, M.G., et al., Developmental validation of the PowerPlex 16 HS 
System: an improved 16-locus fluorescent STR multiplex. Forensic Sci Int Genet, 
2010. 4(4): p. 257-64. 
87. Kaji, E.H. and J.M. Leiden, Gene and stem cell therapies. JAMA, 2001. 285(5): 
p. 545-50. 
88. Li, S. and L. Huang, Nonviral gene therapy: promises and challenges. Gene Ther, 
2000. 7(1): p. 31-4. 
89. Rosenberg, S.A., et al., Gene transfer into humans--immunotherapy of patients 
with advanced melanoma, using tumor-infiltrating lymphocytes modified by 
retroviral gene transduction. N Engl J Med, 1990. 323(9): p. 570-8. 
90. Cavazzana-Calvo, M., et al., Gene therapy of human severe combined 
immunodeficiency (SCID)-X1 disease. Science, 2000. 288(5466): p. 669-72. 
91. Fuhrman, F.A., Tetrodotoxin. It is a powerful poison that is found in two almost 
totally unrelated kinds of animal: puffer fish and newts. It has been serving as a 
tool in nerve physiology and may provide a model for new local anesthetics. Sci 
Am, 1967. 217(2): p. 60-71. 
92. Porsolt, R.D., M. Le Pichon, and M. Jalfre, Depression: a new animal model 
sensitive to antidepressant treatments. Nature, 1977. 266(5604): p. 730-2. 
93. Rao, B.S., J.S. Prasad, and C.V. Sarathy, An animal model to study iron 
availability from human diets. Br J Nutr, 1977. 37(3): p. 451-6. 
94. McKinney, W.T., Jr. and W.E. Bunney, Jr., Animal model of depression. I. 




95. Koshman, R.W., J. Koo, and O.G. Thurston, A human/mouse hybrid model for the 
study of human genetic factors influencing tumor cell growth. J Surg Oncol, 1975. 
7(4): p. 323-7. 
96. Nair, S., M. Faizuddin, and J. Dharmapalan, Role of autoimmune responses in 
periodontal disease. Autoimmune Dis, 2014. 2014: p. 596824. 
97. Tian, C., et al., Ifi204 as the most favored candidate gene that regulates 
susceptibility to spontaneous arthritis in mice. Gene Reports, 2018. 12: p. 21-29. 
98. Ropes, M.W., et al., 1958 Revision of diagnostic criteria for rheumatoid arthritis. 
Bull Rheum Dis, 1958. 9(4): p. 175-6. 
99. Steinbrocker, O., C.H. Traeger, and R.C. Batterman, Therapeutic criteria in 
rheumatoid arthritis. J Am Med Assoc, 1949. 140(8): p. 659-62. 
100. Sandal, I., et al., Bone loss and aggravated autoimmune arthritis in HLA-
DRbeta1-bearing humanized mice following oral challenge with Porphyromonas 
gingivalis. Arthritis Res Ther, 2016. 18(1): p. 249. 
101. Brennan, F.M., et al., Inhibitory effect of TNF alpha antibodies on synovial cell 
interleukin-1 production in rheumatoid arthritis. Lancet, 1989. 2(8657): p. 244-7. 
102. Harris, E.D., Jr., et al., Collagenase and rheumatoid arthritis. Arthritis Rheum, 
1970. 13(1): p. 83-94. 
103. Bhatia, G.S. and R.C. Davis, Rheumatoid arthritis and heart failure. Am J Med, 
2004. 117(9): p. 709; author reply 709. 
104. Bongartz, T., et al., Incidence and mortality of interstitial lung disease in 
rheumatoid arthritis: a population-based study. Arthritis Rheum, 2010. 62(6): p. 
1583-91. 
105. Jayson, M.I., Rheumatoid arthritis and the eye. Proc R Soc Med, 1977. 70(4): p. 
221-2. 
106. Remmers, E.F., et al., A genome scan localizes five non-MHC loci controlling 
collagen-induced arthritis in rats. Nat Genet, 1996. 14(1): p. 82-5. 
107. Otto, J.M., et al., Identification of multiple loci linked to inflammation and 
autoantibody production by a genome scan of a murine model of rheumatoid 
arthritis. Arthritis Rheum, 1999. 42(12): p. 2524-31. 
108. Otto, J.M., et al., A genome scan using a novel genetic cross identifies new 
susceptibility loci and traits in a mouse model of rheumatoid arthritis. J Immunol, 
2000. 165(9): p. 5278-86. 
109. Yu, X., et al., Fine mapping of collagen-induced arthritis quantitative trait loci in 
an advanced intercross line. J Immunol, 2006. 177(10): p. 7042-9. 
110. Ahlqvist, E., R. Bockermann, and R. Holmdahl, Fragmentation of two 
quantitative trait loci controlling collagen-induced arthritis reveals a new set of 
interacting subloci. J Immunol, 2007. 178(5): p. 3084-90. 
111. Campbell, E.C., A.N. Antoniou, and S.J. Powis, The multi-faceted nature of HLA 
class I dimer molecules. Immunology, 2012. 136(4): p. 380-4. 
112. Brand, D.D., K.A. Latham, and E.F. Rosloniec, Collagen-induced arthritis. Nat 
Protoc, 2007. 2(5): p. 1269-75. 
113. Pietrosimone, K.M., et al., Collagen-Induced Arthritis: A model for Murine 
Autoimmune Arthritis. Bio Protoc, 2015. 5(20). 
 
97 
114. Wooley, P.H., et al., Type II collagen-induced arthritis in mice. I. Major 
histocompatibility complex (I region) linkage and antibody correlates. J Exp Med, 
1981. 154(3): p. 688-700. 
115. Griffiths, M.M. and E.F. Remmers, Genetic analysis of collagen-induced arthritis 
in rats: a polygenic model for rheumatoid arthritis predicts a common framework 
of cross-species inflammatory/autoimmune disease loci. Immunol Rev, 2001. 184: 
p. 172-83. 
116. Adarichev, V.A., et al., Combined autoimmune models of arthritis reveal shared 
and independent qualitative (binary) and quantitative trait loci. J Immunol, 2003. 
170(5): p. 2283-92. 
117. Holmdahl, R., et al., Arthritis induced in rats with nonimmunogenic adjuvants as 
models for rheumatoid arthritis. Immunol Rev, 2001. 184: p. 184-202. 
118. Rintisch, C., et al., Finemapping of the arthritis QTL Pia7 reveals co-localization 
with Oia2 and the APLEC locus. Genes Immun, 2010. 11(3): p. 239-45. 
119. Pap, T. and A. Korb-Pap, Cartilage damage in osteoarthritis and rheumatoid 
arthritis--two unequal siblings. Nat Rev Rheumatol, 2015. 11(10): p. 606-15. 
120. Lubberts, E., The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol, 
2015. 11(10): p. 562. 
121. Adlan, A.M., et al., Autonomic function and rheumatoid arthritis: a systematic 
review. Semin Arthritis Rheum, 2014. 44(3): p. 283-304. 
122. Scott, I.C. and D.L. Scott, Spleen tyrosine kinase inhibitors for rheumatoid 
arthritis: where are we now? Drugs, 2014. 74(4): p. 415-22. 
123. O'Shea, J.J., A. Laurence, and I.B. McInnes, Back to the future: oral targeted 
therapy for RA and other autoimmune diseases. Nat Rev Rheumatol, 2013. 9(3): 
p. 173-82. 
124. Jesus, A.A. and R. Goldbach-Mansky, IL-1 blockade in autoinflammatory 
syndromes. Annu Rev Med, 2014. 65: p. 223-44. 
125. Besenyei, T., et al., Non-MHC risk alleles in rheumatoid arthritis and in the 
syntenic chromosome regions of corresponding animal models. Clin Dev 
Immunol, 2012. 2012: p. 284751. 
126. Dinarello, C.A., Biology of interleukin 1. FASEB J, 1988. 2(2): p. 108-15. 
127. Dower, S.K., et al., The cell surface receptors for interleukin-1 alpha and 
interleukin-1 beta are identical. Nature, 1986. 324(6094): p. 266-8. 
128. Dinarello, C.A. and R.C. Thompson, Blocking IL-1: interleukin 1 receptor 
antagonist in vivo and in vitro. Immunol Today, 1991. 12(11): p. 404-10. 
129. Hurme, M. and S. Santtila, IL-1 receptor antagonist (IL-1Ra) plasma levels are 
co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol, 1998. 
28(8): p. 2598-602. 
130. Horai, R., et al., Development of chronic inflammatory arthropathy resembling 
rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp 
Med, 2000. 191(2): p. 313-20. 
131. Zhou, F., et al., Arthritis in mice that are deficient in interleukin-1 receptor 




132. Deng, N., et al., Genomic locus on chromosome 1 regulates susceptibility to 
spontaneous arthritis in mice deficiency of IL-1RA. BMC Immunol, 2014. 15: p. 
57. 
133. Jiao, Y., et al., Identifying a major locus that regulates spontaneous arthritis in 
IL-1ra-deficient mice and analysis of potential candidates. Genet Res (Camb), 
2011. 93(2): p. 95-103. 
134. Liu, X., et al., Decreased expression levels of Ifi genes is associated to the 
increased resistance to spontaneous arthritis disease in mice deficiency of IL-
1RA. BMC Immunol, 2016. 17(1): p. 25. 
135. Cao, Y., et al., Analysis of candidate genes of spontaneous arthritis in mice 
deficient for interleukin-1 receptor antagonist. Genes Genet Syst, 2012. 87(2): p. 
107-13. 
136. Grau, S., et al., The role of human HtrA1 in arthritic disease. J Biol Chem, 2006. 
281(10): p. 6124-9. 
137. Gariglio, M., et al., The murine homolog of the HIN 200 family, Ifi 204, is 
constitutively expressed in myeloid cells and selectively induced in the 
monocyte/macrophage lineage. J Leukoc Biol, 1998. 64(5): p. 608-14. 
138. Lembo, M., et al., Inhibition of cell proliferation by the interferon-inducible 204 
gene, a member of the Ifi 200 cluster. Oncogene, 1998. 16(12): p. 1543-51. 
139. Choubey, D. and P. Lengyel, Interferon action: nucleolar and nucleoplasmic 
localization of the interferon-inducible 72-kD protein that is encoded by the Ifi 
204 gene from the gene 200 cluster. J Cell Biol, 1992. 116(6): p. 1333-41. 
140. Alunno, A., et al., Circulating Interferon-Inducible Protein IFI16 Correlates With 
Clinical and Serological Features in Rheumatoid Arthritis. Arthritis Care Res 
(Hoboken), 2016. 68(4): p. 440-5. 
141. Hoerster, K.D., et al., Health and health behavior differences: U.S. Military, 
veteran, and civilian men. Am J Prev Med, 2012. 43(5): p. 483-9. 
142. Centers for Disease, C. and Prevention, Prevalence of doctor-diagnosed arthritis 
and arthritis-attributable activity limitation--United States, 2010-2012. MMWR 
Morb Mortal Wkly Rep, 2013. 62(44): p. 869-73. 
143. Storek, K.M., et al., cGAS and Ifi204 cooperate to produce type I IFNs in 
response to Francisella infection. J Immunol, 2015. 194(7): p. 3236-45. 
144. Hou, Y., et al., The inhibitory effect of IFN-gamma on protease HTRA1 
expression in rheumatoid arthritis. J Immunol, 2014. 193(1): p. 130-8. 
145. Hsueh, M.F., V.B. Kraus, and P. Onnerfjord, Cartilage matrix remodelling differs 
by disease state and joint type. Eur Cell Mater, 2017. 34: p. 70-82. 
146. Pellett, F., et al., KIRs and autoimmune disease: studies in systemic lupus 
erythematosus and scleroderma. Tissue Antigens, 2007. 69 Suppl 1: p. 106-8. 
147. Zhang, K., et al., Mndal, a new interferon-inducible family member, is highly 
polymorphic, suppresses cell growth, and may modify plasmacytoma 
susceptibility. Blood, 2009. 114(14): p. 2952-60. 
148. Pattanaik, D., et al., Pathogenesis of Systemic Sclerosis. Front Immunol, 2015. 6: 
p. 272. 
149. Rodnan, G.P., E. Lipinski, and J. Luksick, Skin thickness and collagen content in 
progressive systemic sclerosis and localized scleroderma. Arthritis Rheum, 1979. 
22(2): p. 130-40. 
 
99 
150. Tan, E.M., Antinuclear antibodies: diagnostic markers for autoimmune diseases 
and probes for cell biology. Adv Immunol, 1989. 44: p. 93-151. 
151. Maurer, B., et al., Transcription factor fos-related antigen-2 induces progressive 
peripheral vasculopathy in mice closely resembling human systemic sclerosis. 
Circulation, 2009. 120(23): p. 2367-76. 
152. Sell, D.R. and V.M. Monnier, Structure elucidation of a senescence cross-link 
from human extracellular matrix. Implication of pentoses in the aging process. J 
Biol Chem, 1989. 264(36): p. 21597-602. 
153. Kazantsev, V., et al., A homeostatic model of neuronal firing governed by 
feedback signals from the extracellular matrix. PLoS One, 2012. 7(7): p. e41646. 
154. Hocher, B., et al., Endothelin-1 transgenic mice develop glomerulosclerosis, 
interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest, 1997. 
99(6): p. 1380-9. 
155. Yang, Z.H., et al., Threshold concentrations of endothelin-1 potentiate 
contractions to norepinephrine and serotonin in human arteries. A new 
mechanism of vasospasm? Circulation, 1990. 82(1): p. 188-95. 
156. Asano, Y., et al., Endothelial Fli1 deficiency impairs vascular homeostasis: a role 
in scleroderma vasculopathy. Am J Pathol, 2010. 176(4): p. 1983-98. 
157. Artlett, C.M., Animal models of scleroderma: fresh insights. Curr Opin 
Rheumatol, 2010. 22(6): p. 677-82. 
158. Yamamoto, T., et al., Animal model of sclerotic skin. I: Local injections of 
bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol, 1999. 
112(4): p. 456-62. 
159. Yamamoto, T., et al., Animal model of sclerotic skin. II. Bleomycin induced 
scleroderma in genetically mast cell deficient WBB6F1-W/W(V) mice. J 
Rheumatol, 1999. 26(12): p. 2628-34. 
160. Yamamoto, T., M. Kuroda, and K. Nishioka, Animal model of sclerotic skin. III: 
Histopathological comparison of bleomycin-induced scleroderma in various mice 
strains. Arch Dermatol Res, 2000. 292(11): p. 535-41. 
161. Siracusa, L.D., et al., A tandem duplication within the fibrillin 1 gene is 
associated with the mouse tight skin mutation. Genome Res, 1996. 6(4): p. 300-
13. 
162. Long, K.B., C.M. Artlett, and E.P. Blankenhorn, Tight skin 2 mice exhibit a novel 
time line of events leading to increased extracellular matrix deposition and 
dermal fibrosis. Matrix Biol, 2014. 38: p. 91-100. 
163. Dalgleish, R., M. Woodhouse, and S. Reeders, An RFLP associated with the 
human type III collagen gene (COL3A1). Nucleic Acids Res, 1985. 13(12): p. 
4609. 
164. Zafarullah, K., et al., G to A polymorphism in exon 31 of the COL3A1 gene. 
Nucleic Acids Res, 1990. 18(20): p. 6180. 
165. Tromp, G., et al., C to T polymorphism in exon 33 of the COL3A1 gene. Nucleic 
Acids Res, 1991. 19(3): p. 681. 
166. Somasundaram, R. and D. Schuppan, Type I, II, III, IV, V, and VI collagens serve 
as extracellular ligands for the isoforms of platelet-derived growth factor (AA, 
BB, and AB). J Biol Chem, 1996. 271(43): p. 26884-91. 
 
100 
167. Long, K.B., et al., The Tsk2/+ mouse fibrotic phenotype is due to a gain-of-
function mutation in the PIIINP segment of the Col3a1 gene. J Invest Dermatol, 
2015. 135(3): p. 718-27. 
168. Christner, P.J., et al., The tight skin 2 mouse. An animal model of scleroderma 
displaying cutaneous fibrosis and mononuclear cell infiltration. Arthritis Rheum, 
1995. 38(12): p. 1791-8. 
169. Christner, P.J., et al., A high-resolution linkage map of the tight skin 2 (Tsk2) 
locus: a mouse model for scleroderma (SSc) and other cutaneous fibrotic 
diseases. Mamm Genome, 1996. 7(8): p. 610-2. 
170. Barisic-Dujmovic, T., I. Boban, and S.H. Clark, Regulation of collagen gene 
expression in the Tsk2 mouse. J Cell Physiol, 2008. 215(2): p. 464-71. 
171. Kirfel, J., et al., Impaired intestinal wound healing in Fhl2-deficient mice is due to 
disturbed collagen metabolism. Exp Cell Res, 2008. 314(20): p. 3684-91. 
172. Lai, C.F., et al., Four and half lim protein 2 (FHL2) stimulates osteoblast 
differentiation. J Bone Miner Res, 2006. 21(1): p. 17-28. 
173. Johannessen, M., et al., The multifunctional roles of the four-and-a-half-LIM only 
protein FHL2. Cell Mol Life Sci, 2006. 63(3): p. 268-84. 
174. Du, J., et al., The expression pattern of FHL2 during mouse molar development. J 









 Cheng Tian was born in Suzhou, Jiangsu province, China in 1987. He attended 
North Dakota State University and received his Bachelor of biological science degree in 
2012. In same year, he was accepted into the graduate program in the Department of 
Pharmaceutical Science, the University of Tennessee Health Science Center. In 2012, he 
joined Dr. Weikuan Gu’s laboratory and worked in Veterans Affairs Medical Center in 
Memphis. He will graduate with Doctor of Philosophy degree. 
 
